
<html lang="en"     class="pb-page"  data-request-id="7de70e3a-8cbc-4401-b77e-96357871f506"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2017.60.issue-12;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.7b00401;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration" /></meta><meta name="dc.Creator" content="Matthew W. D.  Perry" /></meta><meta name="dc.Creator" content="Karin  Björhall" /></meta><meta name="dc.Creator" content="Britta  Bonn" /></meta><meta name="dc.Creator" content="Johan  Carlsson" /></meta><meta name="dc.Creator" content="Yunhua  Chen" /></meta><meta name="dc.Creator" content="Anders  Eriksson" /></meta><meta name="dc.Creator" content="Linda  Fredlund" /></meta><meta name="dc.Creator" content="Hai’e  Hao" /></meta><meta name="dc.Creator" content="Neil S.  Holden" /></meta><meta name="dc.Creator" content="Kostas  Karabelas" /></meta><meta name="dc.Creator" content="Helena  Lindmark" /></meta><meta name="dc.Creator" content="Feifei  Liu" /></meta><meta name="dc.Creator" content="Nils  Pemberton" /></meta><meta name="dc.Creator" content="Jens  Petersen" /></meta><meta name="dc.Creator" content="Sandra  Rodrigo Blomqvist" /></meta><meta name="dc.Creator" content="Reed W.  Smith" /></meta><meta name="dc.Creator" content="Tor  Svensson" /></meta><meta name="dc.Creator" content="Ina  Terstiege" /></meta><meta name="dc.Creator" content="Christian  Tyrchan" /></meta><meta name="dc.Creator" content="Wenzhen  Yang" /></meta><meta name="dc.Creator" content="Shuchun  Zhao" /></meta><meta name="dc.Creator" content="Linda  Öster" /></meta><meta name="dc.Description" content="PI3Kδ is a lipid kinase that is believed to be important in the migration and activation of cells of the immune system. Inhibition is hypothesized to provide a powerful yet selective immunomodulato..." /></meta><meta name="Description" content="PI3Kδ is a lipid kinase that is believed to be important in the migration and activation of cells of the immune system. Inhibition is hypothesized to provide a powerful yet selective immunomodulato..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 7, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00401" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00401" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00401" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00401" /></link>
        
    
    

<title>Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00401" /></meta><meta property="og:title" content="Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0001.jpeg" /></meta><meta property="og:description" content="PI3Kδ is a lipid kinase that is believed to be important in the migration and activation of cells of the immune system. Inhibition is hypothesized to provide a powerful yet selective immunomodulatory effect that may be beneficial for the treatment of conditions such as asthma or rheumatoid arthritis. In this work, we describe the identification of inhibitors based on a thiazolopyridone core structure and their subsequent optimization for inhalation. The initially identified compound (13) had good potency and isoform selectivity but was not suitable for inhalation. Addition of basic substituents to a region of the molecule pointing to solvent was tolerated (enzyme inhibition pIC50 &gt; 9), and by careful manipulation of the pKa and lipophilicity, we were able to discover compounds (20b, 20f) with good lung retention and cell potency that could be taken forward to in vivo studies where significant target engagement could be demonstrated." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00401"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00401">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00401&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00401&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00401&amp;href=/doi/10.1021/acs.jmedchem.7b00401" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 5057-5071</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00440" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00410" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+W.+D.++Perry">Matthew W. D. Perry</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-9799-0746" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karin++Bj%C3%B6rhall">Karin Björhall</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Britta++Bonn">Britta Bonn</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Johan++Carlsson">Johan Carlsson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yunhua++Chen">Yunhua Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anders++Eriksson">Anders Eriksson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Linda++Fredlund">Linda Fredlund</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-2104-5617" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hai%E2%80%99e++Hao">Hai’e Hao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Neil+S.++Holden">Neil S. Holden</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span><span class="author-xref-symbol "><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kostas++Karabelas">Kostas Karabelas</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Helena++Lindmark">Helena Lindmark</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Feifei++Liu">Feifei Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nils++Pemberton">Nils Pemberton</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jens++Petersen">Jens Petersen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sandra++Rodrigo+Blomqvist">Sandra Rodrigo Blomqvist</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Reed+W.++Smith">Reed W. Smith</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tor++Svensson">Tor Svensson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ina++Terstiege">Ina Terstiege</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Tyrchan">Christian Tyrchan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wenzhen++Yang">Wenzhen Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shuchun++Zhao">Shuchun Zhao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Linda++%C3%96ster">Linda Öster</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Respiratory, Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span></div><div class="aff-info" id="aff2"><span class="aff-text"><sup>‡</sup>Medicinal Chemistry, <sup>§</sup>DMPK, <sup>∥</sup>BioScience, and <sup>⊥</sup>Discovery Sciences, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">#</span> <span class="aff-text">Pharmaron Beijing Co., Ltd., No. 6 Taihe Road, BDA, Beijing 100176, P.R. China</span></div><div class="corresp-info"><strong>*</strong>Phone: +46317761733. E-mail: <a href="/cdn-cgi/l/email-protection#375a5643435f524019475245454e7756444345564d52595254561954585a"><span class="__cf_email__" data-cfemail="5d303c292935382a732d382f2f241d3c2e292f3c273833383e3c733e3230">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00401&amp;href=/doi/10.1021%2Facs.jmedchem.7b00401" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 5057–5071</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 18, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 March 2017</li><li><span class="item_label"><b>Published</b> online</span>7 June 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 June 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00401" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00401</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5057%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMatthew%2BW.%2BD.%2BPerry%252C%2BKarin%2BBj%25C3%25B6rhall%252C%2BBritta%2BBonn%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D12%26contentID%3Dacs.jmedchem.7b00401%26title%3DDesign%2Band%2BSynthesis%2Bof%2BSoluble%2Band%2BCell-Permeable%2BPI3K%25CE%25B4%2BInhibitors%2Bfor%2BLong-Acting%2BInhaled%2BAdministration%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5071%26publicationDate%3DJune%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00401"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1904</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">12</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00401" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;W. D. Perry&quot;},{&quot;first_name&quot;:&quot;Karin&quot;,&quot;last_name&quot;:&quot;Björhall&quot;},{&quot;first_name&quot;:&quot;Britta&quot;,&quot;last_name&quot;:&quot;Bonn&quot;},{&quot;first_name&quot;:&quot;Johan&quot;,&quot;last_name&quot;:&quot;Carlsson&quot;},{&quot;first_name&quot;:&quot;Yunhua&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Anders&quot;,&quot;last_name&quot;:&quot;Eriksson&quot;},{&quot;first_name&quot;:&quot;Linda&quot;,&quot;last_name&quot;:&quot;Fredlund&quot;},{&quot;first_name&quot;:&quot;Hai’e&quot;,&quot;last_name&quot;:&quot;Hao&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;S. Holden&quot;},{&quot;first_name&quot;:&quot;Kostas&quot;,&quot;last_name&quot;:&quot;Karabelas&quot;},{&quot;first_name&quot;:&quot;Helena&quot;,&quot;last_name&quot;:&quot;Lindmark&quot;},{&quot;first_name&quot;:&quot;Feifei&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Nils&quot;,&quot;last_name&quot;:&quot;Pemberton&quot;},{&quot;first_name&quot;:&quot;Jens&quot;,&quot;last_name&quot;:&quot;Petersen&quot;},{&quot;first_name&quot;:&quot;Sandra&quot;,&quot;last_name&quot;:&quot;Rodrigo Blomqvist&quot;},{&quot;first_name&quot;:&quot;Reed&quot;,&quot;last_name&quot;:&quot;W. Smith&quot;},{&quot;first_name&quot;:&quot;Tor&quot;,&quot;last_name&quot;:&quot;Svensson&quot;},{&quot;first_name&quot;:&quot;Ina&quot;,&quot;last_name&quot;:&quot;Terstiege&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Tyrchan&quot;},{&quot;first_name&quot;:&quot;Wenzhen&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Shuchun&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Linda&quot;,&quot;last_name&quot;:&quot;Öster&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;5057-5071&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00401&quot;},&quot;abstract&quot;:&quot;PI3Kδ is a lipid kinase that is believed to be important in the migration and activation of cells of the immune system. Inhibition is hypothesized to provide a powerful yet selective immunomodulatory effect that may be beneficial for the treatment of conditions such as asthma or rheumatoid arthritis. In this work, we describe the identification of inhibitors based on a thiazolopyridone core structure and their subsequent optimization for inhalation. The initially identified compound (13) had good potency and isoform selectivity but was not suitable for inhalation. Addition of basic substituents to a region of the molecule pointing to solvent was tolerated (enzyme inhibition pIC50 &gt; 9), and by careful manipulation of the pKa and lipophilicity, we were able to discover compounds (20b, 20f) with good lung retention and cell potency that could be taken forward to in vivo studies where significant target engagement could be demonstrated.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00401&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00401" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00401&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00401" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00401&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00401" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00401&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00401&amp;href=/doi/10.1021/acs.jmedchem.7b00401" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00401" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00401" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00401%26sid%3Dliteratum%253Aachs%26pmid%3D28520415%26genre%3Darticle%26aulast%3DPerry%26date%3D2017%26atitle%3DDesign%2Band%2BSynthesis%2Bof%2BSoluble%2Band%2BCell-Permeable%2BPI3K%25CE%25B4%2BInhibitors%2Bfor%2BLong-Acting%2BInhaled%2BAdministration%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D12%26spage%3D5057%26epage%3D5071%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290851" title="Half-life">Half-life</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/jmcmar.2017.60.issue-12/20170622/jmcmar.2017.60.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">PI3Kδ is a lipid kinase that is believed to be important in the migration and activation of cells of the immune system. Inhibition is hypothesized to provide a powerful yet selective immunomodulatory effect that may be beneficial for the treatment of conditions such as asthma or rheumatoid arthritis. In this work, we describe the identification of inhibitors based on a thiazolopyridone core structure and their subsequent optimization for inhalation. The initially identified compound (<b>13</b>) had good potency and isoform selectivity but was not suitable for inhalation. Addition of basic substituents to a region of the molecule pointing to solvent was tolerated (enzyme inhibition pIC<sub>50</sub> > 9), and by careful manipulation of the p<i>K</i><sub>a</sub> and lipophilicity, we were able to discover compounds (<b>20b</b>, <b>20f</b>) with good lung retention and cell potency that could be taken forward to in vivo studies where significant target engagement could be demonstrated.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46758" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46758" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Phosphoinositide 3-kinases (PI3Ks) are a group of enzymes that are involved in the phosphorylation of the membrane-bound inositol phospholipids in the 3-position of the inositol moiety. The eight known members are divided into three classes, I, II, and III. Class I PI3Ks have been the most extensively studied of these subclasses; the class is further subdivided into IA (PI3Kα, β, and δ) and IB (PI3Kγ) based upon the types of regulatory subunits with which the catalytic domains combine in the active heterodimeric forms. Class 1A PI3Ks mediate the signal transduction from receptor tyrosine kinases, while PI3Kγ is principally activated by GPCRs. PI3Kδ and γ are restricted to cells of the hematopoietic system, while PI3Kα and β are ubiquitous. Dysregulation of the PI3K system (the kinases and the associated phosphatases) is often observed in cancers, and there has been a great deal of interest in developing pan or selective inhibitors of PI3Ks for applications in oncology.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Evidence is growing that inhibition of PI3Kδ and/or γ can have powerful yet selective effects on the immune response and inhibitors have attracted interest as potential treatments for diseases with a significant immunological component such as rheumatoid arthritis and asthma.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6">(3-6)</a> Understanding of the biology of PI3Ks is developing fast, however, there are still details and subtleties to be worked out. Several reviews describe the current state of knowledge.<a onclick="showRef(event, 'ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10">(7-10)</a></div><div class="NLM_p">Recently the PI3Kδ selective inhibitor idelalisib (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A) has been launched as the first PI3K inhibitor to market for the treatment of B-cell cancers.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The drug is effective but shows a number of significant side effects.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Reference PI3Kδ inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We were interested in PI3Kδ as a potential treatment for lung conditions such as asthma. We have previously described an earlier series of PI3Kδ inhibitors that we investigated but which showed disappointing cell potencies.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> We selected an inhaled approach with a view to minimizing the systemic exposure and thus the potential for side effects from either target-related or off-target interactions. This early decision to follow an inhaled approach mandated several aspects of our medicinal chemistry strategy: (i) The limitations on dose deliverable through standard inhalers meant that achieving subnanomolar potency was crucial. (ii) Soluble compounds are typically cleared from the lungs in a matter of minutes,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> while inflammatory cells are recruited to the lung continuously, so sufficient exposure and retention in the lung is required. (iii) To minimize systemic exposure, oral bioavailability should be low and plasma clearance high.</div><div class="NLM_p">Multiple chemotypes have been described as PI3Kδ selective inhibitors.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Broadly speaking, they fall into two categories, “propeller” shaped compounds, such as idelalisib, that access an induced pocket,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(15)</a> and other chemotypes that all appear to derive selectivity by a combination of optimizing the interactions in the affinity pocket for PI3Kδ and accessing the “tryptophan shelf”. The “tryptophan shelf” describes the face of Tyr760 (PI3Kδ numbering), which is accessible in PI3Kδ owing to the small size of Thr750, whereas larger residues in the corresponding positions of PI3Kα, β and γ occlude this surface.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(16)</a></div><div class="NLM_p last">Since the disclosure of the structure of IC87114<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(17)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>B) in 2003, there has been extensive medicinal chemistry exploration of chemotypes that can give “propeller” type structures.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> We started our search for PI3Kδ inhibitors by looking for a novel propeller-shaped chemotype in view of the heavy patenting around 6,6-fused systems such as isoquinolinones and quinazolinones. We identified the thiazolopyridone ring system as a potentially suitable core for our explorations. Since the completion of the work described herein but prior to the submission of this article, the same core has been described in the patent literature for some PI3Kδ inhibitors.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(18)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67003" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67003" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Synthesis of the compounds described in this paper followed a general route with late-stage diversification in order to introduce changes to the aryl substituents. The route (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) started by following the procedures described by the Almqvist group for the synthesis of 6-bromothiazolidinopyridones.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(19, 20)</a> Initially we used a racemic synthesis with late-stage chiral separation, but the majority of work was carried out starting with chiral (<i>R</i>)-2-chloropropionic acid. Coupling of this acid with Meldrum’s acid gave dioxinone <b>3</b>. This dioxinone reacted thermally with thiazoline <b>2</b> to give the core ring system <b>4</b> as a mixture of diastereomers. Ring bromination of <b>4</b> was followed by sulfoxidation, Pummerer rearrangement, and elimination to deliver the aromatized compound <b>7</b>. Displacement of the chlorine with sodium azide followed by reduction gave amine <b>9</b>. CBZ protection of the free amine produced carbamate <b>10</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0011.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) Lawesson’s reagent, THF, 65 °C; (ii) Meldrum’s acid, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>; (iii) TFA, TFAA, ClCH<sub>2</sub>CH<sub>2</sub>Cl; (iv) isoamyl nitrite, HBr (40% aq), CH<sub>2</sub>Cl<sub>2</sub>, < −5 °C; (v) mCPBA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (vi) TFAA, PhMe, 60 °C then cH<sub>2</sub>SO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to RT; (vii) NaN<sub>3</sub>, DMF, 45 °C; (viii) Ph<sub>3</sub>P, CH<sub>2</sub>Cl<sub>2</sub>, reflux; (ix) CbzCl, K<sub>2</sub>CO<sub>3</sub>, THF:water 10:1, 0 °C.</p></p></figure><div class="NLM_p">Suzuki coupling of racemic <b>10</b> from the initial synthesis with phenyl boronic acid gave <b>11</b> that was deprotected to amine <b>12</b>, which on heating with 4-amino-6-chloropyrimidine-5-carbonitrile, followed by separation of the enantiomers by chiral HPLC, produced initial lead <b>13</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) PhB(OH)<sub>2</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, DME–water, 100 °C; (ii) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to RT; (iii) 4-amino-6-chloropyrimidine-5-carbonitrile, DIEA, <i>n</i>-butanol, 120 °C then chiral HPLC.</p></p></figure><div class="NLM_p">Chiral analysis of <b>10</b> produced using (<i>R</i>)-2-chloropropionic acid showed that some loss of stereochemical purity had occurred during the synthesis. <b>10</b>, however, proved to be suitable for chiral SFC and could be purified to >99% enantiopurity. Cleavage of the carbamate returned chirally pure amine <b>9</b> that was used as the starting point for subsequent exploration (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Heating amine <b>9</b> and 4-amino-6-chloropyrimidine-5-carbonitrile in <i>n</i>-butanol gave the bromide <b>14</b> that was coupled with substituted phenyl boronic acids to give, after deprotections and, where required, reductive amination, compounds <b>15a</b> and <b>17</b>–<b>19</b>. Alternatively, use of an aldehyde functionalized boronic acid gave intermediate <b>16</b> that could be reductively aminated with a range of amines to give, in some cases after additional manipulation, compounds <b>15b</b>–<b>g</b> and <b>20a</b>–<b>l</b>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0013.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to RT; (ii) 4-amino-6-chloropyrimidine-5-carbonitrile, DIEA, <i>n</i>-butanol, 120 °C; (iii) ArB(OH)<sub>2</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME–water, 100 °C then TFA, CH<sub>2</sub>Cl<sub>2</sub>; (iv) ArB(OH)<sub>2</sub> PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME–water, 100 °C; (v) HNRR, NaBH<sub>3</sub>CN, MeOH–CH<sub>2</sub>Cl<sub>2</sub>; (vi) (a) ArB(pinacol), third-generation Pd precatalyst, P(Cy)<sub>3</sub>·HBF<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane–water, 130 °C, (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, (c) CH<sub>2</sub>O, NaBH<sub>3</sub>CN, AcOH, MeOH; (vii) ArB(pinacol), third-generation Pd precatalyst, P(Cy)<sub>3</sub>·HBF<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane–water, 130 °C then DEAD, Me<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>OH, Ph<sub>3</sub>P, THF, 0 °C; (viii) (a) ArB(pinacol), Pd dppf, Cs<sub>2</sub>CO<sub>3</sub>, dioxane–water, 130 °C, (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, (c) acetone, NaBH<sub>3</sub>CN, AcOH, CH<sub>2</sub>Cl<sub>2</sub>–MeOH; (ix) NaBH<sub>3</sub>CN, acetaldehyde or CH<sub>2</sub>O, AcOH, CH<sub>2</sub>Cl<sub>2</sub>–MeOH; (x) (a) CH<sub>2</sub>O, NaBH<sub>3</sub>CN, AcOH, MeOH, (b) TFA/CH<sub>2</sub>Cl<sub>2</sub>–water, (c) amine, NaBH<sub>3</sub>CN, AcOH, CH<sub>2</sub>Cl<sub>2</sub>–MeOH.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67610" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67610" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Initial thiazolopyridone <b>13</b> met our criteria for a lead with excellent PI3Kδ potency in both biochemical and cellular assays, very good selectivity against PI3Kα, and acceptable selectivity against PI3Kβ and γ (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of <i>m</i>-Benzylamines<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0014.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All biological values are mean of ≥3 replicates.</p></div></div><div></div></div><div class="NLM_p">As a model for inhalation, we dosed compounds by intra tracheal (i.t.) administration of a solution of compound to rats followed by termination at time points up to 24 h and subsequent analysis of the residual compound in the lungs. Compound <b>13</b>, a moderately soluble (77 μM) neutral molecule, was cleared extremely rapidly from lung; compound could only be detected at the first time point (3 min after dosing, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Given the rapid clearance from the lung of the parent compound, we needed to find a mechanism by which we could obtain duration. Two main strategies have been described to produce a prolonged effect in lung tissue: low solubility<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(21, 22)</a> or basicity.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(23)</a> Solubility-driven approaches require that material dissolves slowly over the time after dosing to produce the effect while a pH-driven approach relies on dissolved compound being trapped in acidic organelles, such as lysosomes, which are prevalent in lung tissue, to provide a depot that is then released slowly over an extended period of time. We prioritized the addition of basic centers as a potentially predictable method to modulate lung retention.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Lung PK of Compounds <b>13</b>, <b>15a</b>–<b>g</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">lung <i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">residual dose at 4 h (%)</th><th class="colsep0 rowsep0" align="center" char=".">residual dose at 24 h (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="center">NA<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">0.0</td><td class="colsep0 rowsep0" align="char" char=".">0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15a</b></td><td class="colsep0 rowsep0" align="center">1.6</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15b</b></td><td class="colsep0 rowsep0" align="center">4.9</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15c</b></td><td class="colsep0 rowsep0" align="center">2.3</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15d</b></td><td class="colsep0 rowsep0" align="center">1.3</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="char" char=".">0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15e</b></td><td class="colsep0 rowsep0" align="center">NA<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">0.0</td><td class="colsep0 rowsep0" align="char" char=".">0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15f</b></td><td class="colsep0 rowsep0" align="center">1.1</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15g</b></td><td class="colsep0 rowsep0" align="center">3.5</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">0.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">All time points were a mean from three animals.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Compounds <b>13</b> and <b>15e</b> were only detected in lung tissue at the first time-point of the experiment (3 min after dosing) and then only 2% and 6.5% of the total dose, respectively.</p></div></div></div><div class="NLM_p">Crystallization of <b>13</b> in a murine PI3Kδ construct (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) showed that the compound bound in a similar conformation and into the same induced pocket in the enzyme that has been described previously.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(15)</a> Examination of the crystal structure revealed that there might be scope to extend from the meta position of the phenyl ring toward solvent if the phenyl ring made a small rotation, enabling modulation of the physical properties of the compounds without affecting the enzyme affinity.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>13</b> bound in murine PI3Kδ showing the ATP binding pocket with the induced pocket between Trp760 and Met752 and with hydrogen bonds to the NH of Val828 and the carbonyl of Glu826 making the hinge interaction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Addition of a benzylic amine to the meta position of the pendant phenyl in <b>13</b> gave compounds (<b>15a</b>–<b>c</b>) that retained the PI3Kδ potency of <b>13</b> but exhibited differing selectivities toward the other isoforms (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Addition of the basic center increased selectivity toward PI3Kγ by reducing potency at that isoform, particularly for <b>15b</b>,<b>c</b>. Selectivity toward PI3Kβ, on the other hand, was reduced for <b>15a</b>,<b>b</b>, though not for <b>15c</b>. Selectivity against PI3Kα was slightly increased, with <b>15c</b> again the most selective. All three compounds had low lipophilicity, particularly <b>15a</b>,<b>b</b>, and these two showed a significant potency drop-off in the cell assay, probably reflecting poor cell permeability.</div><div class="NLM_p">Crystallization of <b>15c</b> with PI3Kδ (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) showed an almost complete superposition with the structure of <b>13</b> without rotation of the phenyl ring; the dimethylamino group, as expected, pointed into the solvent channel. The dimethylamino group lies in the proximity of Asn836 (PI3Kδ), the amide moiety of which can be seen to rotate slightly to accommodate the ligand; this is one of the few highly variable residues in the vicinity of the ATP binding site of the highly homologous PI3K isoforms. The corresponding residues in the other isoforms PI3Kα Gln859, PI3Kβ Asp856, and PI3Kγ Lys890 are all different. These differences can in part explain the observed selectivity changes, thus the positively charged protonated amines can make a favorable interaction with the aspartate anion of PI3Kβ that is reflected in the increased potency at this isoform but make an unfavorable one with the cation of Lys890 in PI3Kγ, accounting for the big drop in potency observed. The neutral glutamine in PI3Kα has a more modest effect but is a larger group than the asparagine in δ and thus the slight loss of potency as the size of the substituent increases from <b>15a</b> to <b>15b</b> to <b>15c</b> can be understood. These effects were seen consistently for further examples (<b>15d</b>–<b>f</b>), and consequently we shifted our focus to tertiary amines in this position to ensure we obtained sufficient selectivity vs PI3Kβ.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. View of <b>15c</b> (gray) overlaid with <b>13</b> (blue) showing the very similar conformations adopted by the ligands and the almost identical protein conformations. Note the movement of the side chain amide of Asn836 permitting the dimethylamino group to be accommodated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Larger N-substituents were tolerated, as expected based on this group pointing to solvent (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>), and enzyme affinities at all four isoforms were remarkably consistent across the series <b>15a</b>–<b>g</b>, barring the effect already mentioned with PI3Kβ. More lipophilic compounds, however, showed improved cell potencies, consistent with a potential favorable effect on membrane permeability (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). We investigated the preferred location of the basic center by making a series of changes to the linker length between the amine and the aromatic ring (<b>17</b>, <b>18</b>, <b>19</b>, <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). As the distance between the amine and the aromatic ring increased beyond two atoms the potency at PI3Kβ reduced, consistent with loss of a favorable interaction with Asp856; activity against the other isoforms was little changed. Once again cell potency dropped off for compounds with low Log <i>D</i>.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Docked structure of <b>20f</b> (gray) overlaid with <b>13</b> (blue) in murine PI3K showing the large substituted aminopiperidine accommodated in the solvent channel.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Enzyme and cell potencies for compounds <b>13</b>, <b>15a</b>–<b>g</b>, <b>17</b>, <b>18</b>, and <b>19</b> showing cell drop-off at low lipophilicity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR of Alternate Positions for the Base<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0015.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0016.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">All biological values are means of ≥3 replicates except <sup>†</sup>, <i>n</i> = 1, and <sup>‡</sup>, <i>n</i> = 2.</p></div></div><div></div></div><div class="NLM_p">In contrast to compound <b>13</b>, i.t. dosing of <b>15a</b>–<b>g</b> to rat lung showed measurable half-lives for all except <b>15e</b>, but the vast majority of compound was still cleared within a short period and negligible compound was present 24 h after dosing for any of the compounds (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). We focused on the amount of compound retained at 4 and 24 h to guide our design rather than the half-life, as the latter reflected the terminal β-phase only and did not account for differences in the amount of compound lost in the rapid initial α-phase, which was often >99% (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Compounds <b>15e</b> and <b>g</b> both met the criteria of Austin  et al.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(24)</a> for obtaining duration with inhaled β-agonists (p<i>K</i><sub>a</sub> > 8, Log <i>D</i> > 2; p<i>K</i><sub>a</sub> could not be determined for <b>15e</b> but related tertiary benzylamines had p<i>K</i><sub>a</sub> > 9; p<i>K</i><sub>a</sub><b>15g</b> = 9.4). The long phenylethoxyalkyl chain of <b>15g</b> was modeled on that used for β-agonists like Salmeterol and Sibenadet.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(25)</a> Despite these precedents, <b>15e</b> was barely retained at all in lung, while <b>15g</b>, though having the greatest retention of this group of compounds, still exhibited insufficient lung residence for our purposes.</div><div class="NLM_p">In parallel with our investigations of basic side chains, we sought to investigate dibasic analogues (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). The first two compounds synthesized (<b>20a</b>,<b>b</b>) were highly potent PI3Kδ inhibitors. As with the monobases, the secondary amine <b>20a</b> was less selective against PI3Kβ than the tertiary amine <b>20b</b>. Both compounds showed reduced cell potency, consistent with their low lipophilicities. When dosed IT to rats <b>20b</b>, but not <b>20a</b>, showed excellent lung retention with both a long half-life and a substantial proportion of the dose remaining in the lung 24 h after dosing (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>, <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). For <b>20b</b>, there was still an initial α-phase with a rapid decrease of compound over the first 30 min, followed by a prolonged β-phase where the levels declined slowly however dibase <b>20b</b> exhibited the base-driven PK profile that we were seeking for our compounds.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Data for Dibasic Compounds <b>20a</b>–<b>l</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0019.gif" alt="" id="GRAPHIC-d378e1422-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">PI3Kδ pIC<sub>50</sub></th><th class="colsep0 rowsep0" align="center" char=".">PI3Kβ pIC<sub>50</sub></th><th class="colsep0 rowsep0" align="center" char=".">PI3Kδ cell pIC<sub>50</sub></th><th class="colsep0 rowsep0" align="center" char=".">Log <i>D</i></th><th class="colsep0 rowsep0" align="center" char=".">ClogP</th><th class="colsep0 rowsep0" align="center" char=".">p<i>K</i><sub>a</sub> B1</th><th class="colsep0 rowsep0" align="center" char=".">p<i>K</i><sub>a</sub> B2</th><th class="colsep0 rowsep0" align="center" char=".">lung <i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">residual dose at 24 h (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20a</b></td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">7.7</td><td class="colsep0 rowsep0" align="char" char=".">7.9</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">9.6</td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20b</b></td><td class="colsep0 rowsep0" align="char" char=".">9.3</td><td class="colsep0 rowsep0" align="char" char=".">7.2</td><td class="colsep0 rowsep0" align="char" char=".">8.0</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">9.5</td><td class="colsep0 rowsep0" align="char" char=".">6.5</td><td class="colsep0 rowsep0" align="char" char=".">23.2</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20c</b></td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">7.3</td><td class="colsep0 rowsep0" align="char" char=".">8.6</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">9.8</td><td class="colsep0 rowsep0" align="char" char=".">8.0</td><td class="colsep0 rowsep0" align="char" char=".">12.0</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20d</b></td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">8.4</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20e</b></td><td class="colsep0 rowsep0" align="char" char=".">8.8</td><td class="colsep0 rowsep0" align="char" char=".">6.6</td><td class="colsep0 rowsep0" align="char" char=".">7.9</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="char" char=".">7.3</td><td class="colsep0 rowsep0" align="char" char=".">6.0</td><td class="colsep0 rowsep0" align="char" char=".">8.7</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20f</b></td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">7.1</td><td class="colsep0 rowsep0" align="char" char=".">8.9</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">9.7</td><td class="colsep0 rowsep0" align="char" char=".">6.8</td><td class="colsep0 rowsep0" align="char" char=".">9.9</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20g</b></td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">7.2</td><td class="colsep0 rowsep0" align="char" char=".">8.7</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td><td class="colsep0 rowsep0" align="char" char=".">10.9</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20h</b></td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">6.6</td><td class="colsep0 rowsep0" align="char" char=".">8.9</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">8.0</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">0.0</td><td class="colsep0 rowsep0" align="char" char=".">0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20i</b></td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">7.9</td><td class="colsep0 rowsep0" align="char" char=".">8.5</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char=".">6.1</td><td class="colsep0 rowsep0" align="char" char=".">8.8</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="char" char=".">13.0</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20j</b></td><td class="colsep0 rowsep0" align="char" char=".">8.9</td><td class="colsep0 rowsep0" align="char" char=".">6.9</td><td class="colsep0 rowsep0" align="char" char=".">8.3</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td><td class="colsep0 rowsep0" align="char" char=".">8.5</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20k</b></td><td class="colsep0 rowsep0" align="char" char=".">8.9</td><td class="colsep0 rowsep0" align="char" char=".">7.1</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="char" char=".">8.9</td><td class="colsep0 rowsep0" align="char" char=".">6.3</td><td class="colsep0 rowsep0" align="char" char=".">7.6</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20l</b></td><td class="colsep0 rowsep0" align="char" char=".">9.3</td><td class="colsep0 rowsep0" align="char" char=".">7.8</td><td class="colsep0 rowsep0" align="char" char=".">8.7</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td><td class="colsep0 rowsep0" align="char" char=".">17.6</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">pIC<sub>50</sub> values for PI3Kα and γ not shown; these were consistently low (α ≤ 6.2, γ ≤ 6.7) All biological values are means of ≥3 replicates.</p></div></div></div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Rat ITPK time-course profiles of selected examples.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This left the question of why <b>20b</b> but not <b>20a</b> was retained in the lung. Previous work<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(23)</a> has described the benefits of dibases for lung retention, but the precise basicities required have not been defined. Measured p<i>K</i><sub>a</sub>s for the two compounds were surprisingly different, with the second p<i>K</i><sub>a</sub> for <b>20b</b> being markedly higher than that of <b>20a</b> (6.5 vs 4.7). To investigate this effect further, we synthesized a set of compounds with a range of p<i>K</i><sub>a</sub>s for both basic centers (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Inevitably, these compounds (<b>20c</b>–<b>l</b>) also had varying lipophilicities; thus we also investigated the role of lipophilicity on both cell potency and PK (<a class="ref internalNav" href="#fig7" aria-label="Figures 7">Figures 7</a> and <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>).</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Relationships between lung retention (% remaining at 24 h; half-life) and the first and second p<i>K</i><sub>a</sub>s or lipophilicity (Log <i>D</i>) for dibases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Cell drop-off for dibases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Examination of <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a> shows that, for the range of variables tested, the second (weaker) basic p<i>K</i><sub>a</sub> is the most significant factor (<b>6b</b>,<b>e</b>). Thus, for compounds with a second p<i>K</i><sub>a</sub> less than 5 (<b>20a</b>, <b>20h</b>), half-life is short (<4 h) and essentially no compound is retained in the lung at 24 h. As the second p<i>K</i><sub>a</sub> is increased, the half-life increases, but until the second p<i>K</i><sub>a</sub> reaches >∼6, only a small fraction is retained in the lung after 24 h. With a low second p<i>K</i><sub>a</sub>, changes in lipophilicity have little effect (<b>20a</b> vs <b>20h</b>; <b>20d</b> vs <b>20j</b>). For compounds where the second p<i>K</i><sub>a</sub> is greater than 6, further increases provide, in general, an increased lung half-life, but the effect on the absolute retention is less well-defined. The first p<i>K</i><sub>a</sub> (<b>6a</b>,<b>d</b>) appears not to play a significant role in the retention of compounds in the lung over the range of values in this series of compounds (lowest p<i>K</i><sub>a</sub> B1 7.2). Lipophilicity, as determined by Log <i>D</i> (also similarly for CLogP, data not shown) does not appear to affect the amount of dose remaining after 24 h (<b>6f</b>) but does appear to contribute in a small way to the lung half-life (<b>6c</b>).</div><div class="NLM_p">There are two significant outliers to the analysis described above, compounds <b>20b</b> and <b>20l</b>. For both of these compounds, the half-life is surprisingly long; <b>20l</b> also has the highest percentage of sample remaining in the lung after 24 h. <b>20l</b> was designed to contain an aralkyl chain similar to that used to improve retention in β-agonists,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(25)</a> however, the structurally related compound <b>20i</b> does not exhibit any marked effect on retention (both <b>20i</b> and <b>20l</b> surprisingly showed a decreased selectivity toward PI3Kβ, which ruled out <b>20l</b> from further progression despite the excellent lung retention).</div><div class="NLM_p">We rationalize these results as implying that lung retention is driven by trapping of a dication in lung lysosomes (pH 4.5–5<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(26)</a>). The monocation is membrane permeable, and the rate of escape from the lysosome and hence half-life is driven by the fraction of monocation, affected by the second p<i>K</i><sub>a</sub>, and lipophilicity. The effect of lipophilicity on half-life probably principally derives from the greater membrane affinity of the more lipophilic compounds, thus the longest half-life belongs to the least lipophilic dibase <b>20b</b>. Additional structural features, like the long aralkyl chain of <b>20l</b>, also affect the rate of membrane permeability.</div><div class="NLM_p">The most important driver of cell potency appears to be the lipophilicity (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>, <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>) (compounds where the second p<i>K</i><sub>a</sub> is less than 6 are excluded from this analysis as they behave more like monobases). If Log <i>D</i> is greater than approximately 1.6, then a compound with good enzyme inhibition will also have good cell potency. When a larger and more diverse set of dibases were examined (data not shown), the same trend was still apparent, with a lower cutoff of Log <i>D</i> ca. 1.4 and an upper cutoff of ca. 2.8, although structural variations did have an additional effect.</div><div class="NLM_p">Compounds <b>20b</b> and <b>20f</b> were selected for further study based on their good lung retention, high potency coupled with isoform selectivity, and, for <b>20f</b>, excellent cell potency. Both of these compounds were screened against a panel of 345 kinases; neither showed >50% activity at any other kinase at 1 μM. Neither compound showed significant inhibition of the hERG ion channel despite containing basic centers (<20% inhibition at 11 μM).</div><div class="NLM_p">Dosing to rats both IV and PO (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>) showed that the compounds had negligible oral bioavailability and high systemic clearance with <b>20f</b> exhibiting clearance greater than liver blood flow, implying that extrahepatic mechanisms were involved. These results gave us confidence that systemic exposure of these two compounds when dosed by inhalation would be low.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Rat Pharmacokinetics IV and PO<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">example</th><th class="colsep0 rowsep0" align="center" char=".">IV clearance (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">oral bioavailability (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20b</b></td><td class="colsep0 rowsep0" align="char" char=".">57</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char="."><1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20f</b></td><td class="colsep0 rowsep0" align="char" char=".">150</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="char" char="."><1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">All values determined from two animals.</p></div></div></div><div class="NLM_p">To study the effects of the compounds in an inhaled setting, we used a transgenic mouse model as a mechanistic model of T-cell activation. Briefly, transgenic mice (OTII strain, genetically sensitized to ovalbumin<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(27)</a>) were challenged with ovalbumin (dosed i.t.) and then, after a week, dosed with compound (i.t. administration) 2 h prior to a challenge with intranasal anti-CD3. The animals were terminated 6 h after challenge, and the inhibition of the formation of Phospho S6 ribosomal protein (pS6RP) by compound was determined as a biomarker for the inhibition of PI3Kδ.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(28)</a><b>20b</b> showed good activity in this model with a clear dose response although a high dose was required to achieve full effect (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>a). When <b>20f</b> was dosed similarly, a significant effect was observed, however, instead of the 10-fold improvement in efficacy that we were hoping to see based on the significantly better cell potency of this compound, the effect appeared to be weaker (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>b).</div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0010.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Inhibition of pS6RP in lung lavage after anti-CD3 challenge to OTII mice. (a) Compound <b>20b</b>. (b) Compound <b>20f</b>. Target engagement of PI3Kδ activity is shown through measurements of pS6RP in bronchoalveolar lung lavage cells after anti-CD3 challenge to OVA-challenged OTII mice. Phosphorylation of S6RP, measured using phosphospecific antibodies, was significantly inhibited by both <b>20b</b> (a) and <b>20f</b> (b) in a dose-dependent manner, however, the inhibition by <b>20b</b> showed better potency. Data is shown as results for individual animals at each dose with the statistical significance indicated as follows above the columns: <i>p</i> < 0.001, ***; <i>p</i> < 0.005, **; <i>p</i> < 0.05, *.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">This result left us with the question of why the more potent compound in vitro appeared to be less effective in vivo. Our rationalization is that although <b>20f</b> is retained in the lung effectively, we do not know the <i>available levels</i> of drug at the target in the lung. Compound in the lung is expected to be partitioned between acidic organelles, membranes, and lung fluid. Different ratios in this partitioning will produce differing concentrations of free drug available to act on the T-cells that drive the observed results. It is also believed that, for highly permeable compounds such as this series, free drug in lung partitions rapidly into the systemic circulation. Given the very high systemic clearance of these compounds, it is unlikely that an equilibrium can be achieved and instead that free drug in the lung will continually be lost to the systemic circulation, resulting in very low lung free levels once the initial dose has distributed. On the basis of this analysis, we concluded that unfortunately the combination of a lipophilic dibasic molecule with the very high systemic clearance exhibited by this series was unlikely to deliver a compound with sufficient in vivo potency to be capable of being administered at the low dose necessitated by inhaled delivery and that we would require a different chemical series with alternative properties to deliver the effect that we desired.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73880" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73880" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have identified a novel scaffold with excellent potency against PI3Kδ and good selectivity against the other isoforms, particularly PI3Kα. Guided by crystal structure information, we identified a region where we were able to make changes without significantly affecting biochemical potency against PI3Kδ and were able to identify how to maintain selectivity against PI3Kβ. By exploration of the physical properties of the compounds, we were able to identify regions of property space where significant lung retention over 24 h and good cell potency were achievable. From within this property space, compounds suitable for further study were identified and we were able to show an effect in a PD model with i.t. dosing.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28763" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28763" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_99" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Chemistry</h3><div class="NLM_p">All reagents obtained from commercial sources were used without further purification; anhydrous solvents were used without further drying. All compounds were purified to ≥95% purity as judged by HPLC with uv and MS analysis. When Cl or Br was present, expected isotopic distribution patterns were observed. Details of the analytical conditions and observed purities are contained in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b00401/suppl_file/jm7b00401_si_001.pdf" class="ext-link">Supporting Information</a>. Proton (<sup>1</sup>H) and carbon (<sup>13</sup>C) NMR spectra were recorded at ambient temperature. Solutions were typically prepared in deuterated dimethyl sulfoxide (DMSO-<i>d</i><sub>6</sub>), deuteromethanol (CD<sub>3</sub>OD), or duterochloroform (CDCl<sub>3</sub>), with chemical shifts referenced to solvent as an internal standard. <sup>1</sup>H NMR data are reported indicating the chemical shift (δ), the multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad; dd, doublet of doublets; etc.), the coupling constant (<i>J</i>) in Hz, and the integration (e.g., 1H).</div><div id="sec5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> 5-[(2<i>R</i>)-2-Chloro-1-hydroxypropylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione (<b>3</b>)</h4><div class="NLM_p last">A 20 L 4-necked round-bottom flask was charged with (2<i>R</i>)-2-chloropropanoic acid (450 g, 4.15 mol) in dichloromethane (9 L), 2,2-dimethyl-1,3-dioxane-4,6-dione (600 g, 4.16 mol), and 4-dimethylaminopyridine (560 g, 4.58 mol). A solution of DCC (946 g, 4.58 mol) in dichloromethane (2 L) was added dropwise with stirring at 0 °C. The resulting solution was stirred for 3 h at room temperature, recooled to 0 °C, and was then quenched by the addition of 10 L of 6% KHSO<sub>4</sub>. The mixture was filtered, and the filtrate was extracted with 4 × 15 L of dichloromethane. The combined organic layers were washed with 15 L of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The residue was chromatographed (silica gel; PE:EtOAc (10:1)) to give the title compound (460 g, 47%) as a red oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.72–1.77 (m, 9H), 6.05 (q, <i>J</i> = 6.8 Hz, 1H), 15.58 (s, 1H). <i>m</i>/<i>z</i> (ESI) 232.9 [M – H]<sup>−</sup>.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> 7-[(1<i>R</i>)-1-Chloroethyl]-3-methyl-2<i>H</i>,3<i>H</i>,5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-5-one (<b>4</b>)</h4><div class="NLM_p last">A 20 L 4-necked round-bottom flask was charged with 2,4-dimethyl-4,5-dihydro-1,3-thiazole<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(29)</a> (650 g, 5.64 mol), DCE (6.5 L), trifluoroacetic acid (643 g, 5.64 mol), and TFAA (1185 g, 5.64 mol). The mixture was stirred to get a solution and was heated to 50 °C. A solution of 5-[(2<i>R</i>)-2-chloro-1-hydroxypropylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione (<b>3</b>, 3971 g, 16.92 mol) in DCE (4 L) was added dropwise over 2 h. The resulting solution was stirred overnight at 50 °C and then allowed to cool to RT. The pH was adjusted to 8 with aq sodium bicarbonate and the resulting solution was extracted with 3 × 10 L of dichloromethane and the organic layers were combined. The resulting mixture was washed with 1 × 10 L of brine, dried over anhydrous magnesium sulfate, concentrated, and chromatographed (silica gel, ethyl acetate/petroleum ether (1:2–1:1)) to give the title compound (668 g, 52%) as a red oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.49 (d, <i>J</i> = 6.4 Hz, 3H), 1.71 (d, <i>J</i> = 6.8 Hz, 3H), 2.97 (d, <i>J</i> = 11.1 Hz, 1H), 3.67 (dd, <i>J</i> = 11.1, 7.5 Hz, 1H), 4.73 (q, <i>J</i> = 6.8 Hz, 1H), 5.2–5.3 (m, 1H), 6.21 (s, 1H), 6.22 (s, 1H)). <i>m</i>/<i>z</i> (ESI) 230/232 (Cl pattern) [M + H]<sup>+</sup>.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> 6-Bromo-7-[(1<i>R</i>)-1-chloroethyl]-3-methyl-2<i>H</i>,3<i>H</i>,5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-5-one (<b>5</b>)</h4><div class="NLM_p last">A 10 L 4-necked round-bottom flask was charged with 7-[(1<i>R</i>)-1-chloroethyl]-3-methyl-2<i>H</i>,3<i>H</i>,5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-5-one (<b>4</b>, 312 g, 1.36 mol), dichloromethane (6 L), and HBr (40% aq, 288 g, 1.42 mol) and cooled to −10 °C. 3-Methylbutyl nitrite (318 g, 2.72 mol) was added dropwise with stirring, and the resulting solution was stirred overnight at −5 °C. The solution was diluted with 3 L of CH<sub>2</sub>Cl<sub>2</sub> and was washed sequentially with 2 × 3 L of satd sodium bicarbonate, 2 × 3 L of 10% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> and 3 L of brine, then dried (MgSO<sub>4</sub>), filtered, and concentrated. The residue was chromatographed (silica gel; ethyl acetate/petroleum ether (1:2)) to give the title compound (295 g, 70%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.52 (d, <i>J</i> = 6.4 Hz, 3H), 1.70 (d, <i>J</i> = 6.8 Hz, 3H), 3.00 (d, <i>J</i> = 11.2 Hz, 1H), 3.65–3.76 (m, 1H), 5.24–5.34 (m, 1H), 5.34–5.44 (m, 1H), 6.40 (d, <i>J</i> = 2.5 Hz, 1H)). <i>m</i>/<i>z</i> (ESI) 308/310/312 (BrCl pattern) [M + H]<sup>+</sup>.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> 6-Bromo-7-[(1<i>R</i>)-1-chloroethyl]-3-methyl-5-oxo-2,3-dihydro-5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-1-ium-1-olate (<b>6</b>)</h4><div class="NLM_p last">A 5 L 4-necked round-bottom flask was charged with 6-bromo-7-[(1<i>R</i>)-1-chloroethyl]-3-methyl-2<i>H</i>,3<i>H</i>,5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-5-one (<b>5</b>, 290 g, 940 mmol) and dichloromethane (3 L). The resulting solution was cooled to 0 °C, whereupon <i>m</i>-CPBA (178 g, 1.0 mol) was added in several batches. The resulting solution was stirred for 3 h and was then quenched by the addition of 2 L of satd NaHCO<sub>3</sub>. The resulting solution was extracted with 3 × 3 L of dichloromethane, and the organic layers were combined, dried (MgSO<sub>4</sub>), and concentrated. The residue was chromatographed (silica gel; ethyl acetate/petroleum ether (1:1–1:0)) to give the title compound (223 g, 73%) as a yellow solid. Two diastereomers in ca. 1:1 mixture: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.75, 1.79 (2 × d, <i>J</i> = 6.8 Hz, 3H), 1.86 (d, <i>J</i> = 6.7 Hz, 3H), 3.14–3.35 (m, 2H), 5.37–5.53 (m, 2H), 7.16, 7.18 (2 × s, 1H). <i>m</i>/<i>z</i> (ESI) 324/326/328 (BrCl pattern) [M + H]<sup>+</sup>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 6-Bromo-7-[(1<i>R</i>)-1-chloroethyl]-3-methyl-5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-5-one (<b>7</b>)</h4><div class="NLM_p last">A 5 L round-bottom flask was charged with 6-bromo-7-[(1<i>R</i>)-1-chloroethyl]-3-methyl-5-oxo-2,3-dihydro-5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-1-ium-1-olate (<b>6</b>, 223 g, 687 mmol), toluene (2.3 L), and trifluoroacetic anhydride (721 g, 3.43 mol). The resulting solution was heated to 60 °C for 3 h, then allowed to cool and concentrated. The residue was dissolved in dichloromethane (250 mL), which was added dropwise to cooled (0 °C) sulfuric acid (98%, 1.3 L) with stirring. The resulting solution was stirred for 1 h at RT. The reaction was poured onto water/ice, and the resulting mixture was extracted with 4 × 1 L of dichloromethane. The organic layers were combined, washed sequentially with 2 × 1 L of sodium bicarbonate and 1 L of brine, dried (MgSO<sub>4</sub>), concentrated, and chromatographed (silica gel; ethyl acetate/petroleum ether (1:5–1:2)) to give the title compound (121 g, 55%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.76 (d, <i>J</i> = 6.8 Hz, 3H), 2.88 (s, 3H), 5.48 (q, <i>J</i> = 6.7 Hz, 1H), 6.34–6.54 (m, 1H), 6.91 (s, 1H)). <i>m</i>/<i>z</i> (ESI) 308 [M + H]<sup>+</sup>.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 7-[(1<i>S</i>)-1-Azidoethyl]-6-bromo-3-methyl-5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-5-one (<b>8</b>)</h4><div class="NLM_p last">A 2 L 4-necked round-bottom flask was charged with 6-bromo-7-[(1<i>R</i>)-1-chloroethyl]-3-methyl-5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-5-one (<b>7</b>, 118 g, 366 mmol), <i>N</i>,<i>N</i>-dimethylformamide (1.2 L), TEA (3.88 g, 38 mmol), and NaN<sub>3</sub> (27.5 g, 423 mmol). The resulting solution was stirred for 5 h at 45 °C, allowed to cool to room temperature, and poured onto water/ice. The resulting mixture was extracted with 4 × 800 mL of dichloromethane, and the organic layers were combined, washed sequentially with 10 × 1 L of 5% NaCl, dried (MgSO<sub>4</sub>), and filtered to give a yellow solution of the title compound that was used without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.51 (d, <i>J</i> = 6.7 Hz, 3H), 2.90 (d, <i>J</i> = 1.2 Hz, 3H), 5.12 (q, <i>J</i> = 6.7 Hz, 1H), 6.47 (d, <i>J</i> = 1.2 Hz, 1H), 6.77 (s, 1H), 7.28 (s, 1H)). <i>m</i>/<i>z</i> (ESI) 315 [M + H]<sup>+</sup>.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 7-[(1<i>S</i>)-1-Aminoethyl]-6-bromo-3-methyl-5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-5-one (<b>9</b>)</h4><div id="sec5_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i19" class="anchor-spacer"></div><h5 class="article-section__title" id="_i19">a From Compound <b>8</b></h5><div class="NLM_p last">A 5 L 4-necked round-bottom was charged with a solution of 7-[(1<i>S</i>)-1-azidoethyl]-6-bromo-3-methyl-5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-5-one in dichloromethane (3000 mL, previous step) and triphenylphosphine (87.5 g, 334 mmol). The resulting solution was heated to 50 °C for 3 h, allowed to cool, and concentrated. The residue was dissolved in THF (800 mL) and water (400 mL), and the resulting solution was heated overnight at 50 °C and then allowed to cool. The mixture was concentrated, and the residue was chromatographed (silica gel; methanol/dichloromethane (1:100 to 1:20)) to give the title compound (52 g, 60%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.31 (3H, d <i>J</i> = 6.6 Hz), 2.78 (3H, s), 4.40 (1H, q <i>J</i> = 6.6 Hz), 6.84 (1H, s), δ 7.05 (1H, s)). <i>m</i>/<i>z</i> (ESI) 287 [M + H]<sup>+</sup>.</div></div><div id="sec5_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i20" class="anchor-spacer"></div><h5 class="article-section__title" id="_i20">b From Compound <b>10</b></h5><div class="NLM_p last">(<i>S</i>)-Benzyl (1-(6-bromo-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)carbamate (<b>10</b>, 10 g, 23.7 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (200 mL) and cooled to 0 °C. Boron tribromide (59.5 g, 237 mmol) was added dropwise over a period of 15 min. The resulting mixture was stirred at RT for 3 h. The reaction mixture was poured onto ice (150 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 100 mL). The aqueous layer was adjusted to pH = 9 with saturated sodium carbonate and was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 25 mL). The solvent was removed under reduced pressure, and the residue was dried under vacuum to give the title compound (5.50 g, 81%) as a yellow solid. <sup>1</sup>H NMR (500 MHz, DMSO) δ 1.19 (d, <i>J</i> = 6.6 Hz, 3H), 2.00 (s, 2H), 2.71 (s, 3H), 4.23 (q, <i>J</i> = 6.6 Hz, 1H), 7.02 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 17.99, 22.99, 50.64, 97.30, 97.86, 104.08, 108.93, 137.44, 148.75, 157.18. <i>m</i>/<i>z</i> (ESI) 287 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Benzyl [(1<i>S</i>)-1-(6-Bromo-3-methyl-5-oxo-5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl]carbamate (<b>10</b>)</h4><div class="NLM_p last">A 3 L 4-necked round-bottom flask was charged with 7-[(1<i>S</i>)-1-aminoethyl]-6-bromo-3-methyl-5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-5-one (<b>9</b>, 52 g, 181 mmol) in THF/H<sub>2</sub>O (10:1, 1.1 L) and potassium carbonate (62.6 g, 453 mmol) and cooled to 0 °C. Cbz-Cl (46.4 g, 272 mmol) was added dropwise, and the resulting mixture was stirred overnight at room temperature. Water (3 L) was added, the solids were collected by filtration and washed with water (5 × 200 mL) and then with THF/hexane (1:2) (3 × 200 mL). The crude product was purified by preparative-SFC (Chiralpak IC SFC, 5 cm × 25 cm, 5 μm; mobile phase A CO<sub>2</sub> (50%), B methanol: CH<sub>2</sub>Cl<sub>2</sub> = 2:1(0.2% diethylamine) (50%); detection, UV 220 nm) to give the title compound (23.5 g, 31%) as a light-yellow solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.17 (d, <i>J</i> = 7.0 Hz, 3H), 2.80 (s, 3H), 4.58 (s, 1H), 5.04 (s, 2H), 6.83 (s, 1H), 6.94 (s, 1H), 7.11–7.51 (m, 5H). <i>m</i>/<i>z</i> (ESI) 421 [M + H]<sup>+</sup>; α<sub>D</sub> −60.5° (<i>c</i> = 5.30 g/L CH<sub>2</sub>Cl<sub>2</sub>, 21–7 °C). SFC Chiralpak IC-3 5.0 μm; 100 mm × 4.6 mm. Mobile phase A CO<sub>2</sub>, B methanol/0.1% diethylamine; <i>T</i><sub>r</sub> 1.47 min; er 97.7:2.3 (minor isomer <i>T</i><sub>r</sub> 1.14 min)</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Benzyl (1-(3-Methyl-5-oxo-6-phenyl-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)carbamate (<b>11</b>)</h4><div class="NLM_p last">Cs<sub>2</sub>CO<sub>3</sub> (1083 mg, 3.32 mmol), phenylboronic acid (152 mg, 1.25 mmol), PdCl<sub>2</sub>(dppf)–CH<sub>2</sub>Cl<sub>2</sub> adduct (68 mg, 0.08 mmol), and (±)-benzyl (1-(6-bromo-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)carbamate (<b>10</b>, 350 mg, 0.83 mmol) were slurried in DME (10 mL) and water (2 mL) and heated to 100 °C for 30 min in a microwave. The solvent was evaporated, and the crude product was purified by flash chromatography (silica; 80 to 20% petroleum ether in EtOAc) to give the title compound (236 mg, 68%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.17 (d, <i>J</i> = 7.0 Hz, 3H), 2.80 (s, 3H), 4.58 (s, 1H), 5.04 (s, 2H), 6.83 (s, 1H), 6.94 (s, 1H), 7.11–7.51 (m, 11H). <i>m</i>/<i>z</i> (ESI) 419 [M + H]<sup>+</sup>.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 7-(1-Aminoethyl)-3-methyl-6-phenyl-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-5-one (<b>12</b>)</h4><div class="NLM_p last">To a solution of benzyl <i>N</i>-(1-[3-methyl-5-oxo-6-phenyl-5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-7-yl]ethyl) carbamate (<b>11</b>, 240 mg, 0.57 mmol) in dichloromethane (6 mL) at 0 °C was added boron tribromide (863 mg, 3.44 mmol, 6 equiv) dropwise. The resulting solution was stirred for 20 h at room temperature and then cooled to 0 °C. The reaction was quenched by the addition of water/ice, the pH was adjusted to 8 with sodium carbonate (aq), and the mixture was extracted with chloroform. The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated to give the title compound (120 mg, 74%) as a light-yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO) δ 1.05 (d, <i>J</i> = 6.5 Hz, 3H), 1.93 (s, 2H), 2.68 (s, 3H), 3.68 (q, <i>J</i> = 6.6, 1H), 6.91 (s, 1H), 7.09 (s, 1H), 7.20 (d, <i>J</i> = 6.0 Hz, 2H), 7.30 (t, <i>J</i> = 7.3 Hz, 1H), 7.39 (t, <i>J</i> = 7.4, Hz, 2H), 7.50–7.67 (m, 1H). <i>m</i>/<i>z</i> (ESI) 285 [M + H]<sup>+</sup>.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (<i>S</i>)-4-Amino-6-[(1-[3-methyl-5-oxo-6-phenyl-5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-7-yl]ethyl)amino]pyrimidine-5-carbonitrile (<b>13</b>)</h4><div class="NLM_p last">7-(1-Aminoethyl)-3-methyl-6-phenyl-5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-5-one (<b>12</b>, 268 mg, 0.94 mmol) and 4-amino-6-chloropyrimidine-5-carbonitrile<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(30)</a> (145 mg, 0.94 mmol) were dissolved in <i>n</i>-butanol (12 mL). DIEA (1.21 g, 9.36 mmol) was added, and the resulting solution was heated to 120 °C for 2 h, allowed to cool, and then concentrated. Recrystallization (ethyl acetate) gave the title compound (130 mg, 34%) as a light-yellow solid. The enantiomers were separated by chiral HPLC (Reprosil NR column 250 mm × 20 mm eluting with heptane–EtOAc–TEA (40:60:0.1)) collecting the first eluting peak, which was then further purified by preparative SFC (Phenomenex Luna Hilic 250 mm × 30 mm eluting with 20 mM ammonia in methanol) to give the title compound (16 mg). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.23 (d, <i>J</i> = 7.1 Hz, 3H), 2.67 (d, <i>J</i> = 1.2 Hz, 3H), 4.91 (quint, <i>J</i> = 7.0 Hz, 1H), 6.91–6.94 (m, 1H), 6.97 (s, 1H), 7.05–7.60 (m, 5H), 7.22 (brs, 2H), 7.48 (d, <i>J</i> = 7.0 Hz, 1H), 7.95 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 18.09, 20.54, 47.72, 67.92, 96.08, 107.52, 115.41, 120.28, 126.76, 127.78 (2C), 130.71 (2C), 136.00, 137.51, 148.16, 152.48, 159.43, 160.88, 161.57, 164.33. <i>m</i>/<i>z</i> (ESI) 403 [M + H]<sup>+</sup>. HRMS calculated for C<sub>21</sub>H<sub>18</sub>N<sub>6</sub>OS [(M + H)<sup>+</sup>], 403.1341; found, 403.1345.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (<i>S</i>)-4-Amino-6-((1-(6-bromo-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>14</b>)</h4><div class="NLM_p last">(<i>S</i>)-7-(1-Aminoethyl)-6-bromo-3-methyl-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-5-one (<b>9</b>, 1.5 g, 5.2 mmol) and 4-amino-6-chloropyrimidine-5-carbonitrile (0.888 g, 5.75 mmol) were dissolved in <i>n</i>-butanol (20 mL). DIEA (9.12 mL, 52.23 mmol) was added, and the resulting solution was stirred at 120 °C for 12 h. The solvent was evaporated, the reaction mixture was diluted with EtOAc, and the residual solid was collected to give the title compound (1.50 g, 71%) as a yellow solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.44 (d, <i>J</i> = 7.1 Hz, 3H), 2.72 (d, <i>J</i> = 1.0 Hz, 3H), 5.38 (quint, <i>J</i> = 7.1 Hz, 1H), 6.92 (s, 1H), 7.02 (d, <i>J</i> = 1.2 Hz, 1H), 7.28 (brs, 2H), 7.72 (d, <i>J</i> = 7.1 Hz, 1H), 7.93 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 18.0, 19.4, 50.6, 68.3, 96.7, 104.2, 109.1, 115.3, 137.6, 149.0, 153.9, 157.3, 159.6, 161.7, 164.3. <i>m</i>/<i>z</i> (ESI) 405 [M + H]<sup>+</sup> = 405.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (<i>S</i>)-4-Amino-6-((1-(6-(3-(aminomethyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>15a</b>)</h4><div class="NLM_p last">(<i>S</i>)-4-Amino-6-((1-(6-bromo-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>14</b>, 80 mg, 0.20 mmol) was added to a solution of (3-(((<i>tert</i>-butoxycarbonyl)amino)methyl)phenyl)boronic acid (198 mg, 0.79 mmol), cesium carbonate (257 mg, 0.79 mmol), and PdCl<sub>2</sub>(dppf)–CH<sub>2</sub>Cl<sub>2</sub> adduct (16 mg, 0.02 mmol) in DME (2.5 mL) and water (1 mL) at 25 °C over a period of 10 min under nitrogen. The reaction was heated to 100 °C for 45 min in a microwave reactor and then cooled to RT. The solvent was evaporated, and the residue was purified by flash silica chromatography, elution gradient 60 to 40% petroleum ether in EtOAc to give the (<i>S</i>)-<i>tert</i>-butyl 3-(7-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-6-yl)benzylcarbamate (90 mg, 86%) as a yellow solid. TFA (2 mL, 25.96 mmol) was added to (<i>S</i>)-<i>tert</i>-butyl 3-(7-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-6-yl)benzylcarbamate (80 mg, 0.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) under nitrogen. The resulting solution was stirred at room temperature for 16 h. The solvent was evaporated, and the residue was purified by preparative HPLC with the following conditions: Column: X Bridge C<sub>18</sub>, 19 mm × 150 mm, 5 μm. Mobile phase A: water/0.05% TFA. Mobile phase B: MeCN. Flow rate: 20 mL/min. Gradient: 30%B to 70%B in 10 min; 254 nm to give the title compound (60 mg, 73%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.30–1.45 (m, 3H), 2.82 (s, 3H), 4.17 (s, 2H), 5.13–5.23 (m, 1H), 6.86–6.93 (m, 1H), 7.05 (s, 1H), 7.36 (s, 1H), 7.45 (d, <i>J</i> = 7.6 Hz, 1H), 7.54 (t, <i>J</i> = 7.5 Hz, 1H), 7.66 (s, 1H), 8.00–8.25 (m, 1H). <i>m</i>/<i>z</i> (ESI) 432 [M + H]<sup>+</sup>.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> General Procedure for Synthesis of Compounds <b>15b</b>–<b>g</b>, <b>20a</b>–<b>g</b></h4><div class="NLM_p">Aldehyde <b>16</b> (65 mg, 0.15 mmol) was dissolved in a mixture of methanol and dichloromethane (1:1, 10 mL), and the solution was cooled in ice. Sodium cyanoborohydride (14 mg, 1.5 equiv) and acetic acid (43 μL, 5 equiv) were added, followed by the amine (neat or as a solution; 1 equiv) over a period of 15 min. The mixture was allowed to stir overnight at ambient temperature, then water (0.5 mL) was added and the mixture was concentrated. The residue was purified by preparative HPLC (Waters XBridge Prep C<sub>18</sub> OBD or Phenyl OBD column, 5 μ silica, 19 mm diameter, 150 mm length), using decreasingly polar mixtures of water (containing 10% NH<sub>4</sub>HCO<sub>3</sub>) and MeCN as eluents to give the pure products.</div><div id="sec5_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> (<i>S</i>)-4-Amino-6-((1-(3-methyl-6-(3-((methylamino)methyl)phenyl)-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>15b</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.27–1.43 (m, 3H), 2.76 (s, 3H), 2.81 (d, <i>J</i> = 1.1 Hz, 3H), 4.16–4.29 (m, 2H), 4.98–5.14 (m, 1H), 6.87 (d, <i>J</i> = 1.2 Hz, 1H), 7.05 (s, 1H), 7.33–7.78 (m, 4H), 7.96 (s, 1H). <i>m</i>/<i>z</i> (ESI) 446 [M + H]<sup>+</sup>.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> (<i>S</i>)-4-Amino-6-((1-(6-(3-((dimethylamino)methyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>15c</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO) δ 1.24 (d, <i>J</i> = 7.0 Hz, 3H), 2.35 (s, 6H), 2.68 (d, <i>J</i> = 1.2 Hz, 3H), 3.71 (s, 2H), 4.89 (s, 1H), 6.94 (d, <i>J</i> = 1.3 Hz, 1H), 7.00 (s, 1H), 7.1–7.34 (m, 4H), 7.36–7.44 (m, 1H), 7.52 (d, <i>J</i> = 7.2 Hz, 1H), 7.95 (s, 1H), 8.14 (s, 1H). <i>m</i>/<i>z</i> (ESI) 460 [M + H]<sup>+</sup>.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> (<i>S</i>)-4-Amino-6-((1-(6-(3-(((2-methoxyethyl)amino)methyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>15d</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.32 (d, <i>J</i> = 6.9 Hz, 3H), 2.79 (d, <i>J</i> = 1.1 Hz, 5H), 3.48 (s, 2H), 3.84 (s, 2H), 5.10 (d, <i>J</i> = 7.1 Hz, 1H), 6.82 (d, <i>J</i> = 1.2 Hz, 1H), 7.01 (s, 1H), 7.22 (m, 1H), 7.34 (d, <i>J</i> = 7.5 Hz, 1H), 7.43 (t, <i>J</i> = 7.5 Hz, 1H), 7.55 (m, 1H), 7.96–8.01 (m, 1H) (3H obscured). <i>m</i>/<i>z</i> (ESI) 490 [M + H]<sup>+</sup>.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> (<i>S</i>)-4-Amino-6-((1-(6-(3-((isobutyl(methyl)amino)methyl)phenyl)-3-methyl-5-oxo-thiazolo(3,2-<i>a</i>)pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>15e</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO) δ 0.82 (d, <i>J</i> = 6.4 Hz, 6H), 1.22 (d, <i>J</i> = 7.0 Hz, 3H), 1.76 (s, 1H), 2.07 (s, 5H), 2.67 (s, 3H), 3.43 (s, 2H), 4.84–5.01 (m, 1H), 6.92 (s, 1H), 6.97 (s, 1H), 7.23 (s, 3H), 7.33 (s, 2H), 7.48 (d, <i>J</i> = 6.9 Hz, 1H), 7.93 (s, 1H). <i>m</i>/<i>z</i> (ESI) 502 [M + H]<sup>+</sup>.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> (<i>S</i>)-4-Amino-6-((1-(6-(3-(azetidin-1-ylmethyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>15f</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.33 (d, <i>J</i> = 7.1 Hz, 3H), 2.22 (s, 2H), 2.68–2.9 (m, 3H), 3.54 (s, 4H), 3.85 (s, 2H), 5.06 (s, 1H), 6.83 (d, <i>J</i> = 1.1 Hz, 1H), 7.01 (s, 1H), 7.25 (s, 1H), 7.33 (d, <i>J</i> = 7.6 Hz, 1H), 7.45 (t, <i>J</i> = 7.6 Hz, 1H), 7.56 (s, 1H), 7.96–8.02 (m, 1H). <i>m</i>/<i>z</i> (ESI) 472 [M + H]<sup>+</sup>.</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> (<i>S</i>)-4-Amino-6-((1-(3-methyl-5-oxo-6-(3-(((4-phenethoxybutyl)amino)methyl)phenyl)-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>15g</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz; CD<sub>3</sub>OD) δ 1.28–1.42 (3H, m), 1.67–1.79 (4H, d), 2.67–2.86 (5H, m), 2.98–3.09 (2H, m), 3.50–3.51 (2H, m), 3.67.(2H, s), 4.17–4.19 (2H,d), 3.57 (2H,s), 5.00–5.20 (1H, m), 6.89 (1H, s), 7.06 (1H, s), 7.15–7.28 (5H, m), 7.44–7.46 (2H, d), 7.50–7.75 (2H, m), 8.00 (1H, s). <i>m</i>/<i>z</i> (ESI) 608 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>S</i>)-4-Amino-6-((1-(6-(3-formylphenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>16</b>)</h4><div class="NLM_p last">(3-Formylphenyl)boronic acid (370 mg, 2.47 mmol) was added to (<i>S</i>)-4-amino-6-((1-(6-bromo-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>14</b>, 500 mg, 1.23 mmol), cesium carbonate (804 mg, 2.47 mmol), and PdCl<sub>2</sub>(dppf)–CH<sub>2</sub>Cl<sub>2</sub> adduct (101 mg, 0.12 mmol) in DME (10 mL) and water (3 mL) at 25 °C over a period of 15 min under nitrogen. The reaction was heated to 100 °C for 30 min in a microwave reactor and cooled to RT. The reaction mixture was quenched with water (10 mL), extracted with EtOAc (3 × 10 mL), and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The crude product was purified by flash silica chromatography, elution gradient 30 to 50% EtOAc in petroleum ether to give the title compound (400 mg, 75%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.26 (d, <i>J</i> = 7.1 Hz, 3H), 2.68 (d, <i>J</i> = 1.1 Hz, 3H), 4.86 (quint, <i>J</i> = 7.0 Hz, 1H), 6.96 (d, <i>J</i> = 1.3 Hz, 1H), 7.05 (s, 1H), 7.23 (brs, 2H), 7.56 (d, <i>J</i> = 7.1 Hz, 1H), 7.61–7.67 (m, 1H), 7.84–7.88 (m, 1H), 7.94 (s, 1H), 7.4–8.2 (vbrm, 2H), 10.05 (s, 1H). Note: aromatic protons 2 and 6 from the 3-formylphenyl ring are observed as very broad signals in baseline between 7.4 and 8.2 ppm. <sup>13</sup>C NMR (126 MHz, DMSO) δ 18.0, 20.5, 47.7, 67.9, 96.4, 107.8, 115.4, 118.9, 128.0, 128.7, 132.2, 136.0, 137.0, 137.1, 137.6, 152.6, 159.4, 160.7, 161.5, 164.3, 193.2. <i>m</i>/<i>z</i> (ESI) 431 [M + H]<sup>+</sup>.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>S</i>)-4-Amino-6-((1-(6-(3-(2-(dimethylamino)ethyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile Formic Acid Salt (<b>17</b>)</h4><div id="sec5_22_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> Step 1</h5><div class="NLM_p last">Third-generation PCy<sub>3</sub> precatalyst<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(31)</a> (48 mg, 0.07 mmol), (<i>S</i>)-4-amino-6-((1-(6-bromo-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (300 mg, 0.74 mmol), <i>tert</i>-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethylcarbamate (514 mg, 1.48 mmol potassium phosphate (471 mg, 2.22 mmol), and Cy<sub>3</sub>P·HBF<sub>4</sub> (54.5 mg, 0.15 mmol) were mixed in dioxane (12 mL)/water (3 mL) and sealed into a microwave tube. The reaction was heated to 130 °C for 1 h in the microwave reactor and cooled to RT. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (150 mL) and washed with water (100 mL × 1) and saturated brine (100 mL × 1). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified by flash silica chromatography, elution gradient 20 to 50% EtOAc in petroleum ether to give (<i>S</i>)-<i>tert</i>-butyl 3-(7-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-6-yl)phenethylcarbamate (180 mg, 45%) as a yellow solid.</div></div><div id="sec5_22_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> Step 2</h5><div class="NLM_p last">TFA (2.5 mL, 33 mmol) was added to (<i>S</i>)-<i>tert</i>-butyl 3-(7-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-6-yl)phenethylcarbamate (180 mg, 0.33 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) at 25 °C under nitrogen. The resulting mixture was stirred at 25 °C for 4 h. The solvent was removed under reduced pressure, and the crude product was purified by preparative HPLC (Phenomenex Gemini-NX axia Prep C18 OBD column, 5 μ silica, 19 mm diameter, 100 mm length), using water (containing 1% TFA) and MeCN as eluents to give (<i>S</i>)-4-amino-6-((1-(6-(3-(2-aminoethyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (130 mg, 70%) as a pale-yellow solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.32–1.45 (m, 3H), 2.81 (d, <i>J</i> = 0.9 Hz, 3H), 2.9–3.1 (m, 2H), 3.15–3.3 (m, 2H), 5.03–5.21 (m, 1H), 6.88 (s, 1H), 6.99–7.58 (m, 5H), 7.96–8.13 (m, 1H).</div></div><div id="sec5_22_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> Step 3</h5><div class="NLM_p last">Sodium cyanoborohydride (11 mg, 0.18 mmol) was added to (<i>S</i>)-4-amino-6-((1-(6-(3-(2-aminoethyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (40 mg, 0.09 mmol), formaldehyde (20 mg, 0.27 mmol), and AcOH (0.026 mL, 0.45 mmol) in MeOH (5 mL) at 25 °C. The resulting mixture was stirred at 25 °C for 3 h. The crude product was purified by preparative HPLC (Phenomenex Gemini-NX axia Prep C18 OBD column, 5 μ silica, 19 mm diameter, 100 mm length), using water (containing 1% formic acid) and MeCN as eluents to give the title compound (9 mg, 20%) as a pale-yellow solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.26–1.41 (m, 3H), 2.74–2.89 (m, 9H), 2.96–3.11 (m, 2H), 3.19–3.36 (m, 2H), 4.98–5.16 (m, 1H), 6.84–6.86 (m, 1H), 7.00–7.07 (m, 1H), 7.14–7.24 (m, 1H), 7.25–7.34 (m, 1H), 7.38–7.57 (m, 2H), 7.95 (s, 1H), 8.54 (s, 1H). <i>m</i>/<i>z</i> (ESI) 490 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>S</i>)-4-Amino-6-((1-(6-(3-(2-(dimethylamino)ethoxy)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile Formic Acid Salt (<b>18</b>)</h4><div id="sec5_23_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> Step 1</h5><div class="NLM_p last">Third-generation PCy<sub>3</sub> precatalyst<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(31)</a> (48.1 mg, 0.07 mmol), PCy<sub>3</sub>·HBF<sub>4</sub> (54.5 mg, 0.15 mmol), (<i>S</i>)-4-amino-6-((1-(6-bromo-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (14, 100 mg, 0.25 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (163 mg, 0.74 mmol), and K<sub>3</sub>PO<sub>4</sub> (157 mg, 0.74 mmol) were dissolved in dioxane (12 mL)/H<sub>2</sub>O (2 mL) and sealed into a microwave tube. The reaction was heated to 130 °C for 1 h. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (200 mL) and washed sequentially with saturated NaHCO<sub>3</sub> (100 mL), water (100 mL), and saturated brine (100 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The crude product was purified by preparative HPLC (Phenomenex Gemini-NX axia Prep C<sub>18</sub> OBD column, 5 μ, 19 mm × 100 mm; gradient MeCN in 1% aq TFA) to give (<i>S</i>)-4-amino-6-((1-(6-(3-hydroxyphenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (80 mg, 61%) as a yellow solid. <sup>1</sup>H NMR (400 MHz,CD<sub>3</sub>OD) δ 1.40 (d, <i>J</i> = 6.8 Hz, 3H), 2.79 (s, 3H), 5.22 (s, 1H), 6.76 (s, 2H), 6.84 (s, 1H), 6.99 (s, 2H), 7.24 (t, <i>J</i> = 7.8, 7.8 Hz, 1H), 8.07 (s, 1H).</div></div><div id="sec5_23_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> Step 2</h5><div class="NLM_p last">DEAD (75 mg, 0.43 mmol) was added to (<i>S</i>)-4-amino-6-((1-(6-(3-hydroxyphenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (60 mg, 0.14 mmol), 2-(dimethylamino)ethanol (19 mg, 0.22 mmol), and triphenylphosphine (113 mg, 0.43 mmol) in THF (10 mL) at 0 °C over a period of 2 min under nitrogen. The resulting solution was stirred at 40 °C for 12 h. The solvent was removed under reduced pressure, and the crude product was purified by preparative HPLC (XBridge Prep C<sub>18</sub> OBD column, 5 μ silica, 19 mm diameter, 150 mm length), using water (containing 0.05% formic acid) and MeCN as eluents to give the title compound (10 mg, 13%) as a white solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.34 (d, <i>J</i> = 7.1 Hz, 3H), 2.58 (s, 6H), 2.80 (s, 3H), 3.03–3.14 (m, 2H), 4.15–4.29 (m, 2H), 5.07–5.19 (m, 1H), 6.8–6.92 (m, 2H), 6.93–6.99 (m, 1H), 7.00 (s, 1H), 7.15–7.25 (m, 1H), 7.36 (t, <i>J</i> = 7.9 Hz, 1H), 7.95 (s, 1H), 8.52 (s, 1H). <i>m</i>/<i>z</i> (ESI) 474 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>S</i>)-4-Amino-6-((1-(3-methyl-5-oxo-6-(3-((1-(3,3,3-trifluoropropyl)piperidin-4-yl)methyl)phenyl)-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>19</b>)</h4><div id="sec5_24_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> Step 1</h5><div class="NLM_p last">PdCl<sub>2</sub>(dppf)–CH<sub>2</sub>Cl<sub>2</sub> adduct (100 mg, 0.12 mmol), (<i>S</i>)-4-amino-6-((1-(6-bromo-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (14, 250 mg, 0.62 mmol), <i>tert</i>-butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperidine-1-carboxylate<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(32)</a> (990 mg, 2.47 mmol), and cesium carbonate (804 mg, 2.47 mmol) were dissolved in dioxane (12 mL)/water (4 mL) and sealed into a microwave tube. The reaction was heated to 130 °C for 2 h in a microwave reactor and cooled to RT. The reaction mixture was diluted with EtOAc (100 mL) and washed sequentially with water (100 mL × 1) and saturated brine (100 mL × 1). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The residue was purified by preparative TLC (EtOAc–petroleum ether = 1:1), to give <i>tert</i>-butyl 4-[3-(7-{(1<i>S</i>)-1-[(6-amino-5-cyanopyrimidin-4-yl)amino]ethyl}-3-methyl-5-oxo-5<i>H</i>-[1,3]thiazolo[3,2-<i>a</i>]pyridin-6-yl)benzyl]piperidine-1-carboxylate (260 mg, 70%) as a yellow solid.</div></div><div id="sec5_24_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> Step 2</h5><div class="NLM_p last">TFA (1.5 mL, 19 mmol) was added to (<i>S</i>)-<i>tert</i>-butyl 4-(3-(7-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-6-yl)benzyl)piperidine-1-carboxylate (260 mg, 0.43 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) at 0 °C over a period of 15 min under nitrogen. The resulting solution was stirred for 12 h. The reaction mixture was quenched with saturated NaHCO<sub>3</sub> (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 mL), and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to give (<i>S</i>)-4-amino-6-((1-(3-methyl-5-oxo-6-(3-(piperidin-4-ylmethyl)phenyl)-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (230 mg, 106%) as a yellow solid that was used without further purification.</div></div><div id="sec5_24_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> Step 3</h5><div class="NLM_p last">NaCNBH<sub>3</sub> (15 mg, 0.24 mmol) was added to (<i>S</i>)-4-amino-6-((1-(3-methyl-5-oxo-6-(3-(piperidin-4-ylmethyl)phenyl)-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (60 mg, 0.12 mmol), 3,3,3-trifluoropropanal (53.8 mg, 0.48 mmol), and AcOH (0.034 mL, 0.60 mmol) in a mixture of CH<sub>2</sub>Cl<sub>2</sub> (5 mL) and MeOH (5 mL) were added at 25 °C over a period of 15 min. The resulting mixture was stirred at 45 °C for 12 h. The solvent was evaporated, and the residue was purified by preparative HPLC (XBridge Prep C<sub>18</sub> OBD column, 5 μ silica, 19 mm diameter, 150 mm length), using decreasingly polar mixtures of water (containing 0.5% TFA) and MeCN as eluents to give the title compound (20 mg, 16%) as a yellow solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.27–1.41 (m, 10H), 1.42–1.61 (m, 2H), 1.88–2.08 (m, 4H), 2.66 (d, <i>J</i> = 6.6 Hz, 2H), 2.80 (d, <i>J</i> = 1.0 Hz, 3H), 2.87–3.06 (m, 3H), 3.36–3.52 (m, 3H), 5.06–5.21 (m, 1H), 6.86 (d, <i>J</i> = 1.2 Hz, 1H), 7.02 (s, 1H), 7.07–7.22 (m, 2H), 7.33–7.44 (m, 2H), 8.04 (s, 1H). <i>m</i>/<i>z</i> (ESI) 596 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Compounds <b>20a</b>–<b>20g</b> Synthesized Following Procedure Described Earlier for <b>15b</b>–<b>g</b></h4><div id="sec5_25_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> ((<i>S</i>)-4-Amino-6-((1-(3-methyl-6-(3-(((2-morpholinoethyl)amino)methyl)phenyl)-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>20a</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.22 (d, <i>J</i> = 7.0 Hz, 3H), 1.94–2.4 (m, 7H), 2.53–2.62 (m, 2H), 2.68 (s, 3H), 3.4–3.56 (m, 4H), 3.72 (s, 2H), 4.85–4.99 (m, 1H), 6.92 (d, <i>J</i> = 1.2 Hz, 1H), 6.97 (s, 1H), 7.02–7.61 (m, 7H), 7.97 (s, 1H). <i>m</i>/<i>z</i> (ESI) 545 [M + H]<sup>+</sup>.</div></div><div id="sec5_25_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> (<i>S</i>)-4-Amino-6-((1-(6-(3-((4-(dimethylamino)piperidin-1-yl)methyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>20b</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.22 (d, <i>J</i> = 7.0 Hz, 3H), 1.27–1.40 (m, 2H), 1.57–1.75 (m, 2H), 1.83–1.98 (m, 2H), 2.00–2.12 (m, 1H), 2.15 (s, 6H), 2.68 (s, 3H), 2.76–2.91 (m, 2H), 3.44 (s, 2H), 4.84–4.96 (m, 1H), 6.91–6.94 (m, 1H), 6.98 (s, 1H), 7.00–7.47 (m, 6H), 7.48 (d, <i>J</i> = 7.1 Hz, 1H), 7.94 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 18.14, 20.51, 27.90 (2C), 41.33 (2C), 47.72, 52.36, 52.46, 61.68, 62.18, 67.90, 96.23, 107.55, 115.44, 120.39, 127.19, 127.57, 129.19, 130.99, 135.74, 137.53, 138.11, 148.11, 152.42, 159.40, 160.87, 161.56, 164.36. <i>m</i>/<i>z</i> (ESI) 543 [M + H]<sup>+</sup>. HRMS calculated for C<sub>29</sub>H<sub>35</sub>N<sub>8</sub>OS [(M + H)<sup>+</sup>], 543.2649; found, 543.2641</div></div><div id="sec5_25_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (<i>S</i>)-4-Amino-6-((1-(6-(3-((4-((isobutyl(methyl)amino)methyl)piperidin-1-yl)methyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>20c</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 0.88 (d, <i>J</i> = 6.0 Hz, 6H), 1.18–1.35 (m, 5H), 1.50–1.82 (m, 4H), 2.0–2.35 (m, 9H), 2.71–2.87 (m, 3H), 3.06 (s, 2H), 3.71 (s, 2H), 5.05 (s, 1H), 6.83 (s, 1H), 7.01 (s, 1H), 7.26 (s, 1H), 7.35 (d, <i>J</i> = 7.7 Hz, 1H), 7.44 (t, <i>J</i> = 7.6, 7.6 Hz, 1H), 7.52–7.61 (m, 1H), 7.92–8.02 (m, 1H) 3H obscured. <i>m</i>/<i>z</i> (ESI) 599 [M + H]<sup>+</sup>.</div></div><div id="sec5_25_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> (<i>S</i>)-4-Amino-6-((1-(3-methyl-6-(3-((4-(methyl(3,3,3-trifluoropropyl)amino)piperidin-1-yl)methyl)phenyl)-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>20d</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 1.34–1.46 (m, 3H), 2.14 (s, 2H), 2.28–2.41 (m, 2H), 2.79–2.94 (m, 8H), 3.18 (t, <i>J</i> = 12.2 Hz, 2H), 3.47–3.53 (m, 2H), 3.63–3.86 (m, 3H), 4.41 (d, <i>J</i> = 15.0 Hz, 2H), 5.00–5.21 (1H, m), 6.90 (s, 1H), 7.05 (s, 1H), 7.39–7.76 (m, 4H), 8.10 (s, 1H); 3H obscured. <sup>19</sup>F NMR (376 MHz; CD<sub>3</sub>OD) δ −66.6. <i>m</i>/<i>z</i> (ESI) 625 [M + H]<sup>+</sup>.</div></div><div id="sec5_25_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> (<i>S</i>)-4-Amino-6-((1-(3-methyl-6-(3-((4-(2-morpholinoethyl)piperazin-1-yl)methyl)phenyl)-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>20e</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.24–1.57 (m, 3H), 2.35–2.63 (m, 2H), 2.71–2.95 (m, 5H), 3.03–3.31 (m, 7H), 3.44–3.72 (m, 5H), 3.83–4.08 (m, 4H), 4.3–4.52 (m, 2H), 5.16 (s, 1H), 6.91 (s, 1H), 7.07 (s, 1H), 7.36–7.55 (m, 2H), 7.54–7.67 (m, 1H), 7.78 (s, 1H), 8.06 (s, 1H). <i>m</i>/<i>z</i> (ESI) 614 [M + H]<sup>+</sup>.</div></div><div id="sec5_25_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> (<i>S</i>)-4-Amino-6-((1-(6-(3-((4-(isobutyl(methyl)amino)piperidin-1-yl)methyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>20f</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.80 (d, <i>J</i> = 6.6 Hz, 6H), 1.22 (d, <i>J</i> = 7.0 Hz, 3H), 1.29–1.44 (m, 2H), 1.46–1.66 (m, 3H), 1.81–1.95 (m, 2H), 2.05 (d, <i>J</i> = 6.9 Hz, 2H), 2.10 (s, 3H), 2.16–2.28 (m, 1H), 2.68 (s, 3H), 2.76–2.91 (m, 2H), 3.44 (brs, 2H), 4.84–5.01 (brm, 1H), 6.91–6.94 (m, 1H), 6.98 (s, 1H), 7.01–7.45 (m, 6H), 7.47 (d, <i>J</i> = 7.0 Hz, 1H), 7.94 (s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 18.14, 20.49, 20.66 (2C), 26.03, 27.41 (2C), 38.04, 47.71, 52.93 (2C), 61.08, 61.40, 62.23, 67.90, 96.22, 107.55, 115.44, 120.38, 127.14, 127.54, 129.20, 130.92, 135.72, 137.53, 138.24, 148.11, 152.43, 159.39, 160.88, 161.56, 164.35. <i>m</i>/<i>z</i> (ESI) 585 [M + H]<sup>+</sup>. HRMS calculated for C<sub>32</sub>H<sub>41</sub>N<sub>8</sub>OS [(M + H)<sup>+</sup>], 585.3124; found, 585.3109</div></div><div id="sec5_25_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> (<i>S</i>)-4-Amino-6-((1-(3-methyl-6-(3-((4-((methyl(pyridin-2-ylmethyl)amino)methyl)piperidin-1-yl)methyl)phenyl)-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile Formic Acid Salt (<b>20g</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 1.18–1.48 (m, 5H), 1.82–2.17 (m, 3H), 2.33 (s, 3H), 2.41 (d, <i>J</i> = 5.5 Hz, 2H), 2.81 (s, 3H), 2.9–3.05 (m, 2H), 3.39–3.61 (m, 2H), 3.74 (s, 2H), 4.17–4.37 (m, 2H), 4.93–5.16 (m, 1H), 6.87 (s, 1H), 7.05 (s, 1H), 7.3–7.35 (m, 1H), 7.35–7.79 (m, 5H), 7.79–7.86 (m, 1H), 7.96 (s, 1H), 8.42 (brs, 1H), 8.48 (d, <i>J</i> = 4.4 Hz, 1H). <i>m</i>/<i>z</i> (ESI) 634 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_25_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (<i>S</i>)-4-Amino-6-((1-(6-(3-((ethyl(2-morpholinoethyl)amino)methyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>20h</b>)</h4><div class="NLM_p last">Sodium cyanoborohydride (23 mg, 0.37 mmol) was added to (<i>S</i>)-4-amino-6-((1-(3-methyl-6-(3-(((2-morpholinoethyl)amino)methyl)phenyl)-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>20a</b>, 100 mg, 0.18 mmol), acetaldehyde (12 mg, 0.28 mmol), and acetic acid (0.053 mL, 0.92 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) and MeOH (10 mL) at 25 °C. The resulting mixture was stirred at 25 °C for 12 h. The solvent was removed under reduced pressure. The crude product was purified by preparative HPLC (Phenomenex Gemini-NX axia Prep C18 OBD column, 5 μ silica, 19 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH<sub>4</sub>HCO<sub>3</sub>) and MeCN as eluents to give the title compound (55 mg, 52%) as a white solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 1.05–1.13 (m, 3H), 1.23–1.33 (m, 3H), 2.38–2.80 (m, 10H), 2.85 (s, 3H), 3.54–3.84 (m, 6H), 5.03–5.12 (m, 1H), 6.81 (d, <i>J</i> = 1.2 Hz, 1H), 6.99 (s, 1H), 7.14–7.67 (m, 4H), 7.94–8.02 (m, 1H). <i>m</i>/<i>z</i> (ESI) 573 [M + H]<sup>+</sup>.</div></div><div id="sec5_25_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (<i>S</i>)-4-Amino-6-((1-(6-(3-(((3-((4-chlorobenzyl) (methyl)amino)propyl)(methyl)amino)methyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>20i</b>)</h4><div class="NLM_p last">Prepared from aldehyde <b>16</b> and <i>N</i><sup>1</sup>-(4-chlorobenzyl)-<i>N</i><sup>1</sup>-methylpropane-1,3-diamine according to the standard procedure followed by a reductive amination with formaldehyde following the procedure of example <b>20d</b> step 2. <sup>1</sup>H NMR (400 MHz; CD<sub>3</sub>OD): δ 1.28 (s, 3H), 1.72 (s, 2H), 2.12 (d, <i>J</i> = 18.0 Hz, 3H), 2.30–2.40 (m, 2H), 2.63–2.74 (m, 2H), 2.78 (s, 3H), 3.43 (d, <i>J</i> = 20.4 Hz, 2H), 3.84 (s, 2H), 5.08 (s, 1H), 6.81 (s, 1H), 6.99 (s, 1H), 7.23 (s, 5H), 7.34 (d, <i>J</i> = 7.6 Hz, 1H), 7.44 (t, <i>J</i> = 7.6 Hz, 1H), 7.59 (s, 1H), 7.99 (s, 1H). <i>m</i>/<i>z</i> (ESI) 627/629 (Cl pattern) [M + H]<sup>+</sup>.</div></div><div id="sec5_25_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 4-Amino-6-(((<i>S</i>)-1-(6-(3-(((3-((2<i>R</i>,6<i>S</i>)-2,6-dimethylmorpholino)propyl) (methyl)amino)methyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>20j</b>)</h4><div class="NLM_p last">Prepared from aldehyde <b>16</b> and 3-((2<i>R</i>,6<i>S</i>)-2,6-dimethylmorpholino)propan-1-amine according to the standard procedure followed by a reductive amination with formaldehyde following the procedure of Example <b>20d</b> step 2. <sup>1</sup>H NMR (300 MHz; CD<sub>3</sub>OD) δ 1.24 (d, <i>J</i> = 6.3 Hz, 6H), 1.31–1.53 (m, 3H), 2.15–2.37 (m, 2H), 2.69 (t, <i>J</i> = 11.5, 11.5 Hz, 2H), 2.78–2.86 (m, 3H), 2.93 (s, 3H), 3.1–3.24 (m, 2H), 3.24–3.31 (m, 2H), 3.41–3.56 (m, 2H), 3.8–3.98 (m, 2H), 4.34–4.54 (m, 2H), 4.99–5.25 (m, 1H), 6.90 (s, 1H), 7.06 (s, 1H), 7.34–7.82 (m, 4H), 8.12 (s, 1H). <i>m</i>/<i>z</i> (ESI) 601 [M + H]<sup>+</sup>.</div></div><div id="sec5_25_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (<i>S</i>)-4-Amino-6-((1-(6-(3-(((4-(benzyl(methyl)amino)butyl)(methyl)amino)methyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>20k</b>)</h4><div id="sec5_25_11_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> Step 1</h5><div class="NLM_p last">Sodium cyanoborohydride (88 mg, 1.39 mmol) was added in one portion to (<i>S</i>)-4-amino-6-((1-(6-(3-formylphenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (300 mg, 0.70 mmol), 4,4-diethoxybutan-1-amine (337 mg, 2.09 mmol), and AcOH (0.2 mL, 3.48 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and MeOH (10 mL) at 25 °C over a period of 15 min under nitrogen. The resulting mixture was stirred at 25 °C for 2 h. The solvent was removed under reduced pressure, and the residue was quenched with saturated NaHCO<sub>3</sub> (10 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 mL), and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to give (<i>S</i>)-4-amino-6-((1-(6-(3-(((4,4-diethoxybutyl)amino)methyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (380 mg, 95%) as a yellow liquid. The product was used in the next step directly without further purification.</div></div><div id="sec5_25_11_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> Step 2</h5><div class="NLM_p last">Sodium cyanoborohydride (87 mg, 1.39 mmol) was added in one portion to (<i>S</i>)-4-amino-6-((1-(6-(3-(((4,4-diethoxybutyl)amino)methyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (400 mg, 0.69 mmol), formaldehyde (31 mg, 1.0 mmol), and acetic acid (209 mg, 3.47 mmol) in MeOH (20 mL) at 25 °C over a period of 25 min under nitrogen. The resulting mixture was stirred at 25 °C for 2 h. The reaction mixture was quenched with saturated NaHCO<sub>3</sub> (25 mL) and extracted with EtOAc (3 × 25 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to give (<i>S</i>)-4-amino-6-((1-(6-(3-(((4,4-diethoxybutyl) (methyl)amino)methyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (320 mg, 78%) as a yellow oil. The product was used in the next step directly without further purification.</div></div><div id="sec5_25_11_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> Step 3</h5><div class="NLM_p last">TFA (3.38 mL, 44 mmol) was added portionwise to a cold (0 °C) solution of (<i>S</i>)-4-amino-6-((1-(6-(3-(((4,4-diethoxybutyl) (methyl)amino)methyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (400 mg, 0.68 mmol) in CHCl<sub>3</sub> (40 mL) and H<sub>2</sub>O (5 mL) over a period of 15 min. The resulting solution was stirred at 25 °C for 2 h. The reaction mixture was quenched with saturated NaHCO<sub>3</sub> (25 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 25 mL), and the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to give (<i>S</i>)-4-amino-6-((1-(3-methyl-6-(3-((methyl(4-oxobutyl)amino)methyl)phenyl)-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (350 mg, 100%) as a yellow solid.</div></div><div id="sec5_25_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> Step 4: (<i>S</i>)-4-Amino-6-((1-(6-(3-(((4-(benzyl(methyl)amino)butyl) (methyl)amino)methyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile</h5><div class="NLM_p last">Sodium cyanoborohydride (24 mg, 0.39 mmol) was added in one portion to (<i>S</i>)-4-amino-6-((1-(3-methyl-6-(3-((methyl(4-oxobutyl)amino)methyl)phenyl)-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (100 mg, 0.19 mmol), <i>N</i>-methyl-1-phenylmethanamine (47 mg, 0.39 mmol), and acetic acid (58 mg, 0.97 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) and MeOH (10 mL) at 25 °C over a period of 15 min under nitrogen. The resulting solution was stirred at 25 °C for 12 h. The solvent was removed under reduced pressure. The crude product was purified by preparative HPLC (XBridge Prep C18 OBD column, 5 μ silica, 19 mm diameter, 150 mm length; water (0.5% TFA) and MeCN)) to give the title compound (89 mg, 62%) as a yellow solid. <sup>1</sup>H NMR (300 MHz; CD<sub>3</sub>OD) δ 1.36–1.42 (3H, m), 1.76–1.90 (4H, m), 2.73–2.80 (6H, m), 2.90 (3H, brs), 3.08–3.31 (4H, m), 4.30–4.49 (4H, m), 4.98–5.18 (1H, m), 6.89 (1H, s), 7.07 (1H, s), 7.45–7.77 (9H, m), 8.05 (1H, s) 4H obscured. <i>m</i>/<i>z</i> (ESI) 621 [M + H]<sup>+</sup>.</div></div><div id="sec5_25_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> 4-Amino-6-(((<i>S</i>)-1-(6-(3-(((4-((2<i>S</i>,6<i>R</i>)-2,6-dimethylmorpholino)butyl)(methyl)amino)methyl)phenyl)-3-methyl-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>20l</b>)</h5><div class="NLM_p last">Prepared from (<i>S</i>)-4-amino-6-((1-(3-methyl-6-(3-((methyl(4-oxobutyl)amino)methyl)phenyl)-5-oxo-5<i>H</i>-thiazolo[3,2-<i>a</i>]pyridin-7-yl)ethyl)amino)pyrimidine-5-carbonitrile (step 3 <b>20k</b>) and (2<i>S</i>,6<i>R</i>)-2,6-dimethylmorpholine under the conditions of step 4 <b>20k</b>. <sup>1</sup>H NMR (300 MHz; CD<sub>3</sub>OD) δ 1.24 (d, <i>J</i> = 6.3 Hz, 5H), 1.29–1.49 (m, 3H), 1.7–1.96 (m, 4H), 2.67 (t, <i>J</i> = 11.5 Hz, 2H), 2.82 (s, 3H), 2.89 (s, 3H), 3.1–3.31 (m, 5H), 3.4–3.52 (m, 2H), 3.79–3.96 (m, 2H), 4.25–4.56 (m, 2H), 4.98–5.25 (m, 1H), 6.91 (s, 1H), 7.07 (s, 1H), 7.38–7.82 (m, 4H), 8.09 (s, 1H). <i>m</i>/<i>z</i> (ESI) 615 [M + H]<sup>+</sup>.</div></div></div></div><div id="sec5_25_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Enzymatic Activity Assay for Recombinant Human PI3Kα, β, δ, and γ</h3><div class="NLM_p last">The activity of recombinant human PI3Kγ ((aa144-1102)-6His) and PI3Kα, β, δ (6-His(p110–p85α) was determined by measuring the ADP level after phosphorylation of DiC<sub>8</sub>–PIP<sub>2</sub> using a commercially available ADP-Glo  kit from Promega. The assay was carried out in white low volume 384-well plates in a final volume of 14 μL at RT. The assay conditions contained the following: 50 mM Tris buffer pH 7.4, 2.1 mM DTT, 3 mM MgCl<sub>2,</sub> 0.05% CHAPS, 20 μM ATP, 80 μM DiC<sub>8</sub>–PIP<sub>2</sub>, and 1.2 nM PI3Kα, β, γ or 0.6 nM PI3Kδ. Potential inhibitors were made up in DMSO and then diluted in the assay to give a final concentration of not exceeding 1% (v/v) DMSO. A 10-point half-log dilution series of the inhibitors (highest concentration typically 0.1 μM for δ,γ and 33 μM for α,β) was tested, and the pIC<sub>50</sub> determined using a four-parameter logistic equation in a nonlinear curve fitting routine. Routinely, inhibitors were preincubated with 3 μL of enzyme for 15 min prior to the addition of 2 μL of substrate mixture for a further 60 min enzyme reaction. The phosphorylation was stopped with the addition of 3 μL of ADP-Glo reagent (stop solution), followed by a 40 min incubation. Prior to detection, 6 μL of ADP-Glo kinase detection reagent was added and the plates were read in a microplate reader using a Luminescence filter. All additions were followed by a short centrifugation step.</div></div><div id="sec5_25_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Inhibition of Cellular Activity in JeKo-1 Cells</h3><div class="NLM_p last">PI3Kδ inhibitors were identified by measuring the phosphorylation of AKT (at Ser473) using TR-FRET technology (Phospho-AKT (Ser473) kit, Cisbio) in JeKo-1 cells, Lymphoblast B cell line (ATCC). Cryogenically preserved cells were thawed rapidly in RPMI 1640 medium (10% FBS, 2 mM Glutamine) at 37 °C. Cells were plated in white low volume 384-well plates at a density of 1.25 × 10<sup>6</sup> cells/mL in assay buffer (RPMI 1640 medium, 2 mM glutamine). Potential inhibitors were made up in DMSO and then diluted in the assay to give a final concentration of not exceeding 1% (v/v) DMSO. A 10-point half-log dilution series of the inhibitors (highest concentration typically 1 μM) was tested and the pIC<sub>50</sub> determined using a four-parameter logistic equation in a nonlinear curve fitting routine. Inhibitors were incubated with 8 μL of cells for 60 min at 30 °C previously stimulated with 2 μL of Anti-IgM (250 ng/mL) in assay buffer. After an incubation of 10 min at 37 °C, the cells were lysed for 30 min at RT on a plate shaker at 500 rpm. A 5 μL mix of d2/cryptate was added to the plates, and the FRET signals were read in a microplate reader after 3–4 h at 620 and 665 nm.</div></div><div id="sec5_25_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Rat Intratracheal Instillation to Determine the Lung Retention of Inhaled Compounds</h3><div class="NLM_p">All rat experiments were approved by the Gothenburg Ethics Committee for Experimental Animals in Sweden and conform to Directive 2010/63/EU, ethical license no. 135-2014.</div><div class="NLM_p last">The lung half-lives and percentage remaining in the lung at 4 h of the compounds were determined after intratracheal instillation as previously described.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(33)</a> The terminal phase of the time–concentration curve was used for determination of the half-lives. Briefly, a special cannula, connected to a syringe, was inserted in the trachea at the first bifurcation and 0.5 mL/kg was instilled into the trachea. Sampling of lungs were made at predefined time points, and the lungs were placed on ice and stored at −20 °C until homogenization (Bertin technologies) prior to analysis with LC-MS/MS.</div></div><div id="sec5_25_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Target Engagement in Vivo Model</h3><div class="NLM_p">All mouse experiments were approved by the Gothenburg Ethics Committee for Experimental Animals in Sweden and conform to Directive 2010/63/EU, ethical license no. 47-2013.</div><div class="NLM_p">The T-cell receptor transgenic mouse (OT-II; C57BL/6-Tg(TcraTcrb)425Cbn/Crl<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(27)</a> was ordered (Charles River, Sulzfeld, Germany) as 8–10 weeks of age, randomized upon arrival, and allowed to acclimatize at least 1 week in the animal facility before the experimental start.</div><div class="NLM_p last">The mice were OVA (albumin chicken egg, grade V (Sigma-Aldrich), Sweden, catalogue no. A5503) challenged on day 0 by intranasal administration (50 μg/mouse in 50 μL saline) to stimulate and recruit inflammatory cells locally to the lung. Five days later, the lung T-cells were activated by the intranasal administration of 0.5 μg of anti-CD3 (clone 145–2C11, catalogue no. 553057 from BD Bioscience) per mouse in 50 μL of saline. Isotype Hamster IgG1 (clone A19-3 catalogue no. 553968 from BD Bioscience) was used as control. The animals were (2.5 mL/kg Bw) treated intratracheally with PI3Kδ inhibitor (or vehicle for control animals) 18 h prior to anti-CD3 challenge. The bronchoalveolar lung lavage (BAL) cells were isolated 6 h after anti-CD3 challenge, fixed by Phosflow Fix buffer I, and permeabilized by permeabilization buffer III (both from BD Bioscience). Cells were then stained with Phospho-S6 Ribosomal Protein (Ser235/236) (D57.2.2E) XPRabbit mAb (AlexaFluor488 conjugate, Cell Signaling Technology), and data were collected using a LSRFortessa cell analyzer (BD Biosciences). Data analysis was performed using FlowJo (Tree Star) software.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i67"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00401">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12027" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12027" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00401" class="ext-link">10.1021/acs.jmedchem.7b00401</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Ligand diagrams for the crystal structures; kinase selectivity profile for <b>20b</b> and <b>20f</b>; analytical HPLC conditions; HPLCMS results; synthesis procedures for compounds <b>1</b> and <b>2</b>; NMR spectra for compounds <b>3</b>–<b>20l</b>; HPLCMS traces for compounds <b>20b</b> and <b>20f</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00401/suppl_file/jm7b00401_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00401/suppl_file/jm7b00401_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00401/suppl_file/jm7b00401_si_001.pdf">jm7b00401_si_001.pdf (2.51 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00401/suppl_file/jm7b00401_si_002.csv">jm7b00401_si_002.csv (2.23 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Crystal structures for compounds <b>13</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NCY">5NCY</a>) and <b>15c</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NCZ">5NCZ</a>) have been deposited with the Protein Data Bank. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b00401" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28137" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28137" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew W. D. Perry</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9799-0746" title="Orcid link">http://orcid.org/0000-0002-9799-0746</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e984889d9d818c9ec7998c9b9b90a9889a9d9b88938c878c8a88c78a8684"><span class="__cf_email__" data-cfemail="bdd0dcc9c9d5d8ca93cdd8cfcfc4fddccec9cfdcc7d8d3d8dedc93ded2d0">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karin Björhall</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Britta Bonn</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Johan Carlsson</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span>; 
    <span class="hlFld-Affiliation affiliation">‡Medicinal Chemistry, §DMPK, ∥BioScience, and ⊥Discovery Sciences, Innovative
Medicines and Early Development, AstraZeneca
Gothenburg, Pepparedsleden
1, SE-431 83 Mölndal, Sweden</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., No.
6 Taihe Road, BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yunhua Chen</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., No.
6 Taihe Road, BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anders Eriksson</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linda Fredlund</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span>; 
    <span class="hlFld-Affiliation affiliation">‡Medicinal Chemistry, §DMPK, ∥BioScience, and ⊥Discovery Sciences, Innovative
Medicines and Early Development, AstraZeneca
Gothenburg, Pepparedsleden
1, SE-431 83 Mölndal, Sweden</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., No.
6 Taihe Road, BDA, Beijing 100176, P.R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2104-5617" title="Orcid link">http://orcid.org/0000-0002-2104-5617</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hai’e Hao</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., No.
6 Taihe Road, BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil S. Holden</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kostas Karabelas</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helena Lindmark</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span>; 
    <span class="hlFld-Affiliation affiliation">‡Medicinal Chemistry, §DMPK, ∥BioScience, and ⊥Discovery Sciences, Innovative
Medicines and Early Development, AstraZeneca
Gothenburg, Pepparedsleden
1, SE-431 83 Mölndal, Sweden</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., No.
6 Taihe Road, BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feifei Liu</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., No.
6 Taihe Road, BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nils Pemberton</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jens Petersen</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span>; 
    <span class="hlFld-Affiliation affiliation">‡Medicinal Chemistry, §DMPK, ∥BioScience, and ⊥Discovery Sciences, Innovative
Medicines and Early Development, AstraZeneca
Gothenburg, Pepparedsleden
1, SE-431 83 Mölndal, Sweden</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., No.
6 Taihe Road, BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandra Rodrigo Blomqvist</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Reed W. Smith</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tor Svensson</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ina Terstiege</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Tyrchan</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenzhen Yang</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., No.
6 Taihe Road, BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuchun Zhao</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., No.
6 Taihe Road, BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linda Öster</span> - <span class="hlFld-Affiliation affiliation">Respiratory,
Inflammation and Autoimmunity, Innovative Medicines and Early Development, AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 83 Mölndal, Sweden</span>; 
    <span class="hlFld-Affiliation affiliation">‡Medicinal Chemistry, §DMPK, ∥BioScience, and ⊥Discovery Sciences, Innovative
Medicines and Early Development, AstraZeneca
Gothenburg, Pepparedsleden
1, SE-431 83 Mölndal, Sweden</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., No.
6 Taihe Road, BDA, Beijing 100176, P.R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d378e4979-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i71">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64430" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64430" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank our colleagues in the analytical and purification departments at both AstraZeneca R&D Mölndal and Pharmaron Beijing for their support with purification and characterization of the compounds described in this work. We also thank the colleagues at AstraZeneca and Pharmaron whose testing of the compounds provided the results which are described.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i72" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i72"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i73" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i73"> Abbreviations Used</h2><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">PE</td><td class="NLM_def"><p class="first last">petroleum ether</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23542" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23542" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 33 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Fruman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span> </span><span class="NLM_article-title">PI3K and Cancer: Lessons, Challenges and Opportunities</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1038/nrd4204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1038%2Fnrd4204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=24481312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=140-156&author=D.+Frumanauthor=C.+Rommel&title=PI3K+and+Cancer%3A+Lessons%2C+Challenges+and+Opportunities&doi=10.1038%2Fnrd4204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and cancer: lessons, challenges and opportunities</span></div><div class="casAuthors">Fruman, David A.; Rommel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-156</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The central role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biol. has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer.  However, emerging clin. data show limited single-agent activity of inhibitors targeting PI3K, AKT or mTOR at tolerated doses.  One exception is the response to PI3Kδ inhibitors in chronic lymphocytic leukemia, where a combination of cell-intrinsic and -extrinsic activities drive efficacy.  Here, we review key challenges and opportunities for the clin. development of inhibitors targeting the PI3K-AKT-mTOR pathway.  Through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realize the potential of this promising class of targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlD2rY54m9LbVg90H21EOLACvtfcHk0ljLCMwdTEi4Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D&md5=c4f6b4b9f9fcacd6ef55eb17d3a4f425</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd4204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4204%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DPI3K%2520and%2520Cancer%253A%2520Lessons%252C%2520Challenges%2520and%2520Opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D140%26epage%3D156%26doi%3D10.1038%2Fnrd4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Yap, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjerke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Drugging PI3K in Cancer: Refining Targets and Therapeutic Strategies</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1016/j.coph.2015.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1016%2Fj.coph.2015.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=26117819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWrt7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=98-107&author=T.+Yapauthor=L.+Bjerkeauthor=P.+Clarkeauthor=P.+Workman&title=Drugging+PI3K+in+Cancer%3A+Refining+Targets+and+Therapeutic+Strategies&doi=10.1016%2Fj.coph.2015.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging PI3K in cancer: refining targets and therapeutic strategies</span></div><div class="casAuthors">Yap, Timothy A.; Bjerke, Lynn; Clarke, Paul A.; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98-107</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phosphatidylinositol-3 kinase (PI3K) pathway is one of the most frequently activated pathogenic signalling routes in human cancers, making it a rational and important target for innovative anticancer drug development and precision medicine.  The three main classes of PI3K inhibitors currently in clin. testing comprise dual pan-Class I PI3K/mTOR inhibitors, pan-Class I PI3K inhibitors lacking significant mTOR activity and isoform-selective PI3K inhibitors.  A major step forward in recent years is the progression of over 30 small mol. PI3K inhibitors into clin. trials and the first regulatory approval of the PI3Kδ inhibitor idelalisib for multiple B-cell malignancies.  This review article focuses on the progress made in the discovery and development of novel PI3K inhibitors, with an emphasis on antitumor activity and tolerability profiles for agents that have entered clin. trials.  We also discuss the key issues of drug resistance, patient selection approaches and rational targeted combinations.  Finally, we envision the future development and use of PI3K inhibitors for the treatment of patients with a range of malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDxyCAEREi_7Vg90H21EOLACvtfcHk0ljLCMwdTEi4Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWrt7bJ&md5=9a0238f97d8ecdc54e0c5b9b6ce4fc76</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2015.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2015.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%26aulast%3DBjerke%26aufirst%3DL.%26aulast%3DClarke%26aufirst%3DP.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DDrugging%2520PI3K%2520in%2520Cancer%253A%2520Refining%2520Targets%2520and%2520Therapeutic%2520Strategies%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2015%26volume%3D23%26spage%3D98%26epage%3D107%26doi%3D10.1016%2Fj.coph.2015.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Cushing, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, L. R.</span><span> </span><span class="NLM_article-title">PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8559</span><span class="NLM_x">–</span> <span class="NLM_lpage">8581</span><span class="refDoi"> DOI: 10.1021/jm300847w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300847w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1KjsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8559-8581&author=T.+D.+Cushingauthor=D.+P.+Metzauthor=D.+Whittingtonauthor=L.+R.+McGee&title=PI3K%CE%B4+and+PI3K%CE%B3+as+Targets+for+Autoimmune+and+Inflammatory+Diseases&doi=10.1021%2Fjm300847w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases</span></div><div class="casAuthors">Cushing, Timothy D.; Metz, Daniela P.; Whittington, Douglas A.; McGee, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8559-8581</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeting signaling mols. that are required for the activation of multiple immune cells may be a more likely route to success in combating chronic, immune cell-mediated diseases (such as rheumatoid arthritis, systemic lupus erythematosus, and asthma).  This review will highlight two such signaling mols., the related lipid kinases, class I PI3K (phosphoinositide 3-kinase) δ and γ, both of which are primarily expressed in leukocytes and seem to play important roles in their function and activation.  This review will compare and contrast these two kinases as targets for autoimmune and inflammatory diseases and summarize efforts toward the development of small mol. inhibitors of PI3Kδ and PI3Kγ.  Phosphoinositides (PIs) act as second messengers in a wide variety of cellular roles including signal transduction, control of membrane trafficking and transport, cytoskeleton organization, cell survival and death, among many other functions.  The target of PI3K kinase activity is the phosphoinositides within cell membranes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMqItqgMiGp7Vg90H21EOLACvtfcHk0lg77AgHrTFcqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1KjsrjL&md5=76fc05c3bf303174add4aca98f526f8f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm300847w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300847w%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26aulast%3DWhittington%26aufirst%3DD.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26atitle%3DPI3K%25CE%25B4%2520and%2520PI3K%25CE%25B3%2520as%2520Targets%2520for%2520Autoimmune%2520and%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8559%26epage%3D8581%26doi%3D10.1021%2Fjm300847w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Rowan, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amour, A.</span><span> </span><span class="NLM_article-title">Targeting Phosphoinositide 3-Kinase δ for Allergic Asthma</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">245</span><span class="refDoi"> DOI: 10.1042/BST20110665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1042%2FBST20110665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=22260698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFGjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=240-245&author=W.+C.+Rowanauthor=J.+L.+Smithauthor=K.+Affleckauthor=A.+Amour&title=Targeting+Phosphoinositide+3-Kinase+%CE%B4+for+Allergic+Asthma&doi=10.1042%2FBST20110665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting phosphoinositide 3-kinase δ for allergic asthma</span></div><div class="casAuthors">Rowan, Wendy C.; Smith, Janet L.; Affleck, Karen; Amour, Augustin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">240-245</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic inflammation in the lung has long been linked to the pathogenesis of asthma.  Central to this airway inflammation is a T-cell response to allergens, with Th2 cytokines driving the differentiation, survival and function of the major inflammatory cells involved in the allergic cascade.  PI3Kδ (phosphoinositide 3-kinase δ) is a lipid kinase, expressed predominantly in leukocytes, where it plays a crit. role in immune receptor signalling.  A selective PI3Kδ inhibitor is predicted to block T-cell activation in the lung, reducing the prodn. of pro-inflammatory Th2 cytokines.  PI3Kδ is also involved in B-cell and mast cell activation.  Therefore the inhibition of PI3Kδ should dampen down the inflammatory cascade involved in the asthmatic response through a wide breadth of pharmacol.  Current anti-inflammatory therapies, which are based on corticosteroids, are effective in controlling inflammation in mild asthmatics, but moderate/severe asthmatic patients remain poorly controlled, experiencing recurrent exacerbations.  Corticosteroids have no effect on mast cell degranulation and do not act directly on B-cells, so, overall, a PI3Kδ inhibitor has the potential to deliver improvements in onset of action, efficacy and reduced exacerbations in moderate/severe asthmatics.  Addnl., PI3Kδ inhibition is expected to block effects of Th17 cells, which are increasingly implicated in steroid-insensitive asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKwu2SYlFjDbVg90H21EOLACvtfcHk0lg77AgHrTFcqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFGjs7s%253D&md5=db36bc8f79c70e0817e00fb9b04f10ff</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1042%2FBST20110665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20110665%26sid%3Dliteratum%253Aachs%26aulast%3DRowan%26aufirst%3DW.%2BC.%26aulast%3DSmith%26aufirst%3DJ.%2BL.%26aulast%3DAffleck%26aufirst%3DK.%26aulast%3DAmour%26aufirst%3DA.%26atitle%3DTargeting%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520for%2520Allergic%2520Asthma%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2012%26volume%3D40%26spage%3D240%26epage%3D245%26doi%3D10.1042%2FBST20110665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Puri, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gold, M. R.</span><span> </span><span class="NLM_article-title">Selective Inhibitors of Phosphoinositide 3-Kinase Delta: Modulators of B-Cell Function with Potential for Treating Autoimmune Inflammatory Diseases and B-Cell Malignancies</span> <span class="citation_source-journal">Front. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">256</span><span class="refDoi"> DOI: 10.3389/fimmu.2012.00256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.3389%2Ffimmu.2012.00256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=22936933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A280%3ADC%252BC38bivFKqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=256&author=K.+D.+Puriauthor=M.+R.+Gold&title=Selective+Inhibitors+of+Phosphoinositide+3-Kinase+Delta%3A+Modulators+of+B-Cell+Function+with+Potential+for+Treating+Autoimmune+Inflammatory+Diseases+and+B-Cell+Malignancies&doi=10.3389%2Ffimmu.2012.00256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies</span></div><div class="casAuthors">Puri Kamal D; Gold Michael R</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">256</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The delta isoform of the p110 catalytic subunit (p110δ) of phosphoinositide 3-kinase is expressed primarily in hematopoietic cells and plays an essential role in B-cell development and function.  Studies employing mice lacking a functional p110δ protein, as well as the use of highly-selective chemical inhibitors of p110δ, have revealed that signaling via p110δ-containing PI3K complexes (PI3Kδ) is critical for B-cell survival, migration, and activation, functioning downstream of key receptors on B cells including the B-cell antigen receptor, chemokine receptors, pro-survival receptors such as BAFF-R and the IL-4 receptor, and co-stimulatory receptors such as CD40 and Toll-like receptors (TLRs).  Similarly, this PI3K isoform plays a key role in the survival, proliferation, and dissemination of B-cell lymphomas.  Herein we summarize studies showing that these processes can be inhibited in vitro and in vivo by small molecule inhibitors of p110δ enzymatic activity, and that these p110δ inhibitors have shown efficacy in clinical trials for the treatment of several types of B-cell malignancies including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).  PI3Kδ also plays a critical role in the activation, proliferation, and tissue homing of self-reactive B cells that contribute to autoimmune diseases, in particular innate-like B-cell populations such as marginal zone (MZ) B cells and B-1 cells that have been strongly linked to autoimmunity.  We discuss the potential utility of p110δ inhibitors, either alone or in combination with B-cell depletion, for treating autoimmune diseases such as lupus, rheumatoid arthritis, and type 1 diabetes.  Because PI3Kδ plays a major role in both B-cell-mediated autoimmune inflammation and B-cell malignancies, PI3Kδ inhibitors may represent a promising therapeutic approach for treating these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRipfUTvwjJVGK_SFaaT9INfW6udTcc2eayBtaoue7HG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bivFKqtw%253D%253D&md5=243f0709b8e191a074d09c5a0c4c8c3f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2012.00256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2012.00256%26sid%3Dliteratum%253Aachs%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DGold%26aufirst%3DM.%2BR.%26atitle%3DSelective%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520Delta%253A%2520Modulators%2520of%2520B-Cell%2520Function%2520with%2520Potential%2520for%2520Treating%2520Autoimmune%2520Inflammatory%2520Diseases%2520and%2520B-Cell%2520Malignancies%26jtitle%3DFront.%2520Immunol.%26date%3D2012%26volume%3D3%26spage%3D256%26doi%3D10.3389%2Ffimmu.2012.00256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Sriskantharajah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamblin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worsley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calver, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessel, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amour, A.</span><span> </span><span class="NLM_article-title">Targeting Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Diseases</span> <span class="citation_source-journal">Ann. N. Y. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1280</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1111/nyas.12039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1111%2Fnyas.12039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=23551101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslWgtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1280&publication_year=2013&pages=35-39&author=S.+Sriskantharajahauthor=N.+Hamblinauthor=S.+Worsleyauthor=A.+R.+Calverauthor=E.+M.+Hesselauthor=A.+Amour&title=Targeting+Phosphoinositide+3-Kinase+%CE%B4+for+the+Treatment+of+Respiratory+Diseases&doi=10.1111%2Fnyas.12039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting phosphoinositide 3-kinase δ for the treatment of respiratory diseases</span></div><div class="casAuthors">Sriskantharajah, Srividya; Hamblin, Nicole; Worsley, Sally; Calver, Andrew R.; Hessel, Edith M.; Amour, Augustin</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1280</span>
        (<span class="NLM_cas:issue">Inositol Phospholipid Signaling in Physiology and Disease</span>),
    <span class="NLM_cas:pages">35-39</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Asthma and chronic obstructive pulmonary disease (COPD) are characterized in their pathogenesis by chronic inflammation in the airways.  Phosphoinositide 3-kinase δ (PI3Kδ), a lipid kinase expressed predominantly in leukocytes, is thought to hold much promise as a therapeutic target for such inflammatory conditions.  Of particular interest for the treatment of severe respiratory disease is the observation that inhibition of PI3Kδ may restore steroid effectiveness under conditions of oxidative stress.  PI3Kδ inhibition may also prevent recruitment of inflammatory cells, including T lymphocytes and neutrophils, as well as the release of proinflammatory mediators, such as cytokines, chemokines, reactive oxygen species, and proteolytic enzymes.  In addn., targeting the PI3Kδ pathway could reduce the incidence of pathogen-induced exacerbations by improving macrophage-mediated bacterial clearance.  In this review, we discuss the potential and highlight the unknowns of targeting PI3Kδ for the treatment of respiratory disease, focusing on recent developments in the role of the PI3Kδ pathway in inflammatory cell types believed to be crit. to the pathogenesis of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFa4PRY73w17Vg90H21EOLACvtfcHk0lhXtgyXKUx5rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslWgtL0%253D&md5=51549242bdf01d3373ded21565656f1d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fnyas.12039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnyas.12039%26sid%3Dliteratum%253Aachs%26aulast%3DSriskantharajah%26aufirst%3DS.%26aulast%3DHamblin%26aufirst%3DN.%26aulast%3DWorsley%26aufirst%3DS.%26aulast%3DCalver%26aufirst%3DA.%2BR.%26aulast%3DHessel%26aufirst%3DE.%2BM.%26aulast%3DAmour%26aufirst%3DA.%26atitle%3DTargeting%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520for%2520the%2520Treatment%2520of%2520Respiratory%2520Diseases%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2013%26volume%3D1280%26spage%3D35%26epage%3D39%26doi%3D10.1111%2Fnyas.12039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Hawkins, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L. R.</span><span> </span><span class="NLM_article-title">PI3K Signalling in Inflammation</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1851</span><span class="NLM_x">, </span> <span class="NLM_fpage">882</span><span class="NLM_x">–</span> <span class="NLM_lpage">897</span><span class="refDoi"> DOI: 10.1016/j.bbalip.2014.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1016%2Fj.bbalip.2014.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=25514767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvF2iuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1851&publication_year=2015&pages=882-897&author=P.+T.+Hawkinsauthor=L.+R.+Stephens&title=PI3K+Signalling+in+Inflammation&doi=10.1016%2Fj.bbalip.2014.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K signalling in inflammation</span></div><div class="casAuthors">Hawkins, P. T.; Stephens, L. R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1851</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">882-897</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  PI3Ks regulate several key events in the inflammatory response to damage and infection.  There are four Class I PI3K isoforms (PI3Kα,β,γ,δ), three Class II PI3K isoforms (PI3KC2α, C2β, C2γ) and a single Class III PI3K.  The four Class I isoforms synthesize the phospholipid 'PIP3'.  PIP3 is a 'second messenger' used by many different cell surface receptors to control cell movement, growth, survival and differentiation.  These four isoforms have overlapping functions but each is adapted to receive efficient stimulation by particular receptor sub-types.  PI3Kγ is highly expressed in leukocytes and plays a particularly important role in chemokine-mediated recruitment and activation of innate immune cells at sites of inflammation.  PI3Kδ is also highly expressed in leukocytes and plays a key role in antigen receptor and cytokine-mediated B and T cell development, differentiation and function.  Class III PI3K synthesizes the phospholipid PI3P, which regulates endosome-lysosome trafficking and the induction of autophagy, pathways involved in pathogen killing, antigen processing and immune cell survival.  Much less is known about the function of Class II PI3Ks, but emerging evidence indicates they can synthesize PI3P and PI34P2 and are involved in the regulation of endocytosis.The creation of genetically-modified mice with altered PI3K signalling, together with the development of isoform-selective, small-mol. PI3K inhibitors, has allowed the evaluation of the individual roles of Class I PI3K isoforms in several mouse models of chronic inflammation.  Selective inhibition of PI3Kδ, γ or β has each been shown to reduce the severity of inflammation in one or more models of autoimmune disease, respiratory disease or allergic inflammation, with dual γ/δ or β/δ inhibition generally proving more effective.  The inhibition of Class I PI3Ks may therefore offer a therapeutic opportunity to treat non-resolving inflammatory pathologies in humans.  This article is part of a Special Issue entitled Phosphoinositides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_3Ktv0Ju9w7Vg90H21EOLACvtfcHk0lhXtgyXKUx5rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvF2iuw%253D%253D&md5=eb2ce86f49dc58a2146b4ac426497e9c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2014.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2014.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DStephens%26aufirst%3DL.%2BR.%26atitle%3DPI3K%2520Signalling%2520in%2520Inflammation%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2015%26volume%3D1851%26spage%3D882%26epage%3D897%26doi%3D10.1016%2Fj.bbalip.2014.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">So, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fruman, D.</span><span> </span><span class="NLM_article-title">PI3K Signalling in B- and T-Lymphocytes: New Developments and Therapeutic Advances</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">442</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">481</span><span class="refDoi"> DOI: 10.1042/BJ20112092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1042%2FBJ20112092" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=442&publication_year=2012&pages=465-481&author=L.+Soauthor=D.+Fruman&title=PI3K+Signalling+in+B-+and+T-Lymphocytes%3A+New+Developments+and+Therapeutic+Advances&doi=10.1042%2FBJ20112092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1042%2FBJ20112092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20112092%26sid%3Dliteratum%253Aachs%26aulast%3DSo%26aufirst%3DL.%26aulast%3DFruman%26aufirst%3DD.%26atitle%3DPI3K%2520Signalling%2520in%2520B-%2520and%2520T-Lymphocytes%253A%2520New%2520Developments%2520and%2520Therapeutic%2520Advances%26jtitle%3DBiochem.%2520J.%26date%3D2012%26volume%3D442%26spage%3D465%26epage%3D481%26doi%3D10.1042%2FBJ20112092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Fung-Leung, W.-P.</span><span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase Gamma in T Cell Biology and Disease Therapy</span> <span class="citation_source-journal">Ann. N. Y. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1280</span><span class="NLM_x">, </span> <span class="NLM_fpage">40</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span><span class="refDoi"> DOI: 10.1111/nyas.12029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1111%2Fnyas.12029" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1280&publication_year=2013&pages=40-43&author=W.-P.+Fung-Leung&title=Phosphoinositide+3-Kinase+Gamma+in+T+Cell+Biology+and+Disease+Therapy&doi=10.1111%2Fnyas.12029"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fnyas.12029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnyas.12029%26sid%3Dliteratum%253Aachs%26aulast%3DFung-Leung%26aufirst%3DW.-P.%26atitle%3DPhosphoinositide%25203-Kinase%2520Gamma%2520in%2520T%2520Cell%2520Biology%2520and%2520Disease%2520Therapy%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2013%26volume%3D1280%26spage%3D40%26epage%3D43%26doi%3D10.1111%2Fnyas.12029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitehead, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piñeiro, R.</span><span> </span><span class="NLM_article-title">Molecules in Medicine Mini-Review: Isoforms of PI3K in Biology and Disease</span> <span class="citation_source-journal">J. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span><span class="refDoi"> DOI: 10.1007/s00109-015-1352-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1007%2Fs00109-015-1352-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=26658520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVOjs7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=5-11&author=B.+Vanhaesebroeckauthor=M.+A.+Whiteheadauthor=R.+Pi%C3%B1eiro&title=Molecules+in+Medicine+Mini-Review%3A+Isoforms+of+PI3K+in+Biology+and+Disease&doi=10.1007%2Fs00109-015-1352-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Molecules in medicine mini-review: isoforms of PI3K in biology and disease</span></div><div class="casAuthors">Vanhaesebroeck, Bart; Whitehead, Maria A.; Pineiro, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-11</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The PI3K lipid kinases are involved in signal transduction and intracellular vesicular traffic, endowing these enzymes with multiple cellular functions and important roles in normal physiol. and disease.  In this mini-review, we aim to distill from the vast PI3K literature the key relevant concepts for successful targeting of this pathway in disease.  Of the eight isoforms of PI3K, the class I PI3Ks have been implicated in the etiol. and maintenance of various diseases, most prominently cancer, overgrowth syndromes, inflammation and autoimmunity, with emerging potential roles in metabolic and cardiovascular disorders.  The development of class I PI3K inhibitors, mainly for use in cancer and inflammation, is a very active area of drug development.  In 2014, an inhibitor of the p110δ isoform of PI3K was approved for the treatment of specific human B cell malignancies.  The key therapeutic indications of targeting each class I PI3K isoform are summarized and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppc5USj-Hs5rVg90H21EOLACvtfcHk0lh5uU-O388vEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVOjs7bE&md5=7b78f2b78ddeed390ab133c562ec6725</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00109-015-1352-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-015-1352-5%26sid%3Dliteratum%253Aachs%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DWhitehead%26aufirst%3DM.%2BA.%26aulast%3DPi%25C3%25B1eiro%26aufirst%3DR.%26atitle%3DMolecules%2520in%2520Medicine%2520Mini-Review%253A%2520Isoforms%2520of%2520PI3K%2520in%2520Biology%2520and%2520Disease%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2016%26volume%3D94%26spage%3D5%26epage%3D11%26doi%3D10.1007%2Fs00109-015-1352-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Markham, A.</span><span> </span><span class="NLM_article-title">Idelalisib: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1701</span><span class="NLM_x">–</span> <span class="NLM_lpage">1707</span><span class="refDoi"> DOI: 10.1007/s40265-014-0285-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1007%2Fs40265-014-0285-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=25187123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFelurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1701-1707&author=A.+Markham&title=Idelalisib%3A+First+Global+Approval&doi=10.1007%2Fs40265-014-0285-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Idelalisib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1701-1707</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Idelalisib (Zydelig) is a highly specific small-mol. phosphatidylinositol-3-kinase (PI3Kδ) inhibitor that has been developed as an oral treatment for B cell haematol. cancers.  It has received its first approval in the US in July 2014 for the treatment of relapsed chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic leukemia (SLL).  Idelalisib is under regulatory review in the EU-where it has received a pos. opinion from the European Medicines Agency Committee for Medicinal Products for Human Use-and in clin. development for CLL in Australia and Canada.  This article summarizes the milestones in the development of Idelalisib leading to this first approval for relapsed CLL, NHL and SLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqGKFY-IMFGbVg90H21EOLACvtfcHk0lh5uU-O388vEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFelurbL&md5=2d0728f250f0e6eeb907942e5010f12b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0285-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0285-6%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DIdelalisib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D1701%26epage%3D1707%26doi%3D10.1007%2Fs40265-014-0285-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Coutre, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrientos, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pagel, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poleski, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharman, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, N.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zelenetz, A. D.</span><span> </span><span class="NLM_article-title">Management of Adverse Events Associated with Idelalisib Treatment - Expert Panel Opinion</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2779</span><span class="NLM_x">–</span> <span class="NLM_lpage">2786</span><span class="refDoi"> DOI: 10.3109/10428194.2015.1022770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.3109%2F10428194.2015.1022770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=25726955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKju73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=2779-2786&author=S.+E.+Coutreauthor=J.+C.+Barrientosauthor=J.+R.+Brownauthor=S.+de+Vosauthor=R.+R.+Furmanauthor=M.+J.+Keatingauthor=D.+Liauthor=S.+M.+O%E2%80%99Brienauthor=J.+M.+Pagelauthor=M.+H.+Poleskiauthor=J.+P.+Sharmanauthor=N.-S.+Yaoauthor=A.+D.+Zelenetz&title=Management+of+Adverse+Events+Associated+with+Idelalisib+Treatment+-+Expert+Panel+Opinion&doi=10.3109%2F10428194.2015.1022770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Management of adverse events associated with idelalisib treatment: expert panel opinion</span></div><div class="casAuthors">Coutre, Steven E.; Barrientos, Jacqueline C.; Brown, Jennifer R.; de Vos, Sven; Furman, Richard R.; Keating, Michael J.; Li, Daniel; O'Brien, Susan M.; Pagel, John M.; Poleski, Martin H.; Sharman, Jeff P.; Yao, Nai-Shun; Zelenetz, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2779-2786</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood cancer.  Idelalisib has demonstrated significant efficacy and a tolerable safety profile in clin. trials.  However, the US prescribing information contains a black box warning for fatal and/or severe diarrhea or colitis, hepatotoxicity, pneumonitis and intestinal perforation.  An expert panel was convened to review the pathol. of these treatment-emergent adverse events (TEAEs) to propose key management tools for patients receiving idelalisib therapy.  This article provides an overview of idelalisib TEAEs reported in clin. trials, and a summary of the panel's recommendations for identification and management of idelalisib treatment-emergent diarrhea or colitis as well as a discussion of transaminitis and pneumonitis.  For idelalisib-related diarrhea or colitis (including unresolved grade 2 and grade ≥ 3), after exclusion of infectious causes, the panel recommends individualized treatment with budesonide or oral or i.v. steroid therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVGi1H-woJu7Vg90H21EOLACvtfcHk0lh5uU-O388vEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKju73O&md5=649cb8c3d6fe0a60f74b3f9413e4706a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3109%2F10428194.2015.1022770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10428194.2015.1022770%26sid%3Dliteratum%253Aachs%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BM.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DPoleski%26aufirst%3DM.%2BH.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DYao%26aufirst%3DN.-S.%26aulast%3DZelenetz%26aufirst%3DA.%2BD.%26atitle%3DManagement%2520of%2520Adverse%2520Events%2520Associated%2520with%2520Idelalisib%2520Treatment%2520-%2520Expert%2520Panel%2520Opinion%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2015%26volume%3D56%26spage%3D2779%26epage%3D2786%26doi%3D10.3109%2F10428194.2015.1022770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Terstiege, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyrchan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindmark, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Öster, L.</span><span> </span><span class="NLM_article-title">Discovery of Triazole Aminopyrazines as a Highly Potent and Selective Series of PI3Kδ Inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">687</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1016%2Fj.bmcl.2016.11.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=679-687&author=I.+Terstiegeauthor=M.+Perryauthor=J.+Petersenauthor=C.+Tyrchanauthor=T.+Svenssonauthor=H.+Lindmarkauthor=L.+%C3%96ster&title=Discovery+of+Triazole+Aminopyrazines+as+a+Highly+Potent+and+Selective+Series+of+PI3K%CE%B4+Inhibitors&doi=10.1016%2Fj.bmcl.2016.11.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DTerstiege%26aufirst%3DI.%26aulast%3DPerry%26aufirst%3DM.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DTyrchan%26aufirst%3DC.%26aulast%3DSvensson%26aufirst%3DT.%26aulast%3DLindmark%26aufirst%3DH.%26aulast%3D%25C3%2596ster%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Triazole%2520Aminopyrazines%2520as%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Series%2520of%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D679%26epage%3D687%26doi%3D10.1016%2Fj.bmcl.2016.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">El-Sherbiny, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-baz, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yacoub, M. H.</span><span> </span><span class="NLM_article-title">Inhaled Nano- and Microparticles for Drug Delivery</span> <span class="citation_source-journal">Global Cardiol. Sci. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">2015</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="refDoi"> DOI: 10.5339/gcsp.2015.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.5339%2Fgcsp.2015.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=26779496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A280%3ADC%252BC28nhsFCqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=2&author=I.+M.+El-Sherbinyauthor=N.+M.+El-bazauthor=M.+H.+Yacoub&title=Inhaled+Nano-+and+Microparticles+for+Drug+Delivery&doi=10.5339%2Fgcsp.2015.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled nano- and microparticles for drug delivery</span></div><div class="casAuthors">El-Sherbiny Ibrahim M; El-Baz Nancy M; Yacoub Magdi H</div><div class="citationInfo"><span class="NLM_cas:title">Global cardiology science & practice</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2</span>
        ISSN:<span class="NLM_cas:issn">2305-7823</span>.
    </div><div class="casAbstract">The 21st century has seen a paradigm shift to inhaled therapy, for both systemic and local drug delivery, due to the lung's favourable properties of a large surface area and high permeability.  Pulmonary drug delivery possesses many advantages, including non-invasive route of administration, low metabolic activity, control environment for systemic absorption and avoids first bypass metabolism.  However, because the lung is one of the major ports of entry, it has multiple clearance mechanisms, which prevent foreign particles from entering the body.  Although these clearance mechanisms maintain the sterility of the lung, clearance mechanisms can also act as barriers to the therapeutic effectiveness of inhaled drugs.  This effectiveness is also influenced by the deposition site and delivered dose.  Particulate-based drug delivery systems have emerged as an innovative and promising alternative to conventional inhaled drugs to circumvent pulmonary clearance mechanisms and provide enhanced therapeutic efficiency and controlled drug release.  The principle of multiple pulmonary clearance mechanisms is reviewed, including mucociliary, alveolar macrophages, absorptive, and metabolic degradation.  This review also discusses the current approaches and formulations developed to achieve optimal pulmonary drug delivery systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTcht76K6iGeb6AVA-44PTfW6udTcc2eZSHMa4xuP1Frntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nhsFCqsA%253D%253D&md5=20681a9abfc8c759ff6655c6549bbc33</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.5339%2Fgcsp.2015.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5339%252Fgcsp.2015.2%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Sherbiny%26aufirst%3DI.%2BM.%26aulast%3DEl-baz%26aufirst%3DN.%2BM.%26aulast%3DYacoub%26aufirst%3DM.%2BH.%26atitle%3DInhaled%2520Nano-%2520and%2520Microparticles%2520for%2520Drug%2520Delivery%26jtitle%3DGlobal%2520Cardiol.%2520Sci.%2520Pract.%26date%3D2015%26volume%3D2015%26spage%3D2%26doi%3D10.5339%2Fgcsp.2015.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunder, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loewith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">A Pharmacological Map of the PI3-K Family Defines a Role for p110alpha in Insulin Signaling</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span><span class="refDoi"> DOI: 10.1016/j.cell.2006.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1016%2Fj.cell.2006.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=16647110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=733-747&author=Z.+A.+Knightauthor=B.+Gonzalezauthor=M.+E.+Feldmanauthor=E.+R.+Zunderauthor=D.+D.+Goldenbergauthor=O.+Williamsauthor=R.+Loewithauthor=D.+Stokoeauthor=A.+Ballaauthor=B.+Tothauthor=T.+Ballaauthor=W.+A.+Weissauthor=R.+L.+Williamsauthor=K.+M.+Shokat&title=A+Pharmacological+Map+of+the+PI3-K+Family+Defines+a+Role+for+p110alpha+in+Insulin+Signaling&doi=10.1016%2Fj.cell.2006.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling</span></div><div class="casAuthors">Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; Balla, Tamas; Weiss, William A.; Williams, Roger L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-747</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3-Ks) are an important emerging class of drug targets, but the unique roles of PI3-K isoforms remain poorly defined.  We describe here an approach to pharmacol. interrogate the PI3-K family.  A chem. diverse panel of PI3-K inhibitors was synthesized, and their target selectivity was biochem. enumerated, revealing cryptic homologies across targets and chemotypes.  Crystal structures of three inhibitors bound to p110γ identify a conformationally mobile region that is uniquely exploited by selective compds.  This chem. array was then used to define the PI3-K isoforms required for insulin signaling.  We find that p110α is the primary insulin-responsive PI3-K in cultured cells, whereas p110β is dispensable but sets a phenotypic threshold for p110α activity.  Compds. targeting p110α block the acute effects of insulin treatment in vivo, whereas a p110β inhibitor has no effect.  These results illustrate systematic target validation using a matrix of inhibitors that span a protein family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrozjvOeMXP3bVg90H21EOLACvtfcHk0ljDDRTg-hA7Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D&md5=b95a8cb433927ff9a75b33fc4ac2c8a0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DZunder%26aufirst%3DE.%2BR.%26aulast%3DGoldenberg%26aufirst%3DD.%2BD.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DBalla%26aufirst%3DA.%26aulast%3DToth%26aufirst%3DB.%26aulast%3DBalla%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DA%2520Pharmacological%2520Map%2520of%2520the%2520PI3-K%2520Family%2520Defines%2520a%2520Role%2520for%2520p110alpha%2520in%2520Insulin%2520Signaling%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D733%26epage%3D747%26doi%3D10.1016%2Fj.cell.2006.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisconte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaney, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chantry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castanedo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knowles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondru, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadin, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safina, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staben, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seward, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, Z. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waszkowycz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span> </span><span class="NLM_article-title">Potent and Selective Inhibitors of PI3Kδ: Obtaining Isoform Selectivity from the Affinity Pocket and Tryptophan Shelf</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4296</span><span class="NLM_x">–</span> <span class="NLM_lpage">4302</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1016%2Fj.bmcl.2012.05.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=22672799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVegur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4296-4302&author=D.+P.+Sutherlinauthor=S.+Bakerauthor=A.+Bisconteauthor=P.+M.+Blaneyauthor=A.+Brownauthor=B.+K.+Chanauthor=D.+Chantryauthor=G.+Castanedoauthor=P.+Depledgeauthor=P.+Goldsmithauthor=D.+M.+Goldsteinauthor=T.+Hancoxauthor=J.+Kaurauthor=D.+Knowlesauthor=R.+Kondruauthor=J.+Lesnickauthor=M.+C.+Lucasauthor=C.+Lewisauthor=J.+Murrayauthor=A.+J.+Nadinauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=S.+Priceauthor=K.+Reifauthor=B.+S.+Safinaauthor=L.+Salphatiauthor=S.+Stabenauthor=E.+M.+Sewardauthor=S.+Shuttleworthauthor=S.+Sohalauthor=Z.+K.+Sweeneyauthor=M.+Ultschauthor=B.+Waszkowyczauthor=B.+Wei&title=Potent+and+Selective+Inhibitors+of+PI3K%CE%B4%3A+Obtaining+Isoform+Selectivity+from+the+Affinity+Pocket+and+Tryptophan+Shelf&doi=10.1016%2Fj.bmcl.2012.05.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibitors of PI3Kδ: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf</span></div><div class="casAuthors">Sutherlin, Daniel P.; Baker, Stewart; Bisconte, Angelina; Blaney, Paul M.; Brown, Anthony; Chan, Bryan K.; Chantry, David; Castanedo, Georgette; DePledge, Paul; Goldsmith, Paul; Goldstein, David M.; Hancox, Timothy; Kaur, Jasmit; Knowles, David; Kondru, Rama; Lesnick, John; Lucas, Matthew C.; Lewis, Cristina; Murray, Jeremy; Nadin, Alan J.; Nonomiya, Jim; Pang, Jodie; Pegg, Neil; Price, Steve; Reif, Karin; Safina, Brian S.; Salphati, Laurent; Staben, Steven; Seward, Eileen M.; Shuttleworth, Stephen; Sohal, Sukhjit; Sweeney, Zachary K.; Ultsch, Mark; Waszkowycz, Bohdan; Wei, Binqing</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4296-4302</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A potent inhibitor of PI3Kδ that is ≥200 fold selective for the remaining three Class I PI3K isoforms and addnl. kinases is described.  The hypothesis for selectivity is illustrated through structure activity relationships and crystal structures of compds. bound to a K802T mutant of PI3Kγ.  Pharmacokinetic data in rats and mice support the use of 3 as a useful tool compd. to use for in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaSfg4K5zqbLVg90H21EOLACvtfcHk0liq92E85rfL-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVegur0%253D&md5=d15c7cd8ce626cc5e9a13ac355557ce8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBaker%26aufirst%3DS.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DBlaney%26aufirst%3DP.%2BM.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChantry%26aufirst%3DD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DHancox%26aufirst%3DT.%26aulast%3DKaur%26aufirst%3DJ.%26aulast%3DKnowles%26aufirst%3DD.%26aulast%3DKondru%26aufirst%3DR.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNadin%26aufirst%3DA.%2BJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DStaben%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DB.%26atitle%3DPotent%2520and%2520Selective%2520Inhibitors%2520of%2520PI3K%25CE%25B4%253A%2520Obtaining%2520Isoform%2520Selectivity%2520from%2520the%2520Affinity%2520Pocket%2520and%2520Tryptophan%2520Shelf%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4296%26epage%3D4302%26doi%3D10.1016%2Fj.bmcl.2012.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Sadhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masinovsky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowell, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staunton, D. E.</span><span> </span><span class="NLM_article-title">Essential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">170</span><span class="NLM_x">, </span> <span class="NLM_fpage">2647</span><span class="NLM_x">–</span> <span class="NLM_lpage">2654</span><span class="refDoi"> DOI: 10.4049/jimmunol.170.5.2647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.4049%2Fjimmunol.170.5.2647" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2003&pages=2647-2654&author=C.+Sadhuauthor=B.+Masinovskyauthor=K.+Dickauthor=C.+G.+Sowellauthor=D.+E.+Staunton&title=Essential+Role+of+Phosphoinositide+3-Kinase+%CE%B4+in+Neutrophil+Directional+Movement&doi=10.4049%2Fjimmunol.170.5.2647"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.170.5.2647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.170.5.2647%26sid%3Dliteratum%253Aachs%26aulast%3DSadhu%26aufirst%3DC.%26aulast%3DMasinovsky%26aufirst%3DB.%26aulast%3DDick%26aufirst%3DK.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DStaunton%26aufirst%3DD.%2BE.%26atitle%3DEssential%2520Role%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520in%2520Neutrophil%2520Directional%2520Movement%26jtitle%3DJ.%2520Immunol.%26date%3D2003%26volume%3D170%26spage%3D2647%26epage%3D2654%26doi%3D10.4049%2Fjimmunol.170.5.2647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Zhao, X.; Li, T.; Zhou, Z.; Chen, L.; Liu, Q.; Wang, X.; Yang, L.; Rong, Y.; Tan, R.; Yu, C.; Jiang, L.; Liu, Y.; Linghu, L.; Sun, J.; Wang, W.</span><span> </span><span class="NLM_article-title">Certain Protein Kinase Inhibitors</span>. WO2016066142 (A1),<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=X.+Zhao&author=T.+Li&author=Z.+Zhou&author=L.+Chen&author=Q.+Liu&author=X.+Wang&author=L.+Yang&author=Y.+Rong&author=R.+Tan&author=C.+Yu&author=L.+Jiang&author=Y.+Liu&author=L.+Linghu&author=J.+Sun&author=W.+Wang&title=Certain+Protein+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%26atitle%3DCertain%2520Protein%2520Kinase%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Emtenaes, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alderin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almqvist, F.</span><span> </span><span class="NLM_article-title">An Enantioselective Ketene-Imine Cycloaddition Method for Synthesis of Substituted Ring-Fused 2-Pyridinones</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">6756</span><span class="NLM_x">–</span> <span class="NLM_lpage">6761</span><span class="refDoi"> DOI: 10.1021/jo015794u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo015794u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2001&pages=6756-6761&author=H.+Emtenaesauthor=L.+Alderinauthor=F.+Almqvist&title=An+Enantioselective+Ketene-Imine+Cycloaddition+Method+for+Synthesis+of+Substituted+Ring-Fused+2-Pyridinones&doi=10.1021%2Fjo015794u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjo015794u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo015794u%26sid%3Dliteratum%253Aachs%26aulast%3DEmtenaes%26aufirst%3DH.%26aulast%3DAlderin%26aufirst%3DL.%26aulast%3DAlmqvist%26aufirst%3DF.%26atitle%3DAn%2520Enantioselective%2520Ketene-Imine%2520Cycloaddition%2520Method%2520for%2520Synthesis%2520of%2520Substituted%2520Ring-Fused%25202-Pyridinones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2001%26volume%3D66%26spage%3D6756%26epage%3D6761%26doi%3D10.1021%2Fjo015794u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Bengtsson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almqvist, F.</span><span> </span><span class="NLM_article-title">Regioselective Halogenations and Subsequent Suzuki-Miyaura Coupling onto Bicyclic 2-Pyridones</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">972</span><span class="NLM_x">–</span> <span class="NLM_lpage">975</span><span class="refDoi"> DOI: 10.1021/jo902458g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo902458g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=972-975&author=C.+Bengtssonauthor=F.+Almqvist&title=Regioselective+Halogenations+and+Subsequent+Suzuki-Miyaura+Coupling+onto+Bicyclic+2-Pyridones&doi=10.1021%2Fjo902458g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjo902458g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo902458g%26sid%3Dliteratum%253Aachs%26aulast%3DBengtsson%26aufirst%3DC.%26aulast%3DAlmqvist%26aufirst%3DF.%26atitle%3DRegioselective%2520Halogenations%2520and%2520Subsequent%2520Suzuki-Miyaura%2520Coupling%2520onto%2520Bicyclic%25202-Pyridones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2010%26volume%3D75%26spage%3D972%26epage%3D975%26doi%3D10.1021%2Fjo902458g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Hochhaus, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Möllmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derendorf, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Rothi, R. J.</span><span> </span><span class="NLM_article-title">Pharmacokinetic/pharmacodynamic Aspects of Aerosol Therapy Using Glucocorticoids as a Model</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">892</span><span class="refDoi"> DOI: 10.1002/j.1552-4604.1997.tb04262.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1002%2Fj.1552-4604.1997.tb04262.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=9505979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADyaK2sXnsVyjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1997&pages=881-892&author=G.+Hochhausauthor=H.+M%C3%B6llmannauthor=H.+Derendorfauthor=R.+J.+Gonzalez-Rothi&title=Pharmacokinetic%2Fpharmacodynamic+Aspects+of+Aerosol+Therapy+Using+Glucocorticoids+as+a+Model&doi=10.1002%2Fj.1552-4604.1997.tb04262.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model</span></div><div class="casAuthors">Hochhaus, Gunther; Mollmann, Helmut; Derendorf, Hartmut; Gonzalez-Rothi, Ricardo J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">881-892</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">Glucocorticoids are predominantly prescribed in asthma therapy as aerosols to achieve high pulmonary effects with reduced systemic spill-over and pronounced pulmonary selectivity.  A variety of pharmacokinetic parameters are potentially important for detg. pulmonary selectivity.  The intent of this article, is to provide a practice-relevant theor. approach to put the importance of these parameters on pulmonary targeting using pharmacokinetic/pharmacodynamic modeling as a tool in perspective.  The applied pulmonary pharmacokinetic/pharmacodynamic model revealed that, in addn. to recognized parameters such as systemic clearance, oral bioavailability, and efficiency of pulmonary deposition, other factors, such as the pulmonary release (dissoln.) rate and dose, are relevant.  However, the vol. of distribution (for effect parameters not undergoing a diurnal rhythm) and the receptor affinity of a given glucocorticoid are not important for achieving lung targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGMJqOuRqbwLVg90H21EOLACvtfcHk0li0gzO1xEQacA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnsVyjs7g%253D&md5=7877c4f469db937ac7a3aebd7b2b6c3b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fj.1552-4604.1997.tb04262.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1552-4604.1997.tb04262.x%26sid%3Dliteratum%253Aachs%26aulast%3DHochhaus%26aufirst%3DG.%26aulast%3DM%25C3%25B6llmann%26aufirst%3DH.%26aulast%3DDerendorf%26aufirst%3DH.%26aulast%3DGonzalez-Rothi%26aufirst%3DR.%2BJ.%26atitle%3DPharmacokinetic%252Fpharmacodynamic%2520Aspects%2520of%2520Aerosol%2520Therapy%2520Using%2520Glucocorticoids%2520as%2520a%2520Model%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D1997%26volume%3D37%26spage%3D881%26epage%3D892%26doi%3D10.1002%2Fj.1552-4604.1997.tb04262.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Hochhaus, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Rothi, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukyanov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derendorf, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalla Costa, T.</span><span> </span><span class="NLM_article-title">Assessment of Glucocorticoid Lung Targeting by Ex-Vivo Receptor Binding Studies in Rats</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span><span class="refDoi"> DOI: 10.1023/A:1016259225244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1023%2FA%3A1016259225244" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1995&pages=134-137&author=G.+Hochhausauthor=R.+J.+Gonzalez-Rothiauthor=A.+Lukyanovauthor=H.+Derendorfauthor=H.+Schreierauthor=T.+Dalla+Costa&title=Assessment+of+Glucocorticoid+Lung+Targeting+by+Ex-Vivo+Receptor+Binding+Studies+in+Rats&doi=10.1023%2FA%3A1016259225244"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1023%2FA%3A1016259225244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1016259225244%26sid%3Dliteratum%253Aachs%26aulast%3DHochhaus%26aufirst%3DG.%26aulast%3DGonzalez-Rothi%26aufirst%3DR.%2BJ.%26aulast%3DLukyanov%26aufirst%3DA.%26aulast%3DDerendorf%26aufirst%3DH.%26aulast%3DSchreier%26aufirst%3DH.%26aulast%3DDalla%2BCosta%26aufirst%3DT.%26atitle%3DAssessment%2520of%2520Glucocorticoid%2520Lung%2520Targeting%2520by%2520Ex-Vivo%2520Receptor%2520Binding%2520Studies%2520in%2520Rats%26jtitle%3DPharm.%2520Res.%26date%3D1995%26volume%3D12%26spage%3D134%26epage%3D137%26doi%3D10.1023%2FA%3A1016259225244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Cooper, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grime, K.</span><span> </span><span class="NLM_article-title">Optimisation of DMPK by the Inhaled Route. Challenges Approaches</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">457</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span><span class="refDoi"> DOI: 10.2174/138920012800166571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.2174%2F138920012800166571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=22299825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=457-473&author=A.+E.+Cooperauthor=D.+Fergusonauthor=K.+Grime&title=Optimisation+of+DMPK+by+the+Inhaled+Route.+Challenges+Approaches&doi=10.2174%2F138920012800166571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Optimisation of DMPK by the inhaled route: challenges and approaches</span></div><div class="casAuthors">Cooper, Anne E.; Ferguson, Douglas; Grime, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-473</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The renewed interest in inhalation delivery over recent years has led to an expansion in the understanding of lung pharmacokinetics.  Historically optimization of inhaled drugs focused largely on development of material properties, consistent with achieving a good lung deposition, alongside demonstrating appropriate in vivo efficacy with little understanding of the relationship to pharmacokinetics in the lung.  Recent efforts have led to an increased understanding of lung concns. and how to maximize exposure to achieve the desired pharmacol. response at a dose consistent with development of an inhaled product.  Although there is a prerequisite for excellent potency in inhalation delivery, it is essential that this be combined with pharmacokinetic properties that allow sufficient free concn. at the effect site in lung to exert the pharmacol. response for an appropriate dosing interval.  Increases in basicity, polarity and/or decreases in aq. soly. can extend pharmacokinetic duration and assist in finding the right balance between lung and systemic exposure.  Current evidence suggests there are similarities in lung retention in rat and dog and that animal lung concn. data can enable pharmacokinetic-pharmacodynamic relationships to be derived thus providing more confidence in the requirements for man.  Although inhaled delivery is challenging from a pharmacokinetic point of view, direct evaluation of exposure in the target organ has enabled further understanding of the drivers for drug disposition and highlighted the need for further development of predictive lung pharmacokinetic tools in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxztkVtHyCeLVg90H21EOLACvtfcHk0li0gzO1xEQacA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D&md5=1dec4f52aeda55fe6ea888c289216d94</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F138920012800166571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012800166571%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DA.%2BE.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DGrime%26aufirst%3DK.%26atitle%3DOptimisation%2520of%2520DMPK%2520by%2520the%2520Inhaled%2520Route.%2520Challenges%2520Approaches%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D457%26epage%3D473%26doi%3D10.2174%2F138920012800166571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Austin, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnert, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cage, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheshire, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougall, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ince, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, A.</span><span> </span><span class="NLM_article-title">QSAR and the Rational Design of Long-Acting Dual D 2 -Receptor/2 -Adrenoceptor Agonists Approach to Compound Design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3210</span><span class="NLM_x">–</span> <span class="NLM_lpage">3220</span><span class="refDoi"> DOI: 10.1021/jm020886c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020886c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3210-3220&author=R.+P.+Austinauthor=P.+Bartonauthor=R.+V.+Bonnertauthor=R.+C.+Brownauthor=P.+A.+Cageauthor=D.+R.+Cheshireauthor=A.+M.+Davisauthor=I.+G.+Dougallauthor=F.+Inceauthor=G.+Pairaudeauauthor=A.+Young&title=QSAR+and+the+Rational+Design+of+Long-Acting+Dual+D+2+-Receptor%2F2+-Adrenoceptor+Agonists+Approach+to+Compound+Design&doi=10.1021%2Fjm020886c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm020886c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020886c%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%26aufirst%3DR.%2BP.%26aulast%3DBarton%26aufirst%3DP.%26aulast%3DBonnert%26aufirst%3DR.%2BV.%26aulast%3DBrown%26aufirst%3DR.%2BC.%26aulast%3DCage%26aufirst%3DP.%2BA.%26aulast%3DCheshire%26aufirst%3DD.%2BR.%26aulast%3DDavis%26aufirst%3DA.%2BM.%26aulast%3DDougall%26aufirst%3DI.%2BG.%26aulast%3DInce%26aufirst%3DF.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DYoung%26aufirst%3DA.%26atitle%3DQSAR%2520and%2520the%2520Rational%2520Design%2520of%2520Long-Acting%2520Dual%2520D%25202%2520-Receptor%252F2%2520-Adrenoceptor%2520Agonists%2520Approach%2520to%2520Compound%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3210%26epage%3D3220%26doi%3D10.1021%2Fjm020886c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Connolly, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcaraz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadogan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphries, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingall, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocks, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, A.</span><span> </span><span class="NLM_article-title">Design-Driven LO: The Discovery of New Ultra Long Acting Dibasic β2-Adrenoceptor Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4612</span><span class="NLM_x">–</span> <span class="NLM_lpage">4616</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.05.097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1016%2Fj.bmcl.2011.05.097" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4612-4616&author=S.+Connollyauthor=L.+Alcarazauthor=A.+Baileyauthor=E.+Cadoganauthor=J.+Christieauthor=A.+R.+Cookauthor=A.+J.+Fisherauthor=S.+Hillauthor=A.+Humphriesauthor=A.+H.+Ingallauthor=Z.+Kaneauthor=S.+Paineauthor=G.+Pairaudeauauthor=M.+J.+Stocksauthor=A.+Young&title=Design-Driven+LO%3A+The+Discovery+of+New+Ultra+Long+Acting+Dibasic+%CE%B22-Adrenoceptor+Agonists&doi=10.1016%2Fj.bmcl.2011.05.097"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.05.097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.05.097%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DS.%26aulast%3DAlcaraz%26aufirst%3DL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DCadogan%26aufirst%3DE.%26aulast%3DChristie%26aufirst%3DJ.%26aulast%3DCook%26aufirst%3DA.%2BR.%26aulast%3DFisher%26aufirst%3DA.%2BJ.%26aulast%3DHill%26aufirst%3DS.%26aulast%3DHumphries%26aufirst%3DA.%26aulast%3DIngall%26aufirst%3DA.%2BH.%26aulast%3DKane%26aufirst%3DZ.%26aulast%3DPaine%26aufirst%3DS.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26aulast%3DYoung%26aufirst%3DA.%26atitle%3DDesign-Driven%2520LO%253A%2520The%2520Discovery%2520of%2520New%2520Ultra%2520Long%2520Acting%2520Dibasic%2520%25CE%25B22-Adrenoceptor%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4612%26epage%3D4616%26doi%3D10.1016%2Fj.bmcl.2011.05.097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Mindell, J. A.</span><span> </span><span class="NLM_article-title">Lysosomal Acidification Mechanisms</span> <span class="citation_source-journal">Annu. Rev. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span><span class="refDoi"> DOI: 10.1146/annurev-physiol-012110-142317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1146%2Fannurev-physiol-012110-142317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=22335796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC38XjvFynsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2012&pages=69-86&author=J.+A.+Mindell&title=Lysosomal+Acidification+Mechanisms&doi=10.1146%2Fannurev-physiol-012110-142317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal acidification mechanisms</span></div><div class="casAuthors">Mindell, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Physiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-86</span>CODEN:
                <span class="NLM_cas:coden">ARPHAD</span>;
        ISSN:<span class="NLM_cas:issn">0066-4278</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Lysosomes, the terminal organelles on the endocytic pathway, digest macromols. and make their components available to the cell as nutrients.  Hydrolytic enzymes specific to a wide range of targets reside within the lysosome; these enzymes are activated by the highly acidic pH (between 4.5 and 5.0) in the organelles' interior.  Lysosomes generate and maintain their pH gradients by using the activity of a proton-pumping V-type ATPase, which uses metabolic energy in the form of ATP to pump protons into the lysosome lumen.  Because this activity separates elec. charge and generates a transmembrane voltage, another ion must move to dissipate this voltage for net pumping to occur.  This so-called counterion may be either a cation (moving out of the lysosome) or an anion (moving into the lysosome).  Recent data support the involvement of ClC-7, a Cl-/H+ antiporter, in this process, although many open questions remain as to this transporter's involvement.  Although functional results also point to a cation transporter, its mol. identity remains uncertain.  Both the V-ATPase and the counterion transporter are likely to be important players in the mechanisms detg. the steady-state pH of the lysosome interior.  Exciting new results suggest that lysosomal pH may be dynamically regulated in some cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhQ7yyHPp6nrVg90H21EOLACvtfcHk0lgBkJ05FLQaAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjvFynsbo%253D&md5=c9a157aa4b4c9c432ee4e26e4d3bdd13</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1146%2Fannurev-physiol-012110-142317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-physiol-012110-142317%26sid%3Dliteratum%253Aachs%26aulast%3DMindell%26aufirst%3DJ.%2BA.%26atitle%3DLysosomal%2520Acidification%2520Mechanisms%26jtitle%3DAnnu.%2520Rev.%2520Physiol.%26date%3D2012%26volume%3D74%26spage%3D69%26epage%3D86%26doi%3D10.1146%2Fannurev-physiol-012110-142317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Barnden, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allison, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heath, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbone, F. R.</span><span> </span><span class="NLM_article-title">Defective TCR Expression in Transgenic Mice Constructed Using cDNA-Based Alpha- and Bold Beta-Chain Genes under the Control of Heterologous Regulatory Elements</span> <span class="citation_source-journal">Immunol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span><span class="refDoi"> DOI: 10.1046/j.1440-1711.1998.00709.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1046%2Fj.1440-1711.1998.00709.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=9553774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADyaK1cXisFegtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1998&pages=34-40&author=M.+J.+Barndenauthor=J.+Allisonauthor=W.+R.+Heathauthor=F.+R.+Carbone&title=Defective+TCR+Expression+in+Transgenic+Mice+Constructed+Using+cDNA-Based+Alpha-+and+Bold+Beta-Chain+Genes+under+the+Control+of+Heterologous+Regulatory+Elements&doi=10.1046%2Fj.1440-1711.1998.00709.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Defective TCR expression in transgenic mice constructed using cDNA-based α- and β-chain genes under the control of heterologous regulatory elements</span></div><div class="casAuthors">Barnden, Megan J.; Allison, Jan; Heath, William R.; Carbone, Francis R.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology and Cell Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-40</span>CODEN:
                <span class="NLM_cas:coden">ICBIEZ</span>;
        ISSN:<span class="NLM_cas:issn">0818-9641</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Pty Ltd.</span>)
        </div><div class="casAbstract">The authors describe the generation of ovalbumin (OVA)-specific, MHC class II-restricted αβ T cell receptor (TCR) transgenic mice.  Initial attempts at generating these transgenic mice utilized heterologous regulatory elements to drive the expression of cDNA genes encoding the sep. α- and β-chains of the TCR.  Unexpectedly, T cells bearing the transgenic αβ TCR failed to emerge from the thymus in these mice, although the transgenes did modify endogenous TCR expression.  However, subsequent modification of the approach which enabled expression of the TCR β-chain under the control of its natural regulatory elements generated mice whose peripheral T cells expressed the transgenic TCR and were capable of antigen-dependent proliferation.  These results show that successful generation of MHC class II-restricted, OVA-specific αβTCR transgenic mice was dependent upon combining cDNA- and genomic DNA-based constructs for expression of the resp. α- and β-chains of the TCR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCdFTEhiZIWrVg90H21EOLACvtfcHk0liBWEGd3gpIiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisFegtLo%253D&md5=9f74696f328a6268d0e863f85039cdea</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1046%2Fj.1440-1711.1998.00709.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1440-1711.1998.00709.x%26sid%3Dliteratum%253Aachs%26aulast%3DBarnden%26aufirst%3DM.%2BJ.%26aulast%3DAllison%26aufirst%3DJ.%26aulast%3DHeath%26aufirst%3DW.%2BR.%26aulast%3DCarbone%26aufirst%3DF.%2BR.%26atitle%3DDefective%2520TCR%2520Expression%2520in%2520Transgenic%2520Mice%2520Constructed%2520Using%2520cDNA-Based%2520Alpha-%2520and%2520Bold%2520Beta-Chain%2520Genes%2520under%2520the%2520Control%2520of%2520Heterologous%2520Regulatory%2520Elements%26jtitle%3DImmunol.%2520Cell%2520Biol.%26date%3D1998%26volume%3D76%26spage%3D34%26epage%3D40%26doi%3D10.1046%2Fj.1440-1711.1998.00709.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Meyuhas, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreazen, A.</span><span> </span><span class="NLM_article-title">Chapter 3 Ribosomal Protein S6 Kinase: From TOP mRNAs to Cell Size</span> <span class="citation_source-journal">Prog. Mol. Biol. Transl. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">153</span><span class="refDoi"> DOI: 10.1016/S1877-1173(09)90003-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1016%2FS1877-1173%2809%2990003-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=20374740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVajtLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2009&pages=109-153&author=O.+Meyuhasauthor=A.+Dreazen&title=Chapter+3+Ribosomal+Protein+S6+Kinase%3A+From+TOP+mRNAs+to+Cell+Size&doi=10.1016%2FS1877-1173%2809%2990003-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Ribosomal protein S6 kinase: from TOP mRNAs to cell size</span></div><div class="casAuthors">Meyuhas, Oded; Dreazen, Avigail</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Molecular Biology and Translational Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">Translational Control in Health and Disease</span>),
    <span class="NLM_cas:pages">109-153</span>CODEN:
                <span class="NLM_cas:coden">PNARC5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Ribosomal protein S6 kinase (S6K) has been implicated in the phosphorylation of multiple substrates and is subject to activation by a wide variety of signals that converge at mammalian target of rapamycin (mTOR).  In the course of the search for its physiol. role, it was proposed that S6K activation and ribosomal protein S6 (rpS6) phosphorylation account for the translational activation of a subgroup of transcripts, the TOP mRNAs.  The structural hallmark of these mRNAs is an oligopyrimidine tract at their 5'-terminus, known as the 5'-TOP motif.  TOP mRNAs consists of about 90 members that encode multiple components of the translational machinery, such as ribosomal proteins and translation factors.  The translation efficiency of TOP mRNAs indeed correlates with S6K activation and rpS6 phosphorylation, yet recent biochem. and genetic studies have established that, although S6K and TOP mRNAs respond to similar signals and are regulated by mTOR, they maintain no cause and effect relationship.  Instead, S6K is primarily involved in regulation of cell size, and affects glucose homeostasis, but is dispensable for global protein synthesis, whereas translational efficiency of TOP mRNAs is a determinant of the cellular protein synthesis capacity.  Despite extensive studies of their function and mode of regulation, the mechanism underlying the effect of S6K on the cell size, as well as the transacting factor that mediates the translational control of TOP mRNAs, still await their identification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOFXDdrdGxhrVg90H21EOLACvtfcHk0liBWEGd3gpIiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVajtLnJ&md5=9c08dffbb1f38d407426dd6591f63633</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS1877-1173%2809%2990003-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1877-1173%252809%252990003-5%26sid%3Dliteratum%253Aachs%26aulast%3DMeyuhas%26aufirst%3DO.%26aulast%3DDreazen%26aufirst%3DA.%26atitle%3DChapter%25203%2520Ribosomal%2520Protein%2520S6%2520Kinase%253A%2520From%2520TOP%2520mRNAs%2520to%2520Cell%2520Size%26jtitle%3DProg.%2520Mol.%2520Biol.%2520Transl.%2520Sci.%26date%3D2009%26volume%3D90%26spage%3D109%26epage%3D153%26doi%3D10.1016%2FS1877-1173%2809%2990003-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Beger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöde, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, J.</span><span> </span><span class="NLM_article-title">Dreikomponentenreaktionen. II. Nucleophile Substitutionen an N-(β-Haloalkyl)-Imidhalogeniden die Darstellung von Δ 2 -Oxazolinen, Δ 2 -Thiazolinen und Δ 2 -Imidazolinen</span> <span class="citation_source-journal">J. Prakt. Chem. (Leipzig)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1969</span><span class="NLM_x">, </span> <span class="NLM_volume">311</span><span class="NLM_x">, </span> <span class="NLM_fpage">408</span><span class="NLM_x">–</span> <span class="NLM_lpage">419</span><span class="refDoi"> DOI: 10.1002/prac.19693110310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1002%2Fprac.19693110310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADyaF1MXktlyrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=1969&pages=408-419&author=J.+Begerauthor=D.+Sch%C3%B6deauthor=J.+Vogel&title=Dreikomponentenreaktionen.+II.+Nucleophile+Substitutionen+an+N-%28%CE%B2-Haloalkyl%29-Imidhalogeniden+die+Darstellung+von+%CE%94+2+-Oxazolinen%2C+%CE%94+2+-Thiazolinen+und+%CE%94+2+-Imidazolinen&doi=10.1002%2Fprac.19693110310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Three component reactions.  II.  Nucleophilic substitutions in N-(β-haloalkyl)imidoyl halides.  Preparation of Δ2-oxazolines, Δ2-thiazolines, and Δ2-imidazolines</span></div><div class="casAuthors">Beger, Joerg; Schoede, D.; Vogel, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Journal fuer Praktische Chemie (Leipzig)</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">408-19</span>CODEN:
                <span class="NLM_cas:coden">JPCEAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-8383</span>.
    </div><div class="casAbstract">R1XCHCR2R3N:CXR (I) (R, R1, and R2 = H or alkyl, X = halogen) were prepd. from R1CH:CR2R3, X, and RCN.  I treated with H2O, H2S, or NH2R4 (R4 = H or alkyl) in alk. media gave 5-(R1-substituted)-4-(R2-substituted)-4-(R3-substituted)-2-(R-substituted)-2-oxazolines  (I), 5-(R1-substituted)-4-(R2-substituted)-4-(R3-substituted)-2-(R-substituted)-2-thiazolines (II), and 5-(R1-substituted)-4-(R2-substituted)-4-(R3-substituted)-1-(R4-substituted)-2-(R-substituted)-2-imidazolines (III).  The reaction steps were stereospecific.  When Δ1-olefins were used, 5-10% 5-substituted-Δ2-azolines (anti-Markovnikov addn.) were obtained besides the 4-substituted-Δ2-azolines (Markovnikov addn.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMTFe8ze2ov7Vg90H21EOLACvtfcHk0liBWEGd3gpIiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXktlyrtL8%253D&md5=832d6596055140d2d87c7c20395ad191</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fprac.19693110310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprac.19693110310%26sid%3Dliteratum%253Aachs%26aulast%3DBeger%26aufirst%3DJ.%26aulast%3DSch%25C3%25B6de%26aufirst%3DD.%26aulast%3DVogel%26aufirst%3DJ.%26atitle%3DDreikomponentenreaktionen.%2520II.%2520Nucleophile%2520Substitutionen%2520an%2520N-%2528%25CE%25B2-Haloalkyl%2529-Imidhalogeniden%2520die%2520Darstellung%2520von%2520%25CE%2594%25202%2520-Oxazolinen%252C%2520%25CE%2594%25202%2520-Thiazolinen%2520und%2520%25CE%2594%25202%2520-Imidazolinen%26jtitle%3DJ.%2520Prakt.%2520Chem.%2520%2528Leipzig%2529%26date%3D1969%26volume%3D311%26spage%3D408%26epage%3D419%26doi%3D10.1002%2Fprac.19693110310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahman Parvizi, R. C.</span><span> </span><span class="NLM_article-title">Heterocyclic Studies. Part XXXXIX. Ring Cleavage of Some Pyrimidine Derivatives in Alkalai</span> <span class="citation_source-journal">J. Chem. Soc., Perkin Trans. 1 (1972-1999)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1004</span><span class="NLM_x">–</span> <span class="NLM_lpage">1007</span><span class="refDoi"> DOI: 10.1039/p19760001004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1039%2Fp19760001004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1976&pages=1004-1007&author=J.+Clarkauthor=R.+C.+Bahman+Parvizi&title=Heterocyclic+Studies.+Part+XXXXIX.+Ring+Cleavage+of+Some+Pyrimidine+Derivatives+in+Alkalai&doi=10.1039%2Fp19760001004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1039%2Fp19760001004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fp19760001004%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DBahman%2BParvizi%26aufirst%3DR.%2BC.%26atitle%3DHeterocyclic%2520Studies.%2520Part%2520XXXXIX.%2520Ring%2520Cleavage%2520of%2520Some%2520Pyrimidine%2520Derivatives%2520in%2520Alkalai%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%2520%25281972-1999%2529%26date%3D1976%26volume%3D9%26spage%3D1004%26epage%3D1007%26doi%3D10.1039%2Fp19760001004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Bruno, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tudge, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Design and Preparation of New Palladium Precatalysts for C-C and C-N Cross-Coupling Reactions</span> <span class="citation_source-journal">Chem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">916</span><span class="NLM_x">–</span> <span class="NLM_lpage">920</span><span class="refDoi"> DOI: 10.1039/C2SC20903A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1039%2FC2SC20903A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=23667737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFKjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=916-920&author=N.+C.+Brunoauthor=M.+T.+Tudgeauthor=S.+L.+Buchwald&title=Design+and+Preparation+of+New+Palladium+Precatalysts+for+C-C+and+C-N+Cross-Coupling+Reactions&doi=10.1039%2FC2SC20903A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Design and preparation of new palladium precatalysts for C-C and C-N cross-coupling reactions</span></div><div class="casAuthors">Bruno, Nicholas C.; Tudge, Matthew T.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">916-920</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of easily prepd., phosphine-ligated palladium precatalysts based on the 2-aminobiphenyl scaffold have been prepd.  The role of the precatalyst-assocd. labile halide (or pseudohalide) in the formation and stability of the palladacycle has been examd.  It was found that replacing the chloride in the previous version of the precatalyst with a mesylate leads to a new class of precatalysts with improved soln. stability and that are readily prepd. from a wider range of phosphine ligands.  The differences between the previous version of precatalyst and that reported here are explored.  In addn., the reactivity of the latter is examd. in a range of C-C and C-N bond forming reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfHp6oyg4k_bVg90H21EOLACvtfcHk0liMrKVpflzXyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFKjtr0%253D&md5=5b50ac18cb67251e5439199c6746dba8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1039%2FC2SC20903A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2SC20903A%26sid%3Dliteratum%253Aachs%26aulast%3DBruno%26aufirst%3DN.%2BC.%26aulast%3DTudge%26aufirst%3DM.%2BT.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DDesign%2520and%2520Preparation%2520of%2520New%2520Palladium%2520Precatalysts%2520for%2520C-C%2520and%2520C-N%2520Cross-Coupling%2520Reactions%26jtitle%3DChem.%2520Sci.%26date%3D2013%26volume%3D4%26spage%3D916%26epage%3D920%26doi%3D10.1039%2FC2SC20903A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Callahan, J. F.; Li, Tindy; Wan, Zehong; Yan, H.</span><span> </span><span class="NLM_article-title">Preparation of Pyrazolo[3,4-<i>b</i>]pyridine Dual Pharmacophores as PDE4-Muscarinic Antagonists</span>. WO2009100169,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+F.+Callahan&author=Tindy+Li&author=Zehong+Wan&author=H.+Yan&title=Preparation+of+Pyrazolo%5B3%2C4-b%5Dpyridine+Dual+Pharmacophores+as+PDE4-Muscarinic+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCallahan%26aufirst%3DJ.%2BF.%26atitle%3DPreparation%2520of%2520Pyrazolo%255B3%252C4-b%255Dpyridine%2520Dual%2520Pharmacophores%2520as%2520PDE4-Muscarinic%2520Antagonists%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Bäckström, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundqvist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammarlund-Udenaes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridén, M.</span><span> </span><span class="NLM_article-title">Lung Retention by Lysosomal Trapping of Inhaled Drugs Can Be Predicted In Vitro With Lung Slices</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">3432</span><span class="NLM_x">–</span> <span class="NLM_lpage">3439</span><span class="refDoi"> DOI: 10.1016/j.xphs.2016.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1016%2Fj.xphs.2016.08.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2016&pages=3432-3439&author=E.+B%C3%A4ckstr%C3%B6mauthor=E.+Bogerauthor=A.+Lundqvistauthor=M.+Hammarlund-Udenaesauthor=M.+Frid%C3%A9n&title=Lung+Retention+by+Lysosomal+Trapping+of+Inhaled+Drugs+Can+Be+Predicted+In+Vitro+With+Lung+Slices&doi=10.1016%2Fj.xphs.2016.08.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.xphs.2016.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.xphs.2016.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A4ckstr%25C3%25B6m%26aufirst%3DE.%26aulast%3DBoger%26aufirst%3DE.%26aulast%3DLundqvist%26aufirst%3DA.%26aulast%3DHammarlund-Udenaes%26aufirst%3DM.%26aulast%3DFrid%25C3%25A9n%26aufirst%3DM.%26atitle%3DLung%2520Retention%2520by%2520Lysosomal%2520Trapping%2520of%2520Inhaled%2520Drugs%2520Can%2520Be%2520Predicted%2520In%2520Vitro%2520With%2520Lung%2520Slices%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2016%26volume%3D105%26spage%3D3432%26epage%3D3439%26doi%3D10.1016%2Fj.xphs.2016.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 12 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Matthew W. D. Perry, Karin Björhall, Peter Bold, Mikael Brűlls, Ulf Börjesson, Johan Carlsson, Hui-Fang Amy Chang, Yunhua Chen, Anders Eriksson, Britt-Marie Fihn, Rebecca Fransson, Linda Fredlund, Hongbin Ge, Haijuan Huang, Kostas Karabelas, Eva Lamm Bergström, Sarah Lever, Helena Lindmark, Mickael Mogemark, Antonios Nikitidis, Anna-Pia Palmgren, Nils Pemberton, Jens Petersen, Mio Rodrigo Blomqvist, Reed W. Smith, Matthew J. Thomas, Victoria Ullah, Christian Tyrchan, Tiiu Wennberg, Annika Westin Eriksson, Wenzhen Yang, Shuchun Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Linda Öster</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8053-8075. <a href="https://doi.org/10.1021/acs.jmedchem.1c00434" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00434</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00434%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BAZD8154%25252C%252Ba%252BDual%252BPI3K%2525CE%2525B3%2525CE%2525B4%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BAsthma%26aulast%3DPerry%26aufirst%3DMatthew%2BW.%2BD.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D10032021%26date%3D03062021%26volume%3D64%26issue%3D12%26spage%3D8053%26epage%3D8075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joey L. Methot, Hua Zhou, Meredeth A. McGowan, Neville John Anthony, Matthew Christopher, Yudith Garcia, Abdelghani Achab, Kathryn Lipford, Benjamin Wesley Trotter, Michael D. Altman, Xavier Fradera, Charles A. Lesburg, Chaomin Li, Stephen Alves, Craig P. Chappell, Renu Jain, Ruban Mangado, Elaine Pinheiro, Sybill M. G. Williams, Peter Goldenblatt, Armetta Hill, Lynsey Shaffer, Dapeng Chen, Vincent Tong, Robbie L. McLeod, Hyun-Hee Lee, Hongshi Yu, Sanjiv Shah, <span class="NLM_string-name hlFld-ContribAuthor">Jason D. Katz</span>. </span><span class="cited-content_cbyCitation_article-title">Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 5137-5156. <a href="https://doi.org/10.1021/acs.jmedchem.1c00237" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00237</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00237%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProjected%252BDose%252BOptimization%252Bof%252BAmino-%252Band%252BHydroxypyrrolidine%252BPurine%252BPI3K%2525CE%2525B4%252BImmunomodulators%26aulast%3DMethot%26aufirst%3DJoey%2BL.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D06022021%26date%3D02042021%26volume%3D64%26issue%3D8%26spage%3D5137%26epage%3D5156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Feng Li, Xiaofei Liang, Zongru Jiang, Aoli Wang, Junjie Wang, Cheng Chen, Wenliang Wang, Fengming Zou, Ziping Qi, Qingwang Liu, Zhenquan Hu, Jiangyan Cao, Hong Wu, Beilei Wang, Li Wang, Jing Liu, <span class="NLM_string-name hlFld-ContribAuthor">Qingsong Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13973-13993. <a href="https://doi.org/10.1021/acs.jmedchem.0c01544" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01544</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01544%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528S%252529-2-%2525281-%2525284-Amino-3-%2525283-fluoro-4-methoxyphenyl%252529-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-1-yl%252529propyl%252529-3-cyclopropyl-5-fluoroquinazolin-4%2525283H%252529-one%252B%252528IHMT-PI3K%2525CE%2525B4-372%252529%252Bas%252Ba%252BPotent%252Band%252BSelective%252BPI3K%2525CE%2525B4%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BChronic%252BObstructive%252BPulmonary%252BDisease%26aulast%3DLi%26aufirst%3DFeng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03092020%26date%3D12112020%26volume%3D63%26issue%3D22%26spage%3D13973%26epage%3D13993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Matthew W. D. Perry, Raolat Abdulai, Mickael Mogemark, Jens Petersen, Matthew J. Thomas, Barbara Valastro, <span class="NLM_string-name hlFld-ContribAuthor">Annika Westin Eriksson</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 4783-4814. <a href="https://doi.org/10.1021/acs.jmedchem.8b01298" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01298</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01298%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEvolution%252Bof%252BPI3K%2525CE%2525B3%252Band%252B%2525CE%2525B4%252BInhibitors%252Bfor%252BInflammatory%252Band%252BAutoimmune%252BDiseases%26aulast%3DPerry%26aufirst%3DMatthew%2BW.%2BD.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D16082018%26date%3D24122018%26volume%3D62%26issue%3D10%26spage%3D4783%26epage%3D4814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Aimie
E. Garces, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Stocks</span>. </span><span class="cited-content_cbyCitation_article-title">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 4815-4850. <a href="https://doi.org/10.1021/acs.jmedchem.8b01492" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01492</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01492%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DClass%252B1%252BPI3K%252BClinical%252BCandidates%252Band%252BRecent%252BInhibitor%252BDesign%252BStrategies%25253A%252BA%252BMedicinal%252BChemistry%252BPerspective%26aulast%3DGarces%26aufirst%3DAimie%2BE.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D25092018%26date%3D24122018%26volume%3D62%26issue%3D10%26spage%3D4815%26epage%3D4850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Joey L. Methot, Hua Zhou, Sam D. Kattar, Meredeth A. McGowan, Kevin Wilson, Yudith Garcia, Yongi Deng, Michael Altman, Xavier Fradera, Charles Lesburg, Thierry Fischmann, Chaomin Li, Steve Alves, Sanjiv Shah, Rafael Fernandez, Peter Goldenblatt, Armetta Hill, Lynsey Shaffer, Dapeng Chen, Vince Tong, Robbie L. McLeod, Hongshi Yu, Alan Bass, Ray Kemper, Nicholas T. Gatto, Lisa LaFranco-Scheuch, Benjamin Wesley Trotter, Timothy Guzi, <span class="NLM_string-name hlFld-ContribAuthor">Jason D. Katz</span>. </span><span class="cited-content_cbyCitation_article-title">Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved Tolerability. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (9)
                                     , 4370-4382. <a href="https://doi.org/10.1021/acs.jmedchem.8b01818" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01818</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01818%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%252BOverhaul%252BAffords%252Ba%252BPotent%252BPurine%252BPI3K%2525CE%2525B4%252BInhibitor%252Bwith%252BImproved%252BTolerability%26aulast%3DMethot%26aufirst%3DJoey%2BL.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D20112018%26date%3D22042019%26date%3D15042019%26volume%3D62%26issue%3D9%26spage%3D4370%26epage%3D4382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Britta  Bonn</span>, <span class="hlFld-ContribAuthor ">Matthew  Perry</span>. </span><span class="cited-content_cbyCitation_article-title">The API. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 13-34. <a href="https://doi.org/10.1016/B978-0-12-814974-4.00006-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-814974-4.00006-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-814974-4.00006-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-814974-4.00006-7%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BAPI%26aulast%3DBonn%26aufirst%3DBritta%26date%3D2021%26spage%3D13%26epage%3D34%26pub%3DElsevier%26atitle%3DInhaled%252BMedicines%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiajia  Sun</span>, <span class="hlFld-ContribAuthor ">Yifan  Feng</span>, <span class="hlFld-ContribAuthor ">Yuan  Huang</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>. </span><span class="cited-content_cbyCitation_article-title">Research advances on selective phosphatidylinositol 3 kinase δ (PI3Kδ) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (19)
                                     , 127457. <a href="https://doi.org/10.1016/j.bmcl.2020.127457" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127457</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127457%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DResearch%252Badvances%252Bon%252Bselective%252Bphosphatidylinositol%252B3%252Bkinase%252B%2525CE%2525B4%252B%252528PI3K%2525CE%2525B4%252529%252Binhibitors%26aulast%3DSun%26aufirst%3DJiajia%26date%3D2020%26volume%3D30%26issue%3D19%26spage%3D127457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shubham  Srivastava</span>, <span class="hlFld-ContribAuthor ">Bhanwar  Singh Choudhary</span>, <span class="hlFld-ContribAuthor ">Pakhuri  Mehta</span>, <span class="hlFld-ContribAuthor ">Sukanya</span>, <span class="hlFld-ContribAuthor ">Manish  Sharma</span>, <span class="hlFld-ContribAuthor ">Ruchi  Malik</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular dynamics insights for PI3K-δ inhibition & structure guided identification of novel PI3K-δ inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2019,</strong> <em>37 </em>
                                    (9)
                                     , 2404-2414. <a href="https://doi.org/10.1080/07391102.2018.1489304" title="DOI URL">https://doi.org/10.1080/07391102.2018.1489304</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2018.1489304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2018.1489304%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DMolecular%252Bdynamics%252Binsights%252Bfor%252BPI3K-%2525CE%2525B4%252Binhibition%252B%252526%252Bstructure%252Bguided%252Bidentification%252Bof%252Bnovel%252BPI3K-%2525CE%2525B4%252Binhibitors%26aulast%3DSrivastava%26aufirst%3DShubham%26date%3D2019%26date%3D2018%26volume%3D37%26issue%3D9%26spage%3D2404%26epage%3D2414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Malcolm  Begg</span>, <span class="hlFld-ContribAuthor ">Chris D.  Edwards</span>, <span class="hlFld-ContribAuthor ">J. Nicole  Hamblin</span>, <span class="hlFld-ContribAuthor ">Eleni  Pefani</span>, <span class="hlFld-ContribAuthor ">Robert  Wilson</span>, <span class="hlFld-ContribAuthor ">Jane  Gilbert</span>, <span class="hlFld-ContribAuthor ">Giovanni  Vitulli</span>, <span class="hlFld-ContribAuthor ">David  Mallett</span>, <span class="hlFld-ContribAuthor ">Josie  Morrell</span>, <span class="hlFld-ContribAuthor ">Martin I.  Hingle</span>, <span class="hlFld-ContribAuthor ">Sorif  Uddin</span>, <span class="hlFld-ContribAuthor ">Filzah  Ehtesham</span>, <span class="hlFld-ContribAuthor ">Miriam  Marotti</span>, <span class="hlFld-ContribAuthor ">Andrew  Harrell</span>, <span class="hlFld-ContribAuthor ">Carla F.  Newman</span>, <span class="hlFld-ContribAuthor ">Disala  Fernando</span>, <span class="hlFld-ContribAuthor ">Jonathan  Clark</span>, <span class="hlFld-ContribAuthor ">Anthony  Cahn</span>, <span class="hlFld-ContribAuthor ">Edith M.  Hessel</span>. </span><span class="cited-content_cbyCitation_article-title">Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase
              δ
              Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2019,</strong> <em>369 </em>
                                    (3)
                                     , 443-453. <a href="https://doi.org/10.1124/jpet.119.257311" title="DOI URL">https://doi.org/10.1124/jpet.119.257311</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.119.257311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.119.257311%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DTranslation%252Bof%252BInhaled%252BDrug%252BOptimization%252BStrategies%252Binto%252BClinical%252BPharmacokinetics%252Band%252BPharmacodynamics%252BUsing%252BGSK2292767A%25252C%252Ba%252BNovel%252BInhaled%252BPhosphoinositide%252B3-Kinase%252B%2525CE%2525B4%252BInhibitor%26aulast%3DBegg%26aufirst%3DMalcolm%26date%3D2019%26date%3D2019%26volume%3D369%26issue%3D3%26spage%3D443%26epage%3D453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michelle  Miller</span>, <span class="hlFld-ContribAuthor ">Philip  Thompson</span>, <span class="hlFld-ContribAuthor ">Sandra  Gabelli</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Determinants of Isoform Selectivity in PI3K Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2019,</strong> <em>9 </em>
                                    (3)
                                     , 82. <a href="https://doi.org/10.3390/biom9030082" title="DOI URL">https://doi.org/10.3390/biom9030082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom9030082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom9030082%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DStructural%252BDeterminants%252Bof%252BIsoform%252BSelectivity%252Bin%252BPI3K%252BInhibitors%26aulast%3DMiller%26aufirst%3DMichelle%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D3%26spage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Reference PI3Kδ inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0011.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) Lawesson’s reagent, THF, 65 °C; (ii) Meldrum’s acid, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>; (iii) TFA, TFAA, ClCH<sub>2</sub>CH<sub>2</sub>Cl; (iv) isoamyl nitrite, HBr (40% aq), CH<sub>2</sub>Cl<sub>2</sub>, < −5 °C; (v) mCPBA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (vi) TFAA, PhMe, 60 °C then cH<sub>2</sub>SO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to RT; (vii) NaN<sub>3</sub>, DMF, 45 °C; (viii) Ph<sub>3</sub>P, CH<sub>2</sub>Cl<sub>2</sub>, reflux; (ix) CbzCl, K<sub>2</sub>CO<sub>3</sub>, THF:water 10:1, 0 °C.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) PhB(OH)<sub>2</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, DME–water, 100 °C; (ii) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to RT; (iii) 4-amino-6-chloropyrimidine-5-carbonitrile, DIEA, <i>n</i>-butanol, 120 °C then chiral HPLC.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0013.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to RT; (ii) 4-amino-6-chloropyrimidine-5-carbonitrile, DIEA, <i>n</i>-butanol, 120 °C; (iii) ArB(OH)<sub>2</sub>, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME–water, 100 °C then TFA, CH<sub>2</sub>Cl<sub>2</sub>; (iv) ArB(OH)<sub>2</sub> PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DME–water, 100 °C; (v) HNRR, NaBH<sub>3</sub>CN, MeOH–CH<sub>2</sub>Cl<sub>2</sub>; (vi) (a) ArB(pinacol), third-generation Pd precatalyst, P(Cy)<sub>3</sub>·HBF<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane–water, 130 °C, (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, (c) CH<sub>2</sub>O, NaBH<sub>3</sub>CN, AcOH, MeOH; (vii) ArB(pinacol), third-generation Pd precatalyst, P(Cy)<sub>3</sub>·HBF<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane–water, 130 °C then DEAD, Me<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>OH, Ph<sub>3</sub>P, THF, 0 °C; (viii) (a) ArB(pinacol), Pd dppf, Cs<sub>2</sub>CO<sub>3</sub>, dioxane–water, 130 °C, (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, (c) acetone, NaBH<sub>3</sub>CN, AcOH, CH<sub>2</sub>Cl<sub>2</sub>–MeOH; (ix) NaBH<sub>3</sub>CN, acetaldehyde or CH<sub>2</sub>O, AcOH, CH<sub>2</sub>Cl<sub>2</sub>–MeOH; (x) (a) CH<sub>2</sub>O, NaBH<sub>3</sub>CN, AcOH, MeOH, (b) TFA/CH<sub>2</sub>Cl<sub>2</sub>–water, (c) amine, NaBH<sub>3</sub>CN, AcOH, CH<sub>2</sub>Cl<sub>2</sub>–MeOH.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>13</b> bound in murine PI3Kδ showing the ATP binding pocket with the induced pocket between Trp760 and Met752 and with hydrogen bonds to the NH of Val828 and the carbonyl of Glu826 making the hinge interaction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. View of <b>15c</b> (gray) overlaid with <b>13</b> (blue) showing the very similar conformations adopted by the ligands and the almost identical protein conformations. Note the movement of the side chain amide of Asn836 permitting the dimethylamino group to be accommodated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Docked structure of <b>20f</b> (gray) overlaid with <b>13</b> (blue) in murine PI3K showing the large substituted aminopiperidine accommodated in the solvent channel.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Enzyme and cell potencies for compounds <b>13</b>, <b>15a</b>–<b>g</b>, <b>17</b>, <b>18</b>, and <b>19</b> showing cell drop-off at low lipophilicity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Rat ITPK time-course profiles of selected examples.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Relationships between lung retention (% remaining at 24 h; half-life) and the first and second p<i>K</i><sub>a</sub>s or lipophilicity (Log <i>D</i>) for dibases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Cell drop-off for dibases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/medium/jm-2017-00401b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0010.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Inhibition of pS6RP in lung lavage after anti-CD3 challenge to OTII mice. (a) Compound <b>20b</b>. (b) Compound <b>20f</b>. Target engagement of PI3Kδ activity is shown through measurements of pS6RP in bronchoalveolar lung lavage cells after anti-CD3 challenge to OVA-challenged OTII mice. Phosphorylation of S6RP, measured using phosphospecific antibodies, was significantly inhibited by both <b>20b</b> (a) and <b>20f</b> (b) in a dose-dependent manner, however, the inhibition by <b>20b</b> showed better potency. Data is shown as results for individual animals at each dose with the statistical significance indicated as follows above the columns: <i>p</i> < 0.001, ***; <i>p</i> < 0.005, **; <i>p</i> < 0.05, *.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00401/20170616/images/large/jm-2017-00401b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00401&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i74">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63342" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63342" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 33 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Fruman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span> </span><span class="NLM_article-title">PI3K and Cancer: Lessons, Challenges and Opportunities</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1038/nrd4204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1038%2Fnrd4204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=24481312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=140-156&author=D.+Frumanauthor=C.+Rommel&title=PI3K+and+Cancer%3A+Lessons%2C+Challenges+and+Opportunities&doi=10.1038%2Fnrd4204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and cancer: lessons, challenges and opportunities</span></div><div class="casAuthors">Fruman, David A.; Rommel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-156</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The central role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biol. has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer.  However, emerging clin. data show limited single-agent activity of inhibitors targeting PI3K, AKT or mTOR at tolerated doses.  One exception is the response to PI3Kδ inhibitors in chronic lymphocytic leukemia, where a combination of cell-intrinsic and -extrinsic activities drive efficacy.  Here, we review key challenges and opportunities for the clin. development of inhibitors targeting the PI3K-AKT-mTOR pathway.  Through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realize the potential of this promising class of targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlD2rY54m9LbVg90H21EOLACvtfcHk0ligtHublcrj7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D&md5=c4f6b4b9f9fcacd6ef55eb17d3a4f425</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd4204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4204%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DPI3K%2520and%2520Cancer%253A%2520Lessons%252C%2520Challenges%2520and%2520Opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D140%26epage%3D156%26doi%3D10.1038%2Fnrd4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Yap, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjerke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Drugging PI3K in Cancer: Refining Targets and Therapeutic Strategies</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1016/j.coph.2015.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1016%2Fj.coph.2015.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=26117819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWrt7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=98-107&author=T.+Yapauthor=L.+Bjerkeauthor=P.+Clarkeauthor=P.+Workman&title=Drugging+PI3K+in+Cancer%3A+Refining+Targets+and+Therapeutic+Strategies&doi=10.1016%2Fj.coph.2015.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging PI3K in cancer: refining targets and therapeutic strategies</span></div><div class="casAuthors">Yap, Timothy A.; Bjerke, Lynn; Clarke, Paul A.; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98-107</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phosphatidylinositol-3 kinase (PI3K) pathway is one of the most frequently activated pathogenic signalling routes in human cancers, making it a rational and important target for innovative anticancer drug development and precision medicine.  The three main classes of PI3K inhibitors currently in clin. testing comprise dual pan-Class I PI3K/mTOR inhibitors, pan-Class I PI3K inhibitors lacking significant mTOR activity and isoform-selective PI3K inhibitors.  A major step forward in recent years is the progression of over 30 small mol. PI3K inhibitors into clin. trials and the first regulatory approval of the PI3Kδ inhibitor idelalisib for multiple B-cell malignancies.  This review article focuses on the progress made in the discovery and development of novel PI3K inhibitors, with an emphasis on antitumor activity and tolerability profiles for agents that have entered clin. trials.  We also discuss the key issues of drug resistance, patient selection approaches and rational targeted combinations.  Finally, we envision the future development and use of PI3K inhibitors for the treatment of patients with a range of malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDxyCAEREi_7Vg90H21EOLACvtfcHk0ligtHublcrj7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWrt7bJ&md5=9a0238f97d8ecdc54e0c5b9b6ce4fc76</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2015.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2015.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%26aulast%3DBjerke%26aufirst%3DL.%26aulast%3DClarke%26aufirst%3DP.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DDrugging%2520PI3K%2520in%2520Cancer%253A%2520Refining%2520Targets%2520and%2520Therapeutic%2520Strategies%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2015%26volume%3D23%26spage%3D98%26epage%3D107%26doi%3D10.1016%2Fj.coph.2015.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Cushing, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, L. R.</span><span> </span><span class="NLM_article-title">PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8559</span><span class="NLM_x">–</span> <span class="NLM_lpage">8581</span><span class="refDoi"> DOI: 10.1021/jm300847w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300847w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1KjsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8559-8581&author=T.+D.+Cushingauthor=D.+P.+Metzauthor=D.+Whittingtonauthor=L.+R.+McGee&title=PI3K%CE%B4+and+PI3K%CE%B3+as+Targets+for+Autoimmune+and+Inflammatory+Diseases&doi=10.1021%2Fjm300847w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases</span></div><div class="casAuthors">Cushing, Timothy D.; Metz, Daniela P.; Whittington, Douglas A.; McGee, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8559-8581</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeting signaling mols. that are required for the activation of multiple immune cells may be a more likely route to success in combating chronic, immune cell-mediated diseases (such as rheumatoid arthritis, systemic lupus erythematosus, and asthma).  This review will highlight two such signaling mols., the related lipid kinases, class I PI3K (phosphoinositide 3-kinase) δ and γ, both of which are primarily expressed in leukocytes and seem to play important roles in their function and activation.  This review will compare and contrast these two kinases as targets for autoimmune and inflammatory diseases and summarize efforts toward the development of small mol. inhibitors of PI3Kδ and PI3Kγ.  Phosphoinositides (PIs) act as second messengers in a wide variety of cellular roles including signal transduction, control of membrane trafficking and transport, cytoskeleton organization, cell survival and death, among many other functions.  The target of PI3K kinase activity is the phosphoinositides within cell membranes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMqItqgMiGp7Vg90H21EOLACvtfcHk0ligtHublcrj7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1KjsrjL&md5=76fc05c3bf303174add4aca98f526f8f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm300847w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300847w%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26aulast%3DWhittington%26aufirst%3DD.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26atitle%3DPI3K%25CE%25B4%2520and%2520PI3K%25CE%25B3%2520as%2520Targets%2520for%2520Autoimmune%2520and%2520Inflammatory%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8559%26epage%3D8581%26doi%3D10.1021%2Fjm300847w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Rowan, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amour, A.</span><span> </span><span class="NLM_article-title">Targeting Phosphoinositide 3-Kinase δ for Allergic Asthma</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">245</span><span class="refDoi"> DOI: 10.1042/BST20110665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1042%2FBST20110665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=22260698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFGjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=240-245&author=W.+C.+Rowanauthor=J.+L.+Smithauthor=K.+Affleckauthor=A.+Amour&title=Targeting+Phosphoinositide+3-Kinase+%CE%B4+for+Allergic+Asthma&doi=10.1042%2FBST20110665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting phosphoinositide 3-kinase δ for allergic asthma</span></div><div class="casAuthors">Rowan, Wendy C.; Smith, Janet L.; Affleck, Karen; Amour, Augustin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">240-245</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Chronic inflammation in the lung has long been linked to the pathogenesis of asthma.  Central to this airway inflammation is a T-cell response to allergens, with Th2 cytokines driving the differentiation, survival and function of the major inflammatory cells involved in the allergic cascade.  PI3Kδ (phosphoinositide 3-kinase δ) is a lipid kinase, expressed predominantly in leukocytes, where it plays a crit. role in immune receptor signalling.  A selective PI3Kδ inhibitor is predicted to block T-cell activation in the lung, reducing the prodn. of pro-inflammatory Th2 cytokines.  PI3Kδ is also involved in B-cell and mast cell activation.  Therefore the inhibition of PI3Kδ should dampen down the inflammatory cascade involved in the asthmatic response through a wide breadth of pharmacol.  Current anti-inflammatory therapies, which are based on corticosteroids, are effective in controlling inflammation in mild asthmatics, but moderate/severe asthmatic patients remain poorly controlled, experiencing recurrent exacerbations.  Corticosteroids have no effect on mast cell degranulation and do not act directly on B-cells, so, overall, a PI3Kδ inhibitor has the potential to deliver improvements in onset of action, efficacy and reduced exacerbations in moderate/severe asthmatics.  Addnl., PI3Kδ inhibition is expected to block effects of Th17 cells, which are increasingly implicated in steroid-insensitive asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKwu2SYlFjDbVg90H21EOLACvtfcHk0li6IxmbjGdrAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFGjs7s%253D&md5=db36bc8f79c70e0817e00fb9b04f10ff</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1042%2FBST20110665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20110665%26sid%3Dliteratum%253Aachs%26aulast%3DRowan%26aufirst%3DW.%2BC.%26aulast%3DSmith%26aufirst%3DJ.%2BL.%26aulast%3DAffleck%26aufirst%3DK.%26aulast%3DAmour%26aufirst%3DA.%26atitle%3DTargeting%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520for%2520Allergic%2520Asthma%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2012%26volume%3D40%26spage%3D240%26epage%3D245%26doi%3D10.1042%2FBST20110665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Puri, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gold, M. R.</span><span> </span><span class="NLM_article-title">Selective Inhibitors of Phosphoinositide 3-Kinase Delta: Modulators of B-Cell Function with Potential for Treating Autoimmune Inflammatory Diseases and B-Cell Malignancies</span> <span class="citation_source-journal">Front. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">256</span><span class="refDoi"> DOI: 10.3389/fimmu.2012.00256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.3389%2Ffimmu.2012.00256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=22936933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A280%3ADC%252BC38bivFKqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=256&author=K.+D.+Puriauthor=M.+R.+Gold&title=Selective+Inhibitors+of+Phosphoinositide+3-Kinase+Delta%3A+Modulators+of+B-Cell+Function+with+Potential+for+Treating+Autoimmune+Inflammatory+Diseases+and+B-Cell+Malignancies&doi=10.3389%2Ffimmu.2012.00256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies</span></div><div class="casAuthors">Puri Kamal D; Gold Michael R</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">256</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The delta isoform of the p110 catalytic subunit (p110δ) of phosphoinositide 3-kinase is expressed primarily in hematopoietic cells and plays an essential role in B-cell development and function.  Studies employing mice lacking a functional p110δ protein, as well as the use of highly-selective chemical inhibitors of p110δ, have revealed that signaling via p110δ-containing PI3K complexes (PI3Kδ) is critical for B-cell survival, migration, and activation, functioning downstream of key receptors on B cells including the B-cell antigen receptor, chemokine receptors, pro-survival receptors such as BAFF-R and the IL-4 receptor, and co-stimulatory receptors such as CD40 and Toll-like receptors (TLRs).  Similarly, this PI3K isoform plays a key role in the survival, proliferation, and dissemination of B-cell lymphomas.  Herein we summarize studies showing that these processes can be inhibited in vitro and in vivo by small molecule inhibitors of p110δ enzymatic activity, and that these p110δ inhibitors have shown efficacy in clinical trials for the treatment of several types of B-cell malignancies including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).  PI3Kδ also plays a critical role in the activation, proliferation, and tissue homing of self-reactive B cells that contribute to autoimmune diseases, in particular innate-like B-cell populations such as marginal zone (MZ) B cells and B-1 cells that have been strongly linked to autoimmunity.  We discuss the potential utility of p110δ inhibitors, either alone or in combination with B-cell depletion, for treating autoimmune diseases such as lupus, rheumatoid arthritis, and type 1 diabetes.  Because PI3Kδ plays a major role in both B-cell-mediated autoimmune inflammation and B-cell malignancies, PI3Kδ inhibitors may represent a promising therapeutic approach for treating these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRipfUTvwjJVGK_SFaaT9INfW6udTcc2ebRqaxT5EePrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bivFKqtw%253D%253D&md5=243f0709b8e191a074d09c5a0c4c8c3f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2012.00256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2012.00256%26sid%3Dliteratum%253Aachs%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DGold%26aufirst%3DM.%2BR.%26atitle%3DSelective%2520Inhibitors%2520of%2520Phosphoinositide%25203-Kinase%2520Delta%253A%2520Modulators%2520of%2520B-Cell%2520Function%2520with%2520Potential%2520for%2520Treating%2520Autoimmune%2520Inflammatory%2520Diseases%2520and%2520B-Cell%2520Malignancies%26jtitle%3DFront.%2520Immunol.%26date%3D2012%26volume%3D3%26spage%3D256%26doi%3D10.3389%2Ffimmu.2012.00256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Sriskantharajah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamblin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worsley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calver, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessel, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amour, A.</span><span> </span><span class="NLM_article-title">Targeting Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Diseases</span> <span class="citation_source-journal">Ann. N. Y. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1280</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span><span class="refDoi"> DOI: 10.1111/nyas.12039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1111%2Fnyas.12039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=23551101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslWgtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1280&publication_year=2013&pages=35-39&author=S.+Sriskantharajahauthor=N.+Hamblinauthor=S.+Worsleyauthor=A.+R.+Calverauthor=E.+M.+Hesselauthor=A.+Amour&title=Targeting+Phosphoinositide+3-Kinase+%CE%B4+for+the+Treatment+of+Respiratory+Diseases&doi=10.1111%2Fnyas.12039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting phosphoinositide 3-kinase δ for the treatment of respiratory diseases</span></div><div class="casAuthors">Sriskantharajah, Srividya; Hamblin, Nicole; Worsley, Sally; Calver, Andrew R.; Hessel, Edith M.; Amour, Augustin</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1280</span>
        (<span class="NLM_cas:issue">Inositol Phospholipid Signaling in Physiology and Disease</span>),
    <span class="NLM_cas:pages">35-39</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Asthma and chronic obstructive pulmonary disease (COPD) are characterized in their pathogenesis by chronic inflammation in the airways.  Phosphoinositide 3-kinase δ (PI3Kδ), a lipid kinase expressed predominantly in leukocytes, is thought to hold much promise as a therapeutic target for such inflammatory conditions.  Of particular interest for the treatment of severe respiratory disease is the observation that inhibition of PI3Kδ may restore steroid effectiveness under conditions of oxidative stress.  PI3Kδ inhibition may also prevent recruitment of inflammatory cells, including T lymphocytes and neutrophils, as well as the release of proinflammatory mediators, such as cytokines, chemokines, reactive oxygen species, and proteolytic enzymes.  In addn., targeting the PI3Kδ pathway could reduce the incidence of pathogen-induced exacerbations by improving macrophage-mediated bacterial clearance.  In this review, we discuss the potential and highlight the unknowns of targeting PI3Kδ for the treatment of respiratory disease, focusing on recent developments in the role of the PI3Kδ pathway in inflammatory cell types believed to be crit. to the pathogenesis of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFa4PRY73w17Vg90H21EOLACvtfcHk0li6IxmbjGdrAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslWgtL0%253D&md5=51549242bdf01d3373ded21565656f1d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fnyas.12039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnyas.12039%26sid%3Dliteratum%253Aachs%26aulast%3DSriskantharajah%26aufirst%3DS.%26aulast%3DHamblin%26aufirst%3DN.%26aulast%3DWorsley%26aufirst%3DS.%26aulast%3DCalver%26aufirst%3DA.%2BR.%26aulast%3DHessel%26aufirst%3DE.%2BM.%26aulast%3DAmour%26aufirst%3DA.%26atitle%3DTargeting%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520for%2520the%2520Treatment%2520of%2520Respiratory%2520Diseases%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2013%26volume%3D1280%26spage%3D35%26epage%3D39%26doi%3D10.1111%2Fnyas.12039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Hawkins, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L. R.</span><span> </span><span class="NLM_article-title">PI3K Signalling in Inflammation</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1851</span><span class="NLM_x">, </span> <span class="NLM_fpage">882</span><span class="NLM_x">–</span> <span class="NLM_lpage">897</span><span class="refDoi"> DOI: 10.1016/j.bbalip.2014.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1016%2Fj.bbalip.2014.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=25514767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvF2iuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1851&publication_year=2015&pages=882-897&author=P.+T.+Hawkinsauthor=L.+R.+Stephens&title=PI3K+Signalling+in+Inflammation&doi=10.1016%2Fj.bbalip.2014.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K signalling in inflammation</span></div><div class="casAuthors">Hawkins, P. T.; Stephens, L. R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1851</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">882-897</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  PI3Ks regulate several key events in the inflammatory response to damage and infection.  There are four Class I PI3K isoforms (PI3Kα,β,γ,δ), three Class II PI3K isoforms (PI3KC2α, C2β, C2γ) and a single Class III PI3K.  The four Class I isoforms synthesize the phospholipid 'PIP3'.  PIP3 is a 'second messenger' used by many different cell surface receptors to control cell movement, growth, survival and differentiation.  These four isoforms have overlapping functions but each is adapted to receive efficient stimulation by particular receptor sub-types.  PI3Kγ is highly expressed in leukocytes and plays a particularly important role in chemokine-mediated recruitment and activation of innate immune cells at sites of inflammation.  PI3Kδ is also highly expressed in leukocytes and plays a key role in antigen receptor and cytokine-mediated B and T cell development, differentiation and function.  Class III PI3K synthesizes the phospholipid PI3P, which regulates endosome-lysosome trafficking and the induction of autophagy, pathways involved in pathogen killing, antigen processing and immune cell survival.  Much less is known about the function of Class II PI3Ks, but emerging evidence indicates they can synthesize PI3P and PI34P2 and are involved in the regulation of endocytosis.The creation of genetically-modified mice with altered PI3K signalling, together with the development of isoform-selective, small-mol. PI3K inhibitors, has allowed the evaluation of the individual roles of Class I PI3K isoforms in several mouse models of chronic inflammation.  Selective inhibition of PI3Kδ, γ or β has each been shown to reduce the severity of inflammation in one or more models of autoimmune disease, respiratory disease or allergic inflammation, with dual γ/δ or β/δ inhibition generally proving more effective.  The inhibition of Class I PI3Ks may therefore offer a therapeutic opportunity to treat non-resolving inflammatory pathologies in humans.  This article is part of a Special Issue entitled Phosphoinositides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_3Ktv0Ju9w7Vg90H21EOLACvtfcHk0lhpVJvBX_49nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvF2iuw%253D%253D&md5=eb2ce86f49dc58a2146b4ac426497e9c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2014.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2014.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DStephens%26aufirst%3DL.%2BR.%26atitle%3DPI3K%2520Signalling%2520in%2520Inflammation%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2015%26volume%3D1851%26spage%3D882%26epage%3D897%26doi%3D10.1016%2Fj.bbalip.2014.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">So, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fruman, D.</span><span> </span><span class="NLM_article-title">PI3K Signalling in B- and T-Lymphocytes: New Developments and Therapeutic Advances</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">442</span><span class="NLM_x">, </span> <span class="NLM_fpage">465</span><span class="NLM_x">–</span> <span class="NLM_lpage">481</span><span class="refDoi"> DOI: 10.1042/BJ20112092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1042%2FBJ20112092" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=442&publication_year=2012&pages=465-481&author=L.+Soauthor=D.+Fruman&title=PI3K+Signalling+in+B-+and+T-Lymphocytes%3A+New+Developments+and+Therapeutic+Advances&doi=10.1042%2FBJ20112092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1042%2FBJ20112092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20112092%26sid%3Dliteratum%253Aachs%26aulast%3DSo%26aufirst%3DL.%26aulast%3DFruman%26aufirst%3DD.%26atitle%3DPI3K%2520Signalling%2520in%2520B-%2520and%2520T-Lymphocytes%253A%2520New%2520Developments%2520and%2520Therapeutic%2520Advances%26jtitle%3DBiochem.%2520J.%26date%3D2012%26volume%3D442%26spage%3D465%26epage%3D481%26doi%3D10.1042%2FBJ20112092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Fung-Leung, W.-P.</span><span> </span><span class="NLM_article-title">Phosphoinositide 3-Kinase Gamma in T Cell Biology and Disease Therapy</span> <span class="citation_source-journal">Ann. N. Y. Acad. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1280</span><span class="NLM_x">, </span> <span class="NLM_fpage">40</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span><span class="refDoi"> DOI: 10.1111/nyas.12029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1111%2Fnyas.12029" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1280&publication_year=2013&pages=40-43&author=W.-P.+Fung-Leung&title=Phosphoinositide+3-Kinase+Gamma+in+T+Cell+Biology+and+Disease+Therapy&doi=10.1111%2Fnyas.12029"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fnyas.12029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnyas.12029%26sid%3Dliteratum%253Aachs%26aulast%3DFung-Leung%26aufirst%3DW.-P.%26atitle%3DPhosphoinositide%25203-Kinase%2520Gamma%2520in%2520T%2520Cell%2520Biology%2520and%2520Disease%2520Therapy%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2013%26volume%3D1280%26spage%3D40%26epage%3D43%26doi%3D10.1111%2Fnyas.12029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitehead, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piñeiro, R.</span><span> </span><span class="NLM_article-title">Molecules in Medicine Mini-Review: Isoforms of PI3K in Biology and Disease</span> <span class="citation_source-journal">J. Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span><span class="refDoi"> DOI: 10.1007/s00109-015-1352-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1007%2Fs00109-015-1352-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=26658520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVOjs7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2016&pages=5-11&author=B.+Vanhaesebroeckauthor=M.+A.+Whiteheadauthor=R.+Pi%C3%B1eiro&title=Molecules+in+Medicine+Mini-Review%3A+Isoforms+of+PI3K+in+Biology+and+Disease&doi=10.1007%2Fs00109-015-1352-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Molecules in medicine mini-review: isoforms of PI3K in biology and disease</span></div><div class="casAuthors">Vanhaesebroeck, Bart; Whitehead, Maria A.; Pineiro, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Medicine (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-11</span>CODEN:
                <span class="NLM_cas:coden">JMLME8</span>;
        ISSN:<span class="NLM_cas:issn">0946-2716</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The PI3K lipid kinases are involved in signal transduction and intracellular vesicular traffic, endowing these enzymes with multiple cellular functions and important roles in normal physiol. and disease.  In this mini-review, we aim to distill from the vast PI3K literature the key relevant concepts for successful targeting of this pathway in disease.  Of the eight isoforms of PI3K, the class I PI3Ks have been implicated in the etiol. and maintenance of various diseases, most prominently cancer, overgrowth syndromes, inflammation and autoimmunity, with emerging potential roles in metabolic and cardiovascular disorders.  The development of class I PI3K inhibitors, mainly for use in cancer and inflammation, is a very active area of drug development.  In 2014, an inhibitor of the p110δ isoform of PI3K was approved for the treatment of specific human B cell malignancies.  The key therapeutic indications of targeting each class I PI3K isoform are summarized and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppc5USj-Hs5rVg90H21EOLACvtfcHk0lhpVJvBX_49nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVOjs7bE&md5=7b78f2b78ddeed390ab133c562ec6725</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00109-015-1352-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00109-015-1352-5%26sid%3Dliteratum%253Aachs%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DWhitehead%26aufirst%3DM.%2BA.%26aulast%3DPi%25C3%25B1eiro%26aufirst%3DR.%26atitle%3DMolecules%2520in%2520Medicine%2520Mini-Review%253A%2520Isoforms%2520of%2520PI3K%2520in%2520Biology%2520and%2520Disease%26jtitle%3DJ.%2520Mol.%2520Med.%26date%3D2016%26volume%3D94%26spage%3D5%26epage%3D11%26doi%3D10.1007%2Fs00109-015-1352-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Markham, A.</span><span> </span><span class="NLM_article-title">Idelalisib: First Global Approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1701</span><span class="NLM_x">–</span> <span class="NLM_lpage">1707</span><span class="refDoi"> DOI: 10.1007/s40265-014-0285-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1007%2Fs40265-014-0285-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=25187123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFelurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1701-1707&author=A.+Markham&title=Idelalisib%3A+First+Global+Approval&doi=10.1007%2Fs40265-014-0285-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Idelalisib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1701-1707</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Idelalisib (Zydelig) is a highly specific small-mol. phosphatidylinositol-3-kinase (PI3Kδ) inhibitor that has been developed as an oral treatment for B cell haematol. cancers.  It has received its first approval in the US in July 2014 for the treatment of relapsed chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic leukemia (SLL).  Idelalisib is under regulatory review in the EU-where it has received a pos. opinion from the European Medicines Agency Committee for Medicinal Products for Human Use-and in clin. development for CLL in Australia and Canada.  This article summarizes the milestones in the development of Idelalisib leading to this first approval for relapsed CLL, NHL and SLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqGKFY-IMFGbVg90H21EOLACvtfcHk0lhpVJvBX_49nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFelurbL&md5=2d0728f250f0e6eeb907942e5010f12b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0285-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0285-6%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DIdelalisib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D1701%26epage%3D1707%26doi%3D10.1007%2Fs40265-014-0285-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Coutre, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrientos, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pagel, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poleski, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharman, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, N.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zelenetz, A. D.</span><span> </span><span class="NLM_article-title">Management of Adverse Events Associated with Idelalisib Treatment - Expert Panel Opinion</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2779</span><span class="NLM_x">–</span> <span class="NLM_lpage">2786</span><span class="refDoi"> DOI: 10.3109/10428194.2015.1022770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.3109%2F10428194.2015.1022770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=25726955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKju73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2015&pages=2779-2786&author=S.+E.+Coutreauthor=J.+C.+Barrientosauthor=J.+R.+Brownauthor=S.+de+Vosauthor=R.+R.+Furmanauthor=M.+J.+Keatingauthor=D.+Liauthor=S.+M.+O%E2%80%99Brienauthor=J.+M.+Pagelauthor=M.+H.+Poleskiauthor=J.+P.+Sharmanauthor=N.-S.+Yaoauthor=A.+D.+Zelenetz&title=Management+of+Adverse+Events+Associated+with+Idelalisib+Treatment+-+Expert+Panel+Opinion&doi=10.3109%2F10428194.2015.1022770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Management of adverse events associated with idelalisib treatment: expert panel opinion</span></div><div class="casAuthors">Coutre, Steven E.; Barrientos, Jacqueline C.; Brown, Jennifer R.; de Vos, Sven; Furman, Richard R.; Keating, Michael J.; Li, Daniel; O'Brien, Susan M.; Pagel, John M.; Poleski, Martin H.; Sharman, Jeff P.; Yao, Nai-Shun; Zelenetz, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2779-2786</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood cancer.  Idelalisib has demonstrated significant efficacy and a tolerable safety profile in clin. trials.  However, the US prescribing information contains a black box warning for fatal and/or severe diarrhea or colitis, hepatotoxicity, pneumonitis and intestinal perforation.  An expert panel was convened to review the pathol. of these treatment-emergent adverse events (TEAEs) to propose key management tools for patients receiving idelalisib therapy.  This article provides an overview of idelalisib TEAEs reported in clin. trials, and a summary of the panel's recommendations for identification and management of idelalisib treatment-emergent diarrhea or colitis as well as a discussion of transaminitis and pneumonitis.  For idelalisib-related diarrhea or colitis (including unresolved grade 2 and grade ≥ 3), after exclusion of infectious causes, the panel recommends individualized treatment with budesonide or oral or i.v. steroid therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVGi1H-woJu7Vg90H21EOLACvtfcHk0liu7n0m-wT73Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKju73O&md5=649cb8c3d6fe0a60f74b3f9413e4706a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3109%2F10428194.2015.1022770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10428194.2015.1022770%26sid%3Dliteratum%253Aachs%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BM.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DPoleski%26aufirst%3DM.%2BH.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DYao%26aufirst%3DN.-S.%26aulast%3DZelenetz%26aufirst%3DA.%2BD.%26atitle%3DManagement%2520of%2520Adverse%2520Events%2520Associated%2520with%2520Idelalisib%2520Treatment%2520-%2520Expert%2520Panel%2520Opinion%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2015%26volume%3D56%26spage%3D2779%26epage%3D2786%26doi%3D10.3109%2F10428194.2015.1022770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Terstiege, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyrchan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindmark, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Öster, L.</span><span> </span><span class="NLM_article-title">Discovery of Triazole Aminopyrazines as a Highly Potent and Selective Series of PI3Kδ Inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">687</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.11.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1016%2Fj.bmcl.2016.11.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=679-687&author=I.+Terstiegeauthor=M.+Perryauthor=J.+Petersenauthor=C.+Tyrchanauthor=T.+Svenssonauthor=H.+Lindmarkauthor=L.+%C3%96ster&title=Discovery+of+Triazole+Aminopyrazines+as+a+Highly+Potent+and+Selective+Series+of+PI3K%CE%B4+Inhibitors&doi=10.1016%2Fj.bmcl.2016.11.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DTerstiege%26aufirst%3DI.%26aulast%3DPerry%26aufirst%3DM.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DTyrchan%26aufirst%3DC.%26aulast%3DSvensson%26aufirst%3DT.%26aulast%3DLindmark%26aufirst%3DH.%26aulast%3D%25C3%2596ster%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Triazole%2520Aminopyrazines%2520as%2520a%2520Highly%2520Potent%2520and%2520Selective%2520Series%2520of%2520PI3K%25CE%25B4%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D679%26epage%3D687%26doi%3D10.1016%2Fj.bmcl.2016.11.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">El-Sherbiny, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-baz, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yacoub, M. H.</span><span> </span><span class="NLM_article-title">Inhaled Nano- and Microparticles for Drug Delivery</span> <span class="citation_source-journal">Global Cardiol. Sci. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">2015</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="refDoi"> DOI: 10.5339/gcsp.2015.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.5339%2Fgcsp.2015.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=26779496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A280%3ADC%252BC28nhsFCqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=2&author=I.+M.+El-Sherbinyauthor=N.+M.+El-bazauthor=M.+H.+Yacoub&title=Inhaled+Nano-+and+Microparticles+for+Drug+Delivery&doi=10.5339%2Fgcsp.2015.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled nano- and microparticles for drug delivery</span></div><div class="casAuthors">El-Sherbiny Ibrahim M; El-Baz Nancy M; Yacoub Magdi H</div><div class="citationInfo"><span class="NLM_cas:title">Global cardiology science & practice</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2</span>
        ISSN:<span class="NLM_cas:issn">2305-7823</span>.
    </div><div class="casAbstract">The 21st century has seen a paradigm shift to inhaled therapy, for both systemic and local drug delivery, due to the lung's favourable properties of a large surface area and high permeability.  Pulmonary drug delivery possesses many advantages, including non-invasive route of administration, low metabolic activity, control environment for systemic absorption and avoids first bypass metabolism.  However, because the lung is one of the major ports of entry, it has multiple clearance mechanisms, which prevent foreign particles from entering the body.  Although these clearance mechanisms maintain the sterility of the lung, clearance mechanisms can also act as barriers to the therapeutic effectiveness of inhaled drugs.  This effectiveness is also influenced by the deposition site and delivered dose.  Particulate-based drug delivery systems have emerged as an innovative and promising alternative to conventional inhaled drugs to circumvent pulmonary clearance mechanisms and provide enhanced therapeutic efficiency and controlled drug release.  The principle of multiple pulmonary clearance mechanisms is reviewed, including mucociliary, alveolar macrophages, absorptive, and metabolic degradation.  This review also discusses the current approaches and formulations developed to achieve optimal pulmonary drug delivery systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTcht76K6iGeb6AVA-44PTfW6udTcc2eYxg9ixcgbLZLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nhsFCqsA%253D%253D&md5=20681a9abfc8c759ff6655c6549bbc33</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.5339%2Fgcsp.2015.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5339%252Fgcsp.2015.2%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Sherbiny%26aufirst%3DI.%2BM.%26aulast%3DEl-baz%26aufirst%3DN.%2BM.%26aulast%3DYacoub%26aufirst%3DM.%2BH.%26atitle%3DInhaled%2520Nano-%2520and%2520Microparticles%2520for%2520Drug%2520Delivery%26jtitle%3DGlobal%2520Cardiol.%2520Sci.%2520Pract.%26date%3D2015%26volume%3D2015%26spage%3D2%26doi%3D10.5339%2Fgcsp.2015.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunder, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loewith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balla, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">A Pharmacological Map of the PI3-K Family Defines a Role for p110alpha in Insulin Signaling</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span><span class="refDoi"> DOI: 10.1016/j.cell.2006.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1016%2Fj.cell.2006.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=16647110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=733-747&author=Z.+A.+Knightauthor=B.+Gonzalezauthor=M.+E.+Feldmanauthor=E.+R.+Zunderauthor=D.+D.+Goldenbergauthor=O.+Williamsauthor=R.+Loewithauthor=D.+Stokoeauthor=A.+Ballaauthor=B.+Tothauthor=T.+Ballaauthor=W.+A.+Weissauthor=R.+L.+Williamsauthor=K.+M.+Shokat&title=A+Pharmacological+Map+of+the+PI3-K+Family+Defines+a+Role+for+p110alpha+in+Insulin+Signaling&doi=10.1016%2Fj.cell.2006.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling</span></div><div class="casAuthors">Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; Balla, Tamas; Weiss, William A.; Williams, Roger L.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">733-747</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3-Ks) are an important emerging class of drug targets, but the unique roles of PI3-K isoforms remain poorly defined.  We describe here an approach to pharmacol. interrogate the PI3-K family.  A chem. diverse panel of PI3-K inhibitors was synthesized, and their target selectivity was biochem. enumerated, revealing cryptic homologies across targets and chemotypes.  Crystal structures of three inhibitors bound to p110γ identify a conformationally mobile region that is uniquely exploited by selective compds.  This chem. array was then used to define the PI3-K isoforms required for insulin signaling.  We find that p110α is the primary insulin-responsive PI3-K in cultured cells, whereas p110β is dispensable but sets a phenotypic threshold for p110α activity.  Compds. targeting p110α block the acute effects of insulin treatment in vivo, whereas a p110β inhibitor has no effect.  These results illustrate systematic target validation using a matrix of inhibitors that span a protein family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrozjvOeMXP3bVg90H21EOLACvtfcHk0li5P8H6x1MOqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltlSkt7o%253D&md5=b95a8cb433927ff9a75b33fc4ac2c8a0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DGonzalez%26aufirst%3DB.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DZunder%26aufirst%3DE.%2BR.%26aulast%3DGoldenberg%26aufirst%3DD.%2BD.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLoewith%26aufirst%3DR.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DBalla%26aufirst%3DA.%26aulast%3DToth%26aufirst%3DB.%26aulast%3DBalla%26aufirst%3DT.%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DA%2520Pharmacological%2520Map%2520of%2520the%2520PI3-K%2520Family%2520Defines%2520a%2520Role%2520for%2520p110alpha%2520in%2520Insulin%2520Signaling%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D733%26epage%3D747%26doi%3D10.1016%2Fj.cell.2006.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisconte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaney, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chantry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castanedo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depledge, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knowles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondru, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadin, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pegg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Safina, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salphati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staben, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seward, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, Z. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waszkowycz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span> </span><span class="NLM_article-title">Potent and Selective Inhibitors of PI3Kδ: Obtaining Isoform Selectivity from the Affinity Pocket and Tryptophan Shelf</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4296</span><span class="NLM_x">–</span> <span class="NLM_lpage">4302</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1016%2Fj.bmcl.2012.05.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=22672799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVegur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4296-4302&author=D.+P.+Sutherlinauthor=S.+Bakerauthor=A.+Bisconteauthor=P.+M.+Blaneyauthor=A.+Brownauthor=B.+K.+Chanauthor=D.+Chantryauthor=G.+Castanedoauthor=P.+Depledgeauthor=P.+Goldsmithauthor=D.+M.+Goldsteinauthor=T.+Hancoxauthor=J.+Kaurauthor=D.+Knowlesauthor=R.+Kondruauthor=J.+Lesnickauthor=M.+C.+Lucasauthor=C.+Lewisauthor=J.+Murrayauthor=A.+J.+Nadinauthor=J.+Nonomiyaauthor=J.+Pangauthor=N.+Peggauthor=S.+Priceauthor=K.+Reifauthor=B.+S.+Safinaauthor=L.+Salphatiauthor=S.+Stabenauthor=E.+M.+Sewardauthor=S.+Shuttleworthauthor=S.+Sohalauthor=Z.+K.+Sweeneyauthor=M.+Ultschauthor=B.+Waszkowyczauthor=B.+Wei&title=Potent+and+Selective+Inhibitors+of+PI3K%CE%B4%3A+Obtaining+Isoform+Selectivity+from+the+Affinity+Pocket+and+Tryptophan+Shelf&doi=10.1016%2Fj.bmcl.2012.05.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibitors of PI3Kδ: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf</span></div><div class="casAuthors">Sutherlin, Daniel P.; Baker, Stewart; Bisconte, Angelina; Blaney, Paul M.; Brown, Anthony; Chan, Bryan K.; Chantry, David; Castanedo, Georgette; DePledge, Paul; Goldsmith, Paul; Goldstein, David M.; Hancox, Timothy; Kaur, Jasmit; Knowles, David; Kondru, Rama; Lesnick, John; Lucas, Matthew C.; Lewis, Cristina; Murray, Jeremy; Nadin, Alan J.; Nonomiya, Jim; Pang, Jodie; Pegg, Neil; Price, Steve; Reif, Karin; Safina, Brian S.; Salphati, Laurent; Staben, Steven; Seward, Eileen M.; Shuttleworth, Stephen; Sohal, Sukhjit; Sweeney, Zachary K.; Ultsch, Mark; Waszkowycz, Bohdan; Wei, Binqing</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4296-4302</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A potent inhibitor of PI3Kδ that is ≥200 fold selective for the remaining three Class I PI3K isoforms and addnl. kinases is described.  The hypothesis for selectivity is illustrated through structure activity relationships and crystal structures of compds. bound to a K802T mutant of PI3Kγ.  Pharmacokinetic data in rats and mice support the use of 3 as a useful tool compd. to use for in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaSfg4K5zqbLVg90H21EOLACvtfcHk0li5P8H6x1MOqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVegur0%253D&md5=d15c7cd8ce626cc5e9a13ac355557ce8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.027%26sid%3Dliteratum%253Aachs%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DBaker%26aufirst%3DS.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DBlaney%26aufirst%3DP.%2BM.%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DChantry%26aufirst%3DD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DDepledge%26aufirst%3DP.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DHancox%26aufirst%3DT.%26aulast%3DKaur%26aufirst%3DJ.%26aulast%3DKnowles%26aufirst%3DD.%26aulast%3DKondru%26aufirst%3DR.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNadin%26aufirst%3DA.%2BJ.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPegg%26aufirst%3DN.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DStaben%26aufirst%3DS.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSohal%26aufirst%3DS.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DB.%26atitle%3DPotent%2520and%2520Selective%2520Inhibitors%2520of%2520PI3K%25CE%25B4%253A%2520Obtaining%2520Isoform%2520Selectivity%2520from%2520the%2520Affinity%2520Pocket%2520and%2520Tryptophan%2520Shelf%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4296%26epage%3D4302%26doi%3D10.1016%2Fj.bmcl.2012.05.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Sadhu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masinovsky, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowell, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staunton, D. E.</span><span> </span><span class="NLM_article-title">Essential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">170</span><span class="NLM_x">, </span> <span class="NLM_fpage">2647</span><span class="NLM_x">–</span> <span class="NLM_lpage">2654</span><span class="refDoi"> DOI: 10.4049/jimmunol.170.5.2647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.4049%2Fjimmunol.170.5.2647" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2003&pages=2647-2654&author=C.+Sadhuauthor=B.+Masinovskyauthor=K.+Dickauthor=C.+G.+Sowellauthor=D.+E.+Staunton&title=Essential+Role+of+Phosphoinositide+3-Kinase+%CE%B4+in+Neutrophil+Directional+Movement&doi=10.4049%2Fjimmunol.170.5.2647"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.170.5.2647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.170.5.2647%26sid%3Dliteratum%253Aachs%26aulast%3DSadhu%26aufirst%3DC.%26aulast%3DMasinovsky%26aufirst%3DB.%26aulast%3DDick%26aufirst%3DK.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DStaunton%26aufirst%3DD.%2BE.%26atitle%3DEssential%2520Role%2520of%2520Phosphoinositide%25203-Kinase%2520%25CE%25B4%2520in%2520Neutrophil%2520Directional%2520Movement%26jtitle%3DJ.%2520Immunol.%26date%3D2003%26volume%3D170%26spage%3D2647%26epage%3D2654%26doi%3D10.4049%2Fjimmunol.170.5.2647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Zhao, X.; Li, T.; Zhou, Z.; Chen, L.; Liu, Q.; Wang, X.; Yang, L.; Rong, Y.; Tan, R.; Yu, C.; Jiang, L.; Liu, Y.; Linghu, L.; Sun, J.; Wang, W.</span><span> </span><span class="NLM_article-title">Certain Protein Kinase Inhibitors</span>. WO2016066142 (A1),<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=X.+Zhao&author=T.+Li&author=Z.+Zhou&author=L.+Chen&author=Q.+Liu&author=X.+Wang&author=L.+Yang&author=Y.+Rong&author=R.+Tan&author=C.+Yu&author=L.+Jiang&author=Y.+Liu&author=L.+Linghu&author=J.+Sun&author=W.+Wang&title=Certain+Protein+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%26atitle%3DCertain%2520Protein%2520Kinase%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Emtenaes, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alderin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almqvist, F.</span><span> </span><span class="NLM_article-title">An Enantioselective Ketene-Imine Cycloaddition Method for Synthesis of Substituted Ring-Fused 2-Pyridinones</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">6756</span><span class="NLM_x">–</span> <span class="NLM_lpage">6761</span><span class="refDoi"> DOI: 10.1021/jo015794u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo015794u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2001&pages=6756-6761&author=H.+Emtenaesauthor=L.+Alderinauthor=F.+Almqvist&title=An+Enantioselective+Ketene-Imine+Cycloaddition+Method+for+Synthesis+of+Substituted+Ring-Fused+2-Pyridinones&doi=10.1021%2Fjo015794u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjo015794u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo015794u%26sid%3Dliteratum%253Aachs%26aulast%3DEmtenaes%26aufirst%3DH.%26aulast%3DAlderin%26aufirst%3DL.%26aulast%3DAlmqvist%26aufirst%3DF.%26atitle%3DAn%2520Enantioselective%2520Ketene-Imine%2520Cycloaddition%2520Method%2520for%2520Synthesis%2520of%2520Substituted%2520Ring-Fused%25202-Pyridinones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2001%26volume%3D66%26spage%3D6756%26epage%3D6761%26doi%3D10.1021%2Fjo015794u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Bengtsson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almqvist, F.</span><span> </span><span class="NLM_article-title">Regioselective Halogenations and Subsequent Suzuki-Miyaura Coupling onto Bicyclic 2-Pyridones</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">972</span><span class="NLM_x">–</span> <span class="NLM_lpage">975</span><span class="refDoi"> DOI: 10.1021/jo902458g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo902458g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=972-975&author=C.+Bengtssonauthor=F.+Almqvist&title=Regioselective+Halogenations+and+Subsequent+Suzuki-Miyaura+Coupling+onto+Bicyclic+2-Pyridones&doi=10.1021%2Fjo902458g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjo902458g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo902458g%26sid%3Dliteratum%253Aachs%26aulast%3DBengtsson%26aufirst%3DC.%26aulast%3DAlmqvist%26aufirst%3DF.%26atitle%3DRegioselective%2520Halogenations%2520and%2520Subsequent%2520Suzuki-Miyaura%2520Coupling%2520onto%2520Bicyclic%25202-Pyridones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2010%26volume%3D75%26spage%3D972%26epage%3D975%26doi%3D10.1021%2Fjo902458g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Hochhaus, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Möllmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derendorf, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Rothi, R. J.</span><span> </span><span class="NLM_article-title">Pharmacokinetic/pharmacodynamic Aspects of Aerosol Therapy Using Glucocorticoids as a Model</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">892</span><span class="refDoi"> DOI: 10.1002/j.1552-4604.1997.tb04262.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1002%2Fj.1552-4604.1997.tb04262.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=9505979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADyaK2sXnsVyjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1997&pages=881-892&author=G.+Hochhausauthor=H.+M%C3%B6llmannauthor=H.+Derendorfauthor=R.+J.+Gonzalez-Rothi&title=Pharmacokinetic%2Fpharmacodynamic+Aspects+of+Aerosol+Therapy+Using+Glucocorticoids+as+a+Model&doi=10.1002%2Fj.1552-4604.1997.tb04262.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model</span></div><div class="casAuthors">Hochhaus, Gunther; Mollmann, Helmut; Derendorf, Hartmut; Gonzalez-Rothi, Ricardo J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">881-892</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven</span>)
        </div><div class="casAbstract">Glucocorticoids are predominantly prescribed in asthma therapy as aerosols to achieve high pulmonary effects with reduced systemic spill-over and pronounced pulmonary selectivity.  A variety of pharmacokinetic parameters are potentially important for detg. pulmonary selectivity.  The intent of this article, is to provide a practice-relevant theor. approach to put the importance of these parameters on pulmonary targeting using pharmacokinetic/pharmacodynamic modeling as a tool in perspective.  The applied pulmonary pharmacokinetic/pharmacodynamic model revealed that, in addn. to recognized parameters such as systemic clearance, oral bioavailability, and efficiency of pulmonary deposition, other factors, such as the pulmonary release (dissoln.) rate and dose, are relevant.  However, the vol. of distribution (for effect parameters not undergoing a diurnal rhythm) and the receptor affinity of a given glucocorticoid are not important for achieving lung targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGMJqOuRqbwLVg90H21EOLACvtfcHk0ljUwrQTF1waEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnsVyjs7g%253D&md5=7877c4f469db937ac7a3aebd7b2b6c3b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fj.1552-4604.1997.tb04262.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1552-4604.1997.tb04262.x%26sid%3Dliteratum%253Aachs%26aulast%3DHochhaus%26aufirst%3DG.%26aulast%3DM%25C3%25B6llmann%26aufirst%3DH.%26aulast%3DDerendorf%26aufirst%3DH.%26aulast%3DGonzalez-Rothi%26aufirst%3DR.%2BJ.%26atitle%3DPharmacokinetic%252Fpharmacodynamic%2520Aspects%2520of%2520Aerosol%2520Therapy%2520Using%2520Glucocorticoids%2520as%2520a%2520Model%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D1997%26volume%3D37%26spage%3D881%26epage%3D892%26doi%3D10.1002%2Fj.1552-4604.1997.tb04262.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Hochhaus, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Rothi, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukyanov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derendorf, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalla Costa, T.</span><span> </span><span class="NLM_article-title">Assessment of Glucocorticoid Lung Targeting by Ex-Vivo Receptor Binding Studies in Rats</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">134</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span><span class="refDoi"> DOI: 10.1023/A:1016259225244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1023%2FA%3A1016259225244" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1995&pages=134-137&author=G.+Hochhausauthor=R.+J.+Gonzalez-Rothiauthor=A.+Lukyanovauthor=H.+Derendorfauthor=H.+Schreierauthor=T.+Dalla+Costa&title=Assessment+of+Glucocorticoid+Lung+Targeting+by+Ex-Vivo+Receptor+Binding+Studies+in+Rats&doi=10.1023%2FA%3A1016259225244"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1023%2FA%3A1016259225244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1016259225244%26sid%3Dliteratum%253Aachs%26aulast%3DHochhaus%26aufirst%3DG.%26aulast%3DGonzalez-Rothi%26aufirst%3DR.%2BJ.%26aulast%3DLukyanov%26aufirst%3DA.%26aulast%3DDerendorf%26aufirst%3DH.%26aulast%3DSchreier%26aufirst%3DH.%26aulast%3DDalla%2BCosta%26aufirst%3DT.%26atitle%3DAssessment%2520of%2520Glucocorticoid%2520Lung%2520Targeting%2520by%2520Ex-Vivo%2520Receptor%2520Binding%2520Studies%2520in%2520Rats%26jtitle%3DPharm.%2520Res.%26date%3D1995%26volume%3D12%26spage%3D134%26epage%3D137%26doi%3D10.1023%2FA%3A1016259225244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Cooper, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grime, K.</span><span> </span><span class="NLM_article-title">Optimisation of DMPK by the Inhaled Route. Challenges Approaches</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">457</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span><span class="refDoi"> DOI: 10.2174/138920012800166571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.2174%2F138920012800166571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=22299825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=457-473&author=A.+E.+Cooperauthor=D.+Fergusonauthor=K.+Grime&title=Optimisation+of+DMPK+by+the+Inhaled+Route.+Challenges+Approaches&doi=10.2174%2F138920012800166571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Optimisation of DMPK by the inhaled route: challenges and approaches</span></div><div class="casAuthors">Cooper, Anne E.; Ferguson, Douglas; Grime, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">457-473</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The renewed interest in inhalation delivery over recent years has led to an expansion in the understanding of lung pharmacokinetics.  Historically optimization of inhaled drugs focused largely on development of material properties, consistent with achieving a good lung deposition, alongside demonstrating appropriate in vivo efficacy with little understanding of the relationship to pharmacokinetics in the lung.  Recent efforts have led to an increased understanding of lung concns. and how to maximize exposure to achieve the desired pharmacol. response at a dose consistent with development of an inhaled product.  Although there is a prerequisite for excellent potency in inhalation delivery, it is essential that this be combined with pharmacokinetic properties that allow sufficient free concn. at the effect site in lung to exert the pharmacol. response for an appropriate dosing interval.  Increases in basicity, polarity and/or decreases in aq. soly. can extend pharmacokinetic duration and assist in finding the right balance between lung and systemic exposure.  Current evidence suggests there are similarities in lung retention in rat and dog and that animal lung concn. data can enable pharmacokinetic-pharmacodynamic relationships to be derived thus providing more confidence in the requirements for man.  Although inhaled delivery is challenging from a pharmacokinetic point of view, direct evaluation of exposure in the target organ has enabled further understanding of the drivers for drug disposition and highlighted the need for further development of predictive lung pharmacokinetic tools in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxztkVtHyCeLVg90H21EOLACvtfcHk0lj3guZMbKtOtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVeitbg%253D&md5=1dec4f52aeda55fe6ea888c289216d94</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F138920012800166571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012800166571%26sid%3Dliteratum%253Aachs%26aulast%3DCooper%26aufirst%3DA.%2BE.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DGrime%26aufirst%3DK.%26atitle%3DOptimisation%2520of%2520DMPK%2520by%2520the%2520Inhaled%2520Route.%2520Challenges%2520Approaches%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D457%26epage%3D473%26doi%3D10.2174%2F138920012800166571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Austin, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barton, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnert, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cage, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheshire, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougall, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ince, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, A.</span><span> </span><span class="NLM_article-title">QSAR and the Rational Design of Long-Acting Dual D 2 -Receptor/2 -Adrenoceptor Agonists Approach to Compound Design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3210</span><span class="NLM_x">–</span> <span class="NLM_lpage">3220</span><span class="refDoi"> DOI: 10.1021/jm020886c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020886c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3210-3220&author=R.+P.+Austinauthor=P.+Bartonauthor=R.+V.+Bonnertauthor=R.+C.+Brownauthor=P.+A.+Cageauthor=D.+R.+Cheshireauthor=A.+M.+Davisauthor=I.+G.+Dougallauthor=F.+Inceauthor=G.+Pairaudeauauthor=A.+Young&title=QSAR+and+the+Rational+Design+of+Long-Acting+Dual+D+2+-Receptor%2F2+-Adrenoceptor+Agonists+Approach+to+Compound+Design&doi=10.1021%2Fjm020886c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm020886c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020886c%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%26aufirst%3DR.%2BP.%26aulast%3DBarton%26aufirst%3DP.%26aulast%3DBonnert%26aufirst%3DR.%2BV.%26aulast%3DBrown%26aufirst%3DR.%2BC.%26aulast%3DCage%26aufirst%3DP.%2BA.%26aulast%3DCheshire%26aufirst%3DD.%2BR.%26aulast%3DDavis%26aufirst%3DA.%2BM.%26aulast%3DDougall%26aufirst%3DI.%2BG.%26aulast%3DInce%26aufirst%3DF.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DYoung%26aufirst%3DA.%26atitle%3DQSAR%2520and%2520the%2520Rational%2520Design%2520of%2520Long-Acting%2520Dual%2520D%25202%2520-Receptor%252F2%2520-Adrenoceptor%2520Agonists%2520Approach%2520to%2520Compound%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3210%26epage%3D3220%26doi%3D10.1021%2Fjm020886c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Connolly, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcaraz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadogan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphries, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingall, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kane, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocks, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, A.</span><span> </span><span class="NLM_article-title">Design-Driven LO: The Discovery of New Ultra Long Acting Dibasic β2-Adrenoceptor Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4612</span><span class="NLM_x">–</span> <span class="NLM_lpage">4616</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.05.097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1016%2Fj.bmcl.2011.05.097" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4612-4616&author=S.+Connollyauthor=L.+Alcarazauthor=A.+Baileyauthor=E.+Cadoganauthor=J.+Christieauthor=A.+R.+Cookauthor=A.+J.+Fisherauthor=S.+Hillauthor=A.+Humphriesauthor=A.+H.+Ingallauthor=Z.+Kaneauthor=S.+Paineauthor=G.+Pairaudeauauthor=M.+J.+Stocksauthor=A.+Young&title=Design-Driven+LO%3A+The+Discovery+of+New+Ultra+Long+Acting+Dibasic+%CE%B22-Adrenoceptor+Agonists&doi=10.1016%2Fj.bmcl.2011.05.097"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.05.097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.05.097%26sid%3Dliteratum%253Aachs%26aulast%3DConnolly%26aufirst%3DS.%26aulast%3DAlcaraz%26aufirst%3DL.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DCadogan%26aufirst%3DE.%26aulast%3DChristie%26aufirst%3DJ.%26aulast%3DCook%26aufirst%3DA.%2BR.%26aulast%3DFisher%26aufirst%3DA.%2BJ.%26aulast%3DHill%26aufirst%3DS.%26aulast%3DHumphries%26aufirst%3DA.%26aulast%3DIngall%26aufirst%3DA.%2BH.%26aulast%3DKane%26aufirst%3DZ.%26aulast%3DPaine%26aufirst%3DS.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DStocks%26aufirst%3DM.%2BJ.%26aulast%3DYoung%26aufirst%3DA.%26atitle%3DDesign-Driven%2520LO%253A%2520The%2520Discovery%2520of%2520New%2520Ultra%2520Long%2520Acting%2520Dibasic%2520%25CE%25B22-Adrenoceptor%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4612%26epage%3D4616%26doi%3D10.1016%2Fj.bmcl.2011.05.097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Mindell, J. A.</span><span> </span><span class="NLM_article-title">Lysosomal Acidification Mechanisms</span> <span class="citation_source-journal">Annu. Rev. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span><span class="refDoi"> DOI: 10.1146/annurev-physiol-012110-142317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1146%2Fannurev-physiol-012110-142317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=22335796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC38XjvFynsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2012&pages=69-86&author=J.+A.+Mindell&title=Lysosomal+Acidification+Mechanisms&doi=10.1146%2Fannurev-physiol-012110-142317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Lysosomal acidification mechanisms</span></div><div class="casAuthors">Mindell, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Physiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-86</span>CODEN:
                <span class="NLM_cas:coden">ARPHAD</span>;
        ISSN:<span class="NLM_cas:issn">0066-4278</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Lysosomes, the terminal organelles on the endocytic pathway, digest macromols. and make their components available to the cell as nutrients.  Hydrolytic enzymes specific to a wide range of targets reside within the lysosome; these enzymes are activated by the highly acidic pH (between 4.5 and 5.0) in the organelles' interior.  Lysosomes generate and maintain their pH gradients by using the activity of a proton-pumping V-type ATPase, which uses metabolic energy in the form of ATP to pump protons into the lysosome lumen.  Because this activity separates elec. charge and generates a transmembrane voltage, another ion must move to dissipate this voltage for net pumping to occur.  This so-called counterion may be either a cation (moving out of the lysosome) or an anion (moving into the lysosome).  Recent data support the involvement of ClC-7, a Cl-/H+ antiporter, in this process, although many open questions remain as to this transporter's involvement.  Although functional results also point to a cation transporter, its mol. identity remains uncertain.  Both the V-ATPase and the counterion transporter are likely to be important players in the mechanisms detg. the steady-state pH of the lysosome interior.  Exciting new results suggest that lysosomal pH may be dynamically regulated in some cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhQ7yyHPp6nrVg90H21EOLACvtfcHk0lj3guZMbKtOtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjvFynsbo%253D&md5=c9a157aa4b4c9c432ee4e26e4d3bdd13</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1146%2Fannurev-physiol-012110-142317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-physiol-012110-142317%26sid%3Dliteratum%253Aachs%26aulast%3DMindell%26aufirst%3DJ.%2BA.%26atitle%3DLysosomal%2520Acidification%2520Mechanisms%26jtitle%3DAnnu.%2520Rev.%2520Physiol.%26date%3D2012%26volume%3D74%26spage%3D69%26epage%3D86%26doi%3D10.1146%2Fannurev-physiol-012110-142317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Barnden, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allison, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heath, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbone, F. R.</span><span> </span><span class="NLM_article-title">Defective TCR Expression in Transgenic Mice Constructed Using cDNA-Based Alpha- and Bold Beta-Chain Genes under the Control of Heterologous Regulatory Elements</span> <span class="citation_source-journal">Immunol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span><span class="refDoi"> DOI: 10.1046/j.1440-1711.1998.00709.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1046%2Fj.1440-1711.1998.00709.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=9553774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADyaK1cXisFegtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1998&pages=34-40&author=M.+J.+Barndenauthor=J.+Allisonauthor=W.+R.+Heathauthor=F.+R.+Carbone&title=Defective+TCR+Expression+in+Transgenic+Mice+Constructed+Using+cDNA-Based+Alpha-+and+Bold+Beta-Chain+Genes+under+the+Control+of+Heterologous+Regulatory+Elements&doi=10.1046%2Fj.1440-1711.1998.00709.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Defective TCR expression in transgenic mice constructed using cDNA-based α- and β-chain genes under the control of heterologous regulatory elements</span></div><div class="casAuthors">Barnden, Megan J.; Allison, Jan; Heath, William R.; Carbone, Francis R.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology and Cell Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-40</span>CODEN:
                <span class="NLM_cas:coden">ICBIEZ</span>;
        ISSN:<span class="NLM_cas:issn">0818-9641</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Pty Ltd.</span>)
        </div><div class="casAbstract">The authors describe the generation of ovalbumin (OVA)-specific, MHC class II-restricted αβ T cell receptor (TCR) transgenic mice.  Initial attempts at generating these transgenic mice utilized heterologous regulatory elements to drive the expression of cDNA genes encoding the sep. α- and β-chains of the TCR.  Unexpectedly, T cells bearing the transgenic αβ TCR failed to emerge from the thymus in these mice, although the transgenes did modify endogenous TCR expression.  However, subsequent modification of the approach which enabled expression of the TCR β-chain under the control of its natural regulatory elements generated mice whose peripheral T cells expressed the transgenic TCR and were capable of antigen-dependent proliferation.  These results show that successful generation of MHC class II-restricted, OVA-specific αβTCR transgenic mice was dependent upon combining cDNA- and genomic DNA-based constructs for expression of the resp. α- and β-chains of the TCR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCdFTEhiZIWrVg90H21EOLACvtfcHk0li8xLICPAGCSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXisFegtLo%253D&md5=9f74696f328a6268d0e863f85039cdea</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1046%2Fj.1440-1711.1998.00709.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1440-1711.1998.00709.x%26sid%3Dliteratum%253Aachs%26aulast%3DBarnden%26aufirst%3DM.%2BJ.%26aulast%3DAllison%26aufirst%3DJ.%26aulast%3DHeath%26aufirst%3DW.%2BR.%26aulast%3DCarbone%26aufirst%3DF.%2BR.%26atitle%3DDefective%2520TCR%2520Expression%2520in%2520Transgenic%2520Mice%2520Constructed%2520Using%2520cDNA-Based%2520Alpha-%2520and%2520Bold%2520Beta-Chain%2520Genes%2520under%2520the%2520Control%2520of%2520Heterologous%2520Regulatory%2520Elements%26jtitle%3DImmunol.%2520Cell%2520Biol.%26date%3D1998%26volume%3D76%26spage%3D34%26epage%3D40%26doi%3D10.1046%2Fj.1440-1711.1998.00709.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Meyuhas, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreazen, A.</span><span> </span><span class="NLM_article-title">Chapter 3 Ribosomal Protein S6 Kinase: From TOP mRNAs to Cell Size</span> <span class="citation_source-journal">Prog. Mol. Biol. Transl. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">153</span><span class="refDoi"> DOI: 10.1016/S1877-1173(09)90003-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1016%2FS1877-1173%2809%2990003-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=20374740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVajtLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2009&pages=109-153&author=O.+Meyuhasauthor=A.+Dreazen&title=Chapter+3+Ribosomal+Protein+S6+Kinase%3A+From+TOP+mRNAs+to+Cell+Size&doi=10.1016%2FS1877-1173%2809%2990003-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Ribosomal protein S6 kinase: from TOP mRNAs to cell size</span></div><div class="casAuthors">Meyuhas, Oded; Dreazen, Avigail</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Molecular Biology and Translational Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">Translational Control in Health and Disease</span>),
    <span class="NLM_cas:pages">109-153</span>CODEN:
                <span class="NLM_cas:coden">PNARC5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Ribosomal protein S6 kinase (S6K) has been implicated in the phosphorylation of multiple substrates and is subject to activation by a wide variety of signals that converge at mammalian target of rapamycin (mTOR).  In the course of the search for its physiol. role, it was proposed that S6K activation and ribosomal protein S6 (rpS6) phosphorylation account for the translational activation of a subgroup of transcripts, the TOP mRNAs.  The structural hallmark of these mRNAs is an oligopyrimidine tract at their 5'-terminus, known as the 5'-TOP motif.  TOP mRNAs consists of about 90 members that encode multiple components of the translational machinery, such as ribosomal proteins and translation factors.  The translation efficiency of TOP mRNAs indeed correlates with S6K activation and rpS6 phosphorylation, yet recent biochem. and genetic studies have established that, although S6K and TOP mRNAs respond to similar signals and are regulated by mTOR, they maintain no cause and effect relationship.  Instead, S6K is primarily involved in regulation of cell size, and affects glucose homeostasis, but is dispensable for global protein synthesis, whereas translational efficiency of TOP mRNAs is a determinant of the cellular protein synthesis capacity.  Despite extensive studies of their function and mode of regulation, the mechanism underlying the effect of S6K on the cell size, as well as the transacting factor that mediates the translational control of TOP mRNAs, still await their identification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOFXDdrdGxhrVg90H21EOLACvtfcHk0li8xLICPAGCSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVajtLnJ&md5=9c08dffbb1f38d407426dd6591f63633</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS1877-1173%2809%2990003-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1877-1173%252809%252990003-5%26sid%3Dliteratum%253Aachs%26aulast%3DMeyuhas%26aufirst%3DO.%26aulast%3DDreazen%26aufirst%3DA.%26atitle%3DChapter%25203%2520Ribosomal%2520Protein%2520S6%2520Kinase%253A%2520From%2520TOP%2520mRNAs%2520to%2520Cell%2520Size%26jtitle%3DProg.%2520Mol.%2520Biol.%2520Transl.%2520Sci.%26date%3D2009%26volume%3D90%26spage%3D109%26epage%3D153%26doi%3D10.1016%2FS1877-1173%2809%2990003-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Beger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöde, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, J.</span><span> </span><span class="NLM_article-title">Dreikomponentenreaktionen. II. Nucleophile Substitutionen an N-(β-Haloalkyl)-Imidhalogeniden die Darstellung von Δ 2 -Oxazolinen, Δ 2 -Thiazolinen und Δ 2 -Imidazolinen</span> <span class="citation_source-journal">J. Prakt. Chem. (Leipzig)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1969</span><span class="NLM_x">, </span> <span class="NLM_volume">311</span><span class="NLM_x">, </span> <span class="NLM_fpage">408</span><span class="NLM_x">–</span> <span class="NLM_lpage">419</span><span class="refDoi"> DOI: 10.1002/prac.19693110310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1002%2Fprac.19693110310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADyaF1MXktlyrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=1969&pages=408-419&author=J.+Begerauthor=D.+Sch%C3%B6deauthor=J.+Vogel&title=Dreikomponentenreaktionen.+II.+Nucleophile+Substitutionen+an+N-%28%CE%B2-Haloalkyl%29-Imidhalogeniden+die+Darstellung+von+%CE%94+2+-Oxazolinen%2C+%CE%94+2+-Thiazolinen+und+%CE%94+2+-Imidazolinen&doi=10.1002%2Fprac.19693110310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Three component reactions.  II.  Nucleophilic substitutions in N-(β-haloalkyl)imidoyl halides.  Preparation of Δ2-oxazolines, Δ2-thiazolines, and Δ2-imidazolines</span></div><div class="casAuthors">Beger, Joerg; Schoede, D.; Vogel, Johannes</div><div class="citationInfo"><span class="NLM_cas:title">Journal fuer Praktische Chemie (Leipzig)</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">408-19</span>CODEN:
                <span class="NLM_cas:coden">JPCEAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-8383</span>.
    </div><div class="casAbstract">R1XCHCR2R3N:CXR (I) (R, R1, and R2 = H or alkyl, X = halogen) were prepd. from R1CH:CR2R3, X, and RCN.  I treated with H2O, H2S, or NH2R4 (R4 = H or alkyl) in alk. media gave 5-(R1-substituted)-4-(R2-substituted)-4-(R3-substituted)-2-(R-substituted)-2-oxazolines  (I), 5-(R1-substituted)-4-(R2-substituted)-4-(R3-substituted)-2-(R-substituted)-2-thiazolines (II), and 5-(R1-substituted)-4-(R2-substituted)-4-(R3-substituted)-1-(R4-substituted)-2-(R-substituted)-2-imidazolines (III).  The reaction steps were stereospecific.  When Δ1-olefins were used, 5-10% 5-substituted-Δ2-azolines (anti-Markovnikov addn.) were obtained besides the 4-substituted-Δ2-azolines (Markovnikov addn.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMTFe8ze2ov7Vg90H21EOLACvtfcHk0li8xLICPAGCSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXktlyrtL8%253D&md5=832d6596055140d2d87c7c20395ad191</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fprac.19693110310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprac.19693110310%26sid%3Dliteratum%253Aachs%26aulast%3DBeger%26aufirst%3DJ.%26aulast%3DSch%25C3%25B6de%26aufirst%3DD.%26aulast%3DVogel%26aufirst%3DJ.%26atitle%3DDreikomponentenreaktionen.%2520II.%2520Nucleophile%2520Substitutionen%2520an%2520N-%2528%25CE%25B2-Haloalkyl%2529-Imidhalogeniden%2520die%2520Darstellung%2520von%2520%25CE%2594%25202%2520-Oxazolinen%252C%2520%25CE%2594%25202%2520-Thiazolinen%2520und%2520%25CE%2594%25202%2520-Imidazolinen%26jtitle%3DJ.%2520Prakt.%2520Chem.%2520%2528Leipzig%2529%26date%3D1969%26volume%3D311%26spage%3D408%26epage%3D419%26doi%3D10.1002%2Fprac.19693110310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahman Parvizi, R. C.</span><span> </span><span class="NLM_article-title">Heterocyclic Studies. Part XXXXIX. Ring Cleavage of Some Pyrimidine Derivatives in Alkalai</span> <span class="citation_source-journal">J. Chem. Soc., Perkin Trans. 1 (1972-1999)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1004</span><span class="NLM_x">–</span> <span class="NLM_lpage">1007</span><span class="refDoi"> DOI: 10.1039/p19760001004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1039%2Fp19760001004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1976&pages=1004-1007&author=J.+Clarkauthor=R.+C.+Bahman+Parvizi&title=Heterocyclic+Studies.+Part+XXXXIX.+Ring+Cleavage+of+Some+Pyrimidine+Derivatives+in+Alkalai&doi=10.1039%2Fp19760001004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1039%2Fp19760001004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fp19760001004%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DBahman%2BParvizi%26aufirst%3DR.%2BC.%26atitle%3DHeterocyclic%2520Studies.%2520Part%2520XXXXIX.%2520Ring%2520Cleavage%2520of%2520Some%2520Pyrimidine%2520Derivatives%2520in%2520Alkalai%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%2520%25281972-1999%2529%26date%3D1976%26volume%3D9%26spage%3D1004%26epage%3D1007%26doi%3D10.1039%2Fp19760001004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Bruno, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tudge, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Design and Preparation of New Palladium Precatalysts for C-C and C-N Cross-Coupling Reactions</span> <span class="citation_source-journal">Chem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">916</span><span class="NLM_x">–</span> <span class="NLM_lpage">920</span><span class="refDoi"> DOI: 10.1039/C2SC20903A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1039%2FC2SC20903A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=23667737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFKjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=916-920&author=N.+C.+Brunoauthor=M.+T.+Tudgeauthor=S.+L.+Buchwald&title=Design+and+Preparation+of+New+Palladium+Precatalysts+for+C-C+and+C-N+Cross-Coupling+Reactions&doi=10.1039%2FC2SC20903A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Design and preparation of new palladium precatalysts for C-C and C-N cross-coupling reactions</span></div><div class="casAuthors">Bruno, Nicholas C.; Tudge, Matthew T.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">916-920</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of easily prepd., phosphine-ligated palladium precatalysts based on the 2-aminobiphenyl scaffold have been prepd.  The role of the precatalyst-assocd. labile halide (or pseudohalide) in the formation and stability of the palladacycle has been examd.  It was found that replacing the chloride in the previous version of the precatalyst with a mesylate leads to a new class of precatalysts with improved soln. stability and that are readily prepd. from a wider range of phosphine ligands.  The differences between the previous version of precatalyst and that reported here are explored.  In addn., the reactivity of the latter is examd. in a range of C-C and C-N bond forming reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfHp6oyg4k_bVg90H21EOLACvtfcHk0lg-GDYYMQjekQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFKjtr0%253D&md5=5b50ac18cb67251e5439199c6746dba8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1039%2FC2SC20903A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2SC20903A%26sid%3Dliteratum%253Aachs%26aulast%3DBruno%26aufirst%3DN.%2BC.%26aulast%3DTudge%26aufirst%3DM.%2BT.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DDesign%2520and%2520Preparation%2520of%2520New%2520Palladium%2520Precatalysts%2520for%2520C-C%2520and%2520C-N%2520Cross-Coupling%2520Reactions%26jtitle%3DChem.%2520Sci.%26date%3D2013%26volume%3D4%26spage%3D916%26epage%3D920%26doi%3D10.1039%2FC2SC20903A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Callahan, J. F.; Li, Tindy; Wan, Zehong; Yan, H.</span><span> </span><span class="NLM_article-title">Preparation of Pyrazolo[3,4-<i>b</i>]pyridine Dual Pharmacophores as PDE4-Muscarinic Antagonists</span>. WO2009100169,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+F.+Callahan&author=Tindy+Li&author=Zehong+Wan&author=H.+Yan&title=Preparation+of+Pyrazolo%5B3%2C4-b%5Dpyridine+Dual+Pharmacophores+as+PDE4-Muscarinic+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCallahan%26aufirst%3DJ.%2BF.%26atitle%3DPreparation%2520of%2520Pyrazolo%255B3%252C4-b%255Dpyridine%2520Dual%2520Pharmacophores%2520as%2520PDE4-Muscarinic%2520Antagonists%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Bäckström, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundqvist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammarlund-Udenaes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridén, M.</span><span> </span><span class="NLM_article-title">Lung Retention by Lysosomal Trapping of Inhaled Drugs Can Be Predicted In Vitro With Lung Slices</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">3432</span><span class="NLM_x">–</span> <span class="NLM_lpage">3439</span><span class="refDoi"> DOI: 10.1016/j.xphs.2016.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;key=10.1016%2Fj.xphs.2016.08.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2016&pages=3432-3439&author=E.+B%C3%A4ckstr%C3%B6mauthor=E.+Bogerauthor=A.+Lundqvistauthor=M.+Hammarlund-Udenaesauthor=M.+Frid%C3%A9n&title=Lung+Retention+by+Lysosomal+Trapping+of+Inhaled+Drugs+Can+Be+Predicted+In+Vitro+With+Lung+Slices&doi=10.1016%2Fj.xphs.2016.08.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.xphs.2016.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.xphs.2016.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A4ckstr%25C3%25B6m%26aufirst%3DE.%26aulast%3DBoger%26aufirst%3DE.%26aulast%3DLundqvist%26aufirst%3DA.%26aulast%3DHammarlund-Udenaes%26aufirst%3DM.%26aulast%3DFrid%25C3%25A9n%26aufirst%3DM.%26atitle%3DLung%2520Retention%2520by%2520Lysosomal%2520Trapping%2520of%2520Inhaled%2520Drugs%2520Can%2520Be%2520Predicted%2520In%2520Vitro%2520With%2520Lung%2520Slices%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2016%26volume%3D105%26spage%3D3432%26epage%3D3439%26doi%3D10.1016%2Fj.xphs.2016.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NCY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NCY','PDB','5NCY'); return false;">PDB: 5NCY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NCZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NCZ','PDB','5NCZ'); return false;">PDB: 5NCZ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i67"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00401">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_32663"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00401">10.1021/acs.jmedchem.7b00401</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Ligand diagrams for the crystal structures; kinase selectivity profile for <b>20b</b> and <b>20f</b>; analytical HPLC conditions; HPLCMS results; synthesis procedures for compounds <b>1</b> and <b>2</b>; NMR spectra for compounds <b>3</b>–<b>20l</b>; HPLCMS traces for compounds <b>20b</b> and <b>20f</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00401/suppl_file/jm7b00401_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00401/suppl_file/jm7b00401_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00401/suppl_file/jm7b00401_si_001.pdf">jm7b00401_si_001.pdf (2.51 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00401/suppl_file/jm7b00401_si_002.csv">jm7b00401_si_002.csv (2.23 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Crystal structures for compounds <b>13</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NCY">5NCY</a>) and <b>15c</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NCZ">5NCZ</a>) have been deposited with the Protein Data Bank. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00401&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-12%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00401%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00401" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67991a407d1022a8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
